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This thesis aims at improving adult neurogenesis yield, using 
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Several evidences support carbon monoxide (CO) for modulating 
cellular differentiation, in particular for neuronal cells. First, there are 
some reported studies documenting the biogenesis of mitochondria 
during spontaneous cell differentiation and it was demonstrated that 
CO promotes mitochondrial biogenesis. Secondly, ROS are signalling 
molecules in CO-induced pathways and are also key-players in 
neuronal differentiation. Third, CO has been described as anti-
proliferative molecule in different cell types, namely smooth muscle, 
cancer and T cells, which can be involved in the balance between 
differentiation and proliferation that occurs during neurogenesis. 
Therefore, CO presents a strong potential for modulating neuronal 
differentiation, opening windows for the development of novel cell 
therapy strategies for neurological disorders. Thus, the main goal of 
this PhD thesis was to improve adult neurogenesis yield, using CO as 
modulator of cellular and biochemical pathways. In Chapter I one can 
find a general introduction about adult neurogenesis and cellular 
processes that directly modulate this process. 
During regeneration process and adult neurogenesis, all 
precursor cells must maintain the capacity to self-renew and a 
positive balance of proliferation versus differentiation or death. Thus, 
in Chapter II, CO effect in proliferation, differentiation and cell death 
during neuronal differentiation was studied using three different 
models with increasing complexity: human neuroblastoma SH-S5Y5 
cell line, human teratocarcinoma NT2 cell line and hippocampal 
organotypic slice cultures (HOSC). Here it was proved that CO 
improves neurogenesis by preventing cell death. In Chapter III, 
hMVbcl-XL cell line was used to assess other mechanisms of CO for 
modulating neuronal differentiation besides prevention of cell death. 
The cell model was generated from human fetal ventral 
mesencephalic region, presenting genuine characteristics of their 
regional identity, which discharged the need of complex patterning 
procedures, however these cells over-express the anti-apoptotic 
protein BclXL. Thus, this model allowed to understand that, besides 
cell death protection, CO was promoting a metabolic modulation 
during the process of neuronal differentiation. Therefore, in Chapter 
IV, NT2 cell line was used to deeper understand the effect of CO in 
metabolism modulation, namely the shift from glycolysis to oxidative 
metabolism. In fact, it was observed that CO stimulated neuronal 
production by promoting oxidative metabolism over glycolysis. 
Finally, one cannot disregard that during neurogenesis there is the 
need of building blocks such as nucleotides, electron donors like 
NADPH and antioxidant defenses, obtained by glutathione recycling. 
Thus, in Chapter V, CO modulation of pentose phosphate pathway 
and glutathione metabolism was assessed using SH-SY5Y cell line. 
In Chapter VI is presented a general discussion that integrates 
this thesis’ results in the current scientific context. In conclusion, this 
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thesis highlights biochemical modulation of neurogenesis and reveals 
CO as a promising therapeutic molecule to improve neuronal 




























Várias evidências suportam que exista modulação da 
diferenciação celular pelo monóxido de carbono (CO), em particular 
para as células neuronais. Em primeiro lugar, alguns estudos 
documentam a biogénese de mitocôndrias durante a diferenciação de 
células e demonstrou-se que o CO promove a biogénese 
mitocondrial. Em segundo lugar, as espécies reactivas de oxigénio  
são moléculas de sinalização nas vias induzidas pelo CO e também 
são fulcrais na diferenciação neuronal. Em terceiro lugar, o CO foi 
descrito como molécula anti-proliferativa em diferentes tipos de 
células, nomeadamente músculo liso, células cancerígenas e células 
T, pelo que pode estar envolvido no equilíbrio entre a proliferação e 
diferenciação que ocorre durante a neurogénese. Portanto, o CO 
apresenta um forte potencial para modular a diferenciação neuronal, 
surgindo oportunidades para o desenvolvimento de novas estratégias 
de terapia celular para doenças neurológicas. Assim, o principal 
objetivo desta tese de doutoramento foi para melhorar o rendimento 
da neurogénese adulta, usando CO como modulador de vias celulares 
e bioquímicas. No Capítulo I encontra-se uma introdução geral sobre 
a neurogénese em adultos e os processos celulares que modulam 
directamente este processo. 
Durante a regeneração e neurogénese em adultos, todas as 
células precursoras mantêm a capacidade de auto-renovação e um 
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saldo positivo de proliferação relativamente a diferenciação ou morte. 
Assim, no Capítulo II, o efeito do CO na proliferação, diferenciação e 
morte celular durante a diferenciação neuronal foi estudada usando 
três modelos diferentes com complexidade crescente: linha celular 
humana SH-S5Y5 isolada de neuroblastoma, linha celular humana 
NT2 isolada de teratocarcinoma e culturas organotípicas de 
hipocampo. Aqui, provou-se que o CO melhora a neurogénese por 
prevenção da morte celular. No Capítulo III, a linha celular hMVbcl-XL 
foi utilizado para avaliar a modulação de outros mecanismos pelo CO 
durante a diferenciação neuronal, para além de prevenção de morte 
celular. Este modelo celular foi gerado a partir da região do 
mesencéfalo ventral fetal humano, apresentando características 
genuínas de sua identidade regional mas estas células sobre-
expressam a proteína anti-apoptótica Bcl-XL. Assim, este modelo 
permitiu compreender que, para além da protecção da morte celular, 
o CO promove uma modulação metabólica durante o processo de 
diferenciação neuronal. Portanto, no Capítulo IV, a linha celular NT2 
foi usada para compreender mais profundamente o efeito do CO na 
modulação do metabolismo, ou seja, a transição do metbolismo 
glicolítico para o metabolismo oxidativo. De facto, observou-se que o 
CO estimulou a produção neuronal, promovendo o metabolismo 
oxidativo. Finalmente, há que considerar que, durante a 
neurogénese, há a necessidade de (i) metabolitos específicos, tais 
como nucleótidos e (ii) defesas antioxidantes que necessitam de 
dadores de eletrões como NADPH que vai permitir a reciclagem do 
glutationo. Assim, no Capítulo V, a modulação exercida pelo CO na 
via de pentoses fosfato (PPP) e no metabolismo do glutationo foi 
avaliada utilizando linha de células SH-SY5Y. 
No Capítulo VI é apresentada uma discussão geral que integra os 
resultados desta tese no contexto científico atual. Em conclusão, esta 
tese destaca a modulação bioquímica durante neurogénese e 
apresenta o CO como uma molécula terapêutica promissora para a 
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1. STEM CELLS  
Embryonic and adult stem cells have the capability to produce 
identical copies of themselves via cell division (self-renewal) and the 
ability to generate multiple functional differentiated cells types 
(multipotency). Thus, stem cells can proliferate into an increasingly 
undifferentiated stem cell population that possesses the same 
potential as the parent cell, or they can originate different tissues 
during embryonic and postnatal development, which is crucial for 
tissue repair [1]–[3]. 
Due to their potency or the diversity of cell types stem cells can 
generate, different types of stem cells can be identified. The best 
example of potency is the zygote, however it is not generally 
regarded as stem cell because of their transient feature, no self-
renewing capacity, despite the ability to give rise to both embryonic 
and extraembryonic tissues [4]. Amongst true stem cells, embryonic 
stem cells (ESCs), isolated from the inner mass of the blastocyst, have 
the broadest potential. These cells are pluripotent stem cells that can 
generate all cell types during embryo development.  However, stem 
cells are not restricted to development stages. Actually, adult 
individuals also have a large number of tissue-specific stem cells, 
which are capable of generating certain cell types but not those from 
unrelated tissues. The best-studied tissue-specific stem cell is the 
hematopoietic stem cell, which generates all blood cell types. Other 
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tissue-specific stem cells have been identified in numerous organs 
including muscle, skin, gut, liver, pancreas and brain. Herein it will be 
targeted neural stem cells that originate several cell types from the 
nervous system. 
 
1.1. Neural stem cells (NSCs) and adult neurogenesis 
In the last 20 years, several reports contradicted the dogma 
proclaiming that no new neurons are born in the adult brain [5]. Now 
it is broadly accepted that neural stem cells (NSCs) are present 
through live in neurogenic niches. Thousands of NSCs exist on the 
border of the lateral ventricle and striatum of the subventricular zone 
(SVZ) and on subgranular zone (SGZ) of the dentate gyrus (DG) in the 
hippocampus, where they differentiate and persist for long periods of 
time (Fig.1.1) [6], [7]. Neurons generated in the SVZ migrate to the 
olfactory bulb and differentiate into interneurons. Neurogenesis in 
the dentate SGZ gives rise to neurons in the granule cell layer (GCL) 
[8].  
In addition to in vivo studies, NSCs have been isolated from 
various regions of the adult brain and cultured in vitro in order to 
extensively characterize them at different developmental stages [9]–
[11]. NSCs can differentiate into neurons under defined culture 
conditions and are able to synapse with each other or with co-















astrocytes, and oligodendrocytes [3], [15] depending on culture 
conditions.  
Neural stem and progenitor cells (NSCs) in the lateral ganglionic 
eminence (LGE) and subventricular zone (SVZ) ensure neurogenesis 
during embryonic development and throughout adult life, which is 
called adult neurogenesis. However, NSC proliferation and neuroblast 




Figure 1.1 – Stem cell niches in the brain. (A) scheme of a sagittal section 
through adult rat brain; (B) coronal sections through adult rat brain showing 
the SVZ (upper panel) and SGZ of the hippocampus (lower panel); (C) left 
panel: enlargement of the vasculature in a niche site, depicting fenestrations 
between endothelial cells and gaps in the glial end feet; right panel: further 
enlargement at a fenestration site showing the permeability of the BBB and 





Adult neurogenesis consists of generation of neurons from 
neural stem/precursor cells and occurs in specific brain regions 
called neurogenic zones. This process occurs in the hippocampus of 
several vertebrate species such as rodents [19], [20] and primates 
including humans [21]–[23]. 
At least five steps appear to be involved in the neurogenesis 
process: (i) proliferation of stem/progenitor cells, (ii) migration of 
newborn neurons, (iii) neuronal differentiation and maturation, (iv) 
integration into neuronal circuits and (v) survival of cells [3]. The 
integration of newly born neurons into the mature hippocampal 
network, as well as the physiological implications of this 
neurogenesis are far less understood. Anatomical studies have shown 
that the newly born neurons receive synaptic inputs on their dendritic 
arbors and send axonal projections toward their normal targets: the 
CA3 pyramidal cells [24]. Electrophysiological recordings suggest that 
CA3 pyramidal cells develop functional properties of mature dentate 
granule cells [25]. Furthermore, neurogenesis in the adult 
hippocampus has been correlated with learning and memory in some, 
but not all, hippocampus-dependent behavioral studies [1], [26], [27].  
Neurogenesis process can be modulated by hormones, growth 
factors, neurotransmitters as well as by environmental factors and 
under pathologic conditions [1], [28]–[31]. Namely, EGF, IGF-1 and 















[28], [29], as well as scenarios of ischemia and exercise increase 
neurogenesis [30], [31]. 
 
1.2. Neurogenesis in pathological scenarios 
Neurogenesis occurs through life, but there is a significant 
decline during aging [29], [32], [33]. Nevertheless, some studies with 
mice, rat and primates models showed that it is possible to treat old 
brains with infusion of growth factors [32], [34] or promoting an 
enriched environment [33], which stimulates the production of new 
neurons [2], [8], [32], [35], [36]. These strategies are particularly 
relevant in pathological scenarios such as ischemic stroke, seizures 
and neurodegenerative diseases development. 
Ischemic stroke causes neuronal loss mainly in the striatum and 
cerebral cortex, whereas hippocampal formation is spared [37]. This 
injury leads to deficits in hippocampus-associated spatial memory 
[37]. Improvement of neurogenesis might counteract cognitive 
impairments and contribute to recovery of stroke-impaired motor 
function [8]. 
Following acute seizures there is an increased production of new 
neurons in the adult dentate gyrus (DG) by NSCs [38]. Seizure-
induced enhancement of neurogenesis is decreased in aged rats [38], 
[39]. However, available data indicate that, despite diminished 
baseline levels, aged NSCs maintain the potential to respond to 
extrinsic cues similar to NSCs in adult animals, which is important in 
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the perspective of a potential future therapeutic use of neuronal 
replacement from endogenous NSCs in human neurodegenerative 
disorders [40], [41]. 
 
 
2. IN VITRO MODELS FOR NEUROGENESIS RESEARCH 
The culture of NSCs is an essential tool for assessing the 
molecular mechanisms controlling differentiation in the nervous 
system [42], [43]. Human NPCs can be obtained from brain biopsy or 
can be differentiated from pluripotent stem cells. Regardless of their 
source, one of the main challenges in this field is to mimic in vitro 
neural development as similar as possible to the in vivo situation. 
Much has been done in order to confirm similarities between cells 
growing in dishes and cells in the in vivo context in the brain. Indeed, 
in vitro models have evolved as reliable tools for studying cellular 
and molecular aspects of neural differentiation [42], [43]. 
 
 
2.1. Neural Stem Cell lines  
Mouse embryonic (ES) and carcinoma (EC) cell lines are in vitro 
models to study the neuronal differentiation process, allowing the 
assessment of the involved cellular mechanisms [44]. These immortal 















pluripotency, providing unlimited supply of cells capable of 
proliferating in culture for long periods and of differentiating into 
several cell types [44], [45], including post-mitotic neurons. Neuronal 
differentiation occurs upon removal of growth factors from the 
culture medium [46], [47] or treatment with retinoic acid (RA) [48]–
[54]. RA is a derivative of vitamin A, which is essential for promoting 
normal patterning and neurogenesis during development. RA 
signaling pathway, leading to neuronal differentiation, is dependent 
on retinoic acid binding proteins (CRABP)-I and II, which in turn 
deliver RA into the nuclear RA receptors (RARs). Then RARs directly 
regulate the expression of specific RA-inducible genes and neuronal 
differentiation [45], [52]–[54].  
 
2.1.1. hVMbcl-XL cell line 
The human ventral mesencephalic (VM) stem cell line hVMbcl-XL 
was generated from a 10-week-old foetus (Lund University, Sweden) 
and immortalized by infecting the cells with a retroviral vector coding 
for v-myc (LTR-vmyc-SV40p-Neo-LTR), creating a multipotent cell line 
[46]. Derivatives of these cells were genetically modified (retrovirus) 
to overexpress the anti-apoptotic gene B-cell lymphoma-extra large 
(BclXL), essentially as described by Liste et al. in 2007 [47]. hMVbcl-XL 
cell line proliferates in the presence of growth factors (EGF and bFGF). 
Upon removal of growth factors, the cells readily differentiated into 
neurons, astrocytes and oligodendrocytes [46], [47].  
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hVMbcl-XL cell line has been used in studies of 
microtransplantation into striatal slice cultures [55] and in validation 
of 3D systems that allow an efficient differentiation combined with 
real-time in situ confirmation of neuronal fate [56]. 
 
2.1.2. SH-SY5Y cell line 
SH-SY5Y human neuroblastoma cells were derived from a thrice-
cloned cell line, SK-N-SH [57], [58]. These cells were derived from 
neural crest [48], [49], [58] and represents a rapid and representative 
model for studying neuronal differentiation processes [50]. These 
cells differentiate into neuron-like cells that fulfill the morphological, 
biochemical and functional neuronal criteria [49], [50], [59]. Due to 
their neuronal characteristics, these cells have been used extensively 
to study neuron-like behavior [57] and constitute a valuable model 
for neuronal toxicity studies [60]–[63]. 
 
2.1.3. NT2 cell line 
NT2 lineage is derived from human testicular embryonic 
teratocarcinoma and differentiates into functional post-mitotic 
neurons. Obtained NT2-derived-neurons express many neuronal 
markers [51], such as cytoskeletal proteins, secretory markers and 
surface markers. Also, NT2 cells express nestin and vimentin 















express MAP2, NF-L and α-internexin, among other neuronal specific 
proteins, and produce a variety of neurotransmitters, namely GABA 
and glutamine [64], [65]. Moreover, NT2-derived neurons can form 
functional synapses [66] have also been used in several 




2.2. Ex vivo models 
2.2.1. Hippocampal organotypic cell cultures 
In order to increase the model complexity, organotypic cultures 
were used. Organotypic slice cultures are a great in vivo-like model 
for assessing cell proliferation, differentiation and migration in a 
tissue context. This model better mimics in vivo cerebral 
environment, which facilitates the study of new factors for 
improvement of neuronal differentiation [70], [71]. 
Continuous formation of new neurons and glial cells in some 
specific brain zones can be evaluated using this in vivo-like model of 
adult neurogenesis, which occurs mainly in the Subventricular zone 
and in the Hippocampus, specifically in both Subgranular region of 
the Dentate gyrus and in Cornu Ammonis region 1 (Fig.1.2).  Contrary 
to what is generally thought, there is evidence that neurons can also 





Figure 1.2 - Adult hyppocampal neurogenesis (A) Dissection of the rodent 
telecephalon. (B) Enlarged schematic of the dentate gyrus shows the superior 
and inferior blades of the granule cell layer (GCL, brown) and the subgranular 
zone (SGZ, red) where the hippocampal neurogenesis occurs in the postnatal 
period through adulthood. (C) Higher magnification of the boxed region from 
(B) displays the phases of adult hippocampal neurogenesis as a function of 
time. The neural stem cells (NSCs, green) putatively give rise to the 
transiently-amplifying progenitors (blue and violet) whose progeny 
differentiate into immature neurons (dark violet) and finally into fully mature 
dentate gyrus GC neurons (red) (adapted from [72]). 
 
The organotipic brain tissue slice cultures are derived from 
postnatal mice and can be grown for several weeks in vitro. They 
mature into organotypically organized brain tissue with display of a 
basic cellular content and connective axonal network characteristic of 
the donor brain area in vivo [73]. 
 
3. CELL DEATH IN STEM CELLS NICHES 
Adult stem cell proliferation and cell death appear to be coupled 
in many systems to control cell number, patterning and lineages 
[74]–[76]. Indeed, genetically modified in vivo models, where 
executor or regulatory apoptotic genes (caspase-3, caspase-9, Bak, 
Bax, among others) are knock out, resulted in supernumerary 
neurons in the brain [75].  However, the incidence and role of cell 
death in the different stages are yet not well understood.  Despite 















healthy brain and that is dependent on the balance between 
proliferation/differentiation and cell death[2], [75], [77]–[79], 
apoptosis of differentiating neurons during embryonic development 
has been intensively studied [74]–[76], whereas cell death affecting 
adult neural stem cells is much less characterized.  
 
4. OXYGEN LEVELS, REDOX STATE AND 
MITOCHONDRIAL FUNCTION DURING NEUROGENESIS 
Since embryonic life, oxygen (O2) levels control crucial events 
such as formation of placenta, vascular system and skeleton. 
Furthermore, in adulthood O2 demands, consumption and flow vary 
not only amongst organs but also between regions of same organ 
[80]–[83]. These variations influence cell fate in a gradient manner 
and, consequently O2 has been considered as a morphogen, which 
promotes regulatory roles in diverse pathways controlling also adult 
neuronal differentiation [81], [84]–[86]. Actually, it was suggested 
that fluctuations in O2 levels misbalances the intracellular redox 
control, impairing the balance between stem cell proliferation, 
differentiation and death [87].  
The cellular redox potential depends on the balance between 
relative amounts of the reduced and oxidized forms of redox 
couples, such as NADP
+
/NADPH, GSSG/GSH, superoxide anion 
radical/oxygen and hydrogen peroxide/water. It is known that the 
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accumulation of reactive redox species persists only during early 
stages of differentiation, whereas a reductive environment is acquired 
in terminally differentiated neurons [87], [88]. 
Reactive oxygen species (ROS) are key factors in neuronal 
differentiation since the impairment of ROS formation prevents 
neuronal differentiation in different in vitro models, such as 
embryonic stem cells (ESCs), teratocarcinoma stem cells and 
neuroblastoma cells [89]–[93].  Furthermore, growing evidences also 
indicate ROS as hub regulators of various processes and pathways 
during neurodevelopment, namely stem cell self-renewal and 
differentiation [90], [94]. Thus, one can speculate that the final 
decision whether the NSCs will proliferate or differentiate is mainly 
based on redox-sensitive factors [84], [87], [91], [95]–[97]. Although 
the exact mechanism involved in ROS-mediated neurogenesis remains 
unclear, ROS generation might be closely related to alterations in O2 
levels. 
Besides being a result of alterations in oxygen levels, ROS can be 
endogenously produced by mitochondria during oxidative 
phosphorylation, mainly at complexes I and III, since about 1-2% of 
oxygen is not totally reduced into H2O (Fig.1.6) [88], [98]. During 
neuronal differentiation, mitochondrial population not only increases 
through mitochondrial biogenesis [93], [99]–[102], but it also occurs 
a reprogramming of mitochondrial structure and bioenergetics: 















functional cristae morphology [103]. Accordingly to Cho and 
colleagues, the modifications of mitochondrial population during 
differentiation might permit more cellular respiration and, therefore, 
an increase of cellular ATP production [93], which is needed for cell 
differentiation from progenitor to fully mature and functional cell. 
Moreover, one cannot disregard the central role of mitochondria in 
integrating survival and death signals in intrinsic pathways of 
apoptotic cell death [98]. 
 
 
5. BIOENERGETIC PATTERN DURING NEURONAL 
DIFFERENTIATION 
Cell differentiation goes hand-in-hand with metabolic alterations 
needed to provide new bioenergetic, synthetic and catabolic 
requirements important for cell identity. Actually, it was showed by 
mass spectroscopy that, during differentiation, it occurs the 
modulation of several genes involved in redox hemostasis, energy 
metabolism, RNA processing, retinoic acid signaling and ubiquitin 
dependent proteolysis [104].  
Stem cell differentiation is dependent on cell metabolic shifts, 
mitochondrial function and oxygen levels [105]–[110]. Thus, 
metabolism is an important indicator of cell function, since it shifts 
together with differentiation, growth or anabolic capacities. For 
example, both neuronal and hematopoietic stem cells preferentially 
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rely to a greater extent on glycolysis whereas differentiated cells up-
regulate oxidative phosphorylation to generate ATP [111]–[114]. 
However, little information exists regarding stem cell metabolism 
during proliferation and differentiation. 
 
5.1. Glycolysis 
Glycolytic breakdown of glucose is the exclusive source of energy 
in some mammalian tissues and cell types, such as brain, thus this 
pathway assumes a central position in glucose catabolism [115].  
In glycolysis, a molecule of glucose is metabolized to two 
molecules of pyruvate (Fig. 1.3). During the sequential conversion of 
a single glucose molecule into two pyruvate molecules, it is released 
energy that is conserved in the form of ATP and NADH. These 



























In aerobic organisms or tissues, glycolysis is only the first 
stage of glucose degradation. The obtained pyruvate can be 
(reversibly) converted into lactate in the cytosol, which results in the 
production of NAD+ from NADH or it can be oxidized to yield the 
acetyl group of acetyl-coenzyme A that will be completely oxidized by 




















Figure 1.4 – Possible catabolic fates of the pyruvate formed in glycolysis 
(adapted from [115]). Glycolysis was the first metabolic pathway to be 
elucidated and, due to the hypoxic provenience of living organisms, 
anaerobic glycolysis is the probably the most ancient biological mechanism 
for obtaining energy [115], [117]. However, aerobic glycolysis can occur and 
it is a functional marker of dividing cells, whether they are stem or 




5.2. Pentose Phosphate Pathway 
Glucose metabolism can also have other catabolic fates, such as 
the particular important biosynthetic pathway termed pentose 
phosphate pathway (PPP), which leads to specialized products needed 
by the cell. PPP consists in a network of interconversion reactions 
between sugar phosphates and can be divided in two parts: the 
oxidative phase and the nonoxidative phase (Fig.1.5). The overall 
reaction catalyzed by the oxidative phase is the oxidation of glucose-
6-phosphate to ribulose-5-phosphate and CO2. Also, NADP+ is 
converted into nicotinamide adenine dinucleotide phosphate (NADPH) 
that acts as an important reducing agent that may participate in lipid 
and steroid synthesis or in the regeneration of glutathione and 
thioredoxin, which are involved in the cell’s defense mechanism 
against oxidative stress. In the second phase of the PPP, 5-carbon 
sugars are nonoxidatively synthetized. The PPP is connected to the 
glycolytic pathway at the level of their common intermediates 
glyceraldehyde-3-phosphate and fructose-6-phosphate [115], [116], 
[118]. 
Rapidly dividing cells, like stem cells, use PPP to obtain NADPH 
(for maintaining an antioxidant status) and ribose-5-phosphate (for 
making RNA, DNA and coenzymes). Thus, during brain development 
PPP is extremely important. The prominent function of this pathway 
is supported by the increase in enzyme activity and flux rates of 
































5.3. TCA cycle and oxidative phosphorylation 
In the presence of oxygen, the pyruvate produced by glycolysis or 
by the PPP can be converted to acetyl-CoA by the pyruvate 
dehydrogenase (PDH) complex, and subsequently metabolized in the 
TCA cycle (Fig. 1.6), to further produce ATP via coupling to the 
mitochondrial electron transport chain and cycle intermediates that 
will be precursors for a wide variety of products [115].  
The oxidation of pyruvate to CO2 in the TCA cycle generates 
energy-rich molecules such as GTP, NADH and FADH2. The latter two 
will transfer electrons to oxygen in the electron transport chain, 
leading to the production of ATP in a process named oxidative 






Figure 1.6 – TCA cycle and oxidative phosphorylation. (A) Reactions of the 
TCA cycle; (B) Mitochondrial electron-transfer reactions and coupled 


















Recently, NSC dynamics studies had demonstrated that the 
activation of NSCs is accompanied by downregulation of glycolytic 
metabolism and upregulation of mitochondrial oxidation [119]. The 
currently accepted model defends that upon lineage differentiation, 
cell switch to oxidative metabolism, which is needed to support the 
growing energetic demands of specialized progeny. For instance, it is 
known that NSCs are more resistant to hypoxia and have lower 
requirement for oxidative metabolism but are more dependent on 
glycolysis than neurons [120] and that activation of NSCs is 
accompanied by a downregulation of glycolytic metabolism and an 
upregulation of mitochondrial oxidation [121], [122]. 
 
5.4. Other carbon sources 
Although glucose is still considered the main substrate for brain, 
it is now known that lactate utilization by neurons also occurs. 
Actually both neurons and NPCs can survive with lactate as exclusive 
metabolic substrate [114], [123]. Moreover, in the developing brain 
lactate is a major substrate for oxidation metabolism in addition to 
being selectively utilized as an anabolic source for cell proliferation 
and differentiation. Álvarez and colleagues, showed that lactate 
intake and its subsequent oxidative metabolism direct progenitor 
commitment to a neuronal progenitor fate. These results support the 
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hypothesis of NSC and progenitor cells with different metabolic 
signatures coexisting in the neurovascular niche [114], [123]. 
 
 
6. CARBON MONOXIDE 
Carbon monoxide (CO) is an endogenous product of heme 
degradation by heme oxygenase (HO), along with free iron and 
biliverdin (Fig. 1.7), which is rapidly converted into the anti-oxidant 
bilirubin [124]. Administration of CO at low concentrations produces 
several beneficial effects in distinct tissues, such as anti-




Figure 1.7 - The haem degradation pathway. Haem is catalysed into 
biliverdin by haem oxygenase with the release of a molecule of carbon 
monoxide (CO) and ferric iron. 
  
CO is mostly known as a silent-killer due to its great affinity to 
hemoglobin, which compromises oxygen delivery and promotes high 















CO are cytotoxic by inhibition of cytochrome c oxidase (COX), 
excessive ROS generation or uncoupling effect [126]. Nevertheless, 
CO is an endogenously produced gasotransmitter generated by the 
cleavage of heme group via the enzymatic activity of heme-oxygenase 
(HO) [124]. HO is a stress-related enzyme, whose expression or 
activity increases in response to several stresses, namely: oxidative 
stress, hypoxia, hyperoxia, hyperthermia, inflammation, UV, 
misfolded protein response, among others [124], [127], [128]. 
 
 
6.1. Carbon monoxide, cytoprotection and ROS signalling 
Carbon monoxide has been reported as an anti-apoptotic agent in 
endothelial cells [129], pulmonary cells [130] and muscle [131]. 
Regarding the anti-apoptotic capacity of CO in the brain, it has been 
described in neurons and astrocytes [125], [127], [132]–[136] (for 
further review [137]). Although the beneficial effects of CO and its 
capacity to bind to transition metals, the physiological targets of this 
molecule are not identified. However, it is known that CO-induced 
cytoprotection can be dependent on generation of low amounts of 
ROS, which function as signaling molecules [125], [138]–[141]. 
Likewise, these low concentrations of CO promote mitochondrial 
biogenesis [141], increase COX activity [132], [142], [143], improve 
oxidative metabolism [144] and induce mild mitochondrial 
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uncoupling that protects mitochondria from oxidative stress [145], 
[146] (further reading [147]–[149]) (Fig. 1.8). 
 
 
Figure 1.8 - The main described mechanisms of carbon monoxide on 
mitochondria: modulation of mitochondrial membrane permeabilization and 
cell death control; improvement of mitochondrial metabolism (modulation of 
cytochrome c oxidase activity and mitochondrial biogenesis), ROS generation 




6.2. Carbon monoxide and cell differentiation 
Although few data report CO as a factor involved in stem cell 
differentiation, several studies describe modulation of HO activity in 
different models of cell differentiation, such as T cells and 
mesenchymal stem cells [127], [150]–[157]. Endogenous CO was 
shown to stimulate differentiation of myeloid cells into functional 















proliferation and differentiation [159]. Recently, Suliman and 
colleagues showed that HO-1/CO system can modulate embryonic 
stem cell differentiation and maturation into functional cardiac cells, 
through enhancement of mitochondrial biogenesis [160]. 
 
 
6.3. CO and therapeutic application 
 
Accumulating evidence of beneficial CO effects and its potential 
therapeutic application led to the development of CO releasing 
molecules (CORMs), which can be clinically more relevant approach to 
administer CO. The use of CORMs avoid some of the limitations of 
CO gas inhalation: need of hospital environment and devices, risk of 
high levels of carboxyhemoglobin and tissue/organ unspecific deliver 
of CO [161]. 
In this study it was used CORM-A1 (carbon-monoxide releasing 
molecule A1), which is a boronocarbonate compound containing a 
carboxylic acid for delivering CO [162]. CORM-A1 releases CO in a 
temperature and pH dependent manner, presenting a half-life of 
approximately 21 minutes for transfer of CO to myoglobin in vitro at 
pH of 7,4 and 37ºC [126], [162] (Fig.1.9).  
 
 




7. AIMS AND SCOPE OF THE THESIS 
The main goal of this PhD thesis was to improve adult 
neurogenesis yield, using CO as modulator, and to disclose the 
associated cellular and biochemical pathways. To evaluate CO effect 
on adult neurogenesis, two strategies were adopted: 
(i) Cell lines are simpler models to study neuronal 
differentiation process. They are good models for studies requiring a 
more controlled setting and cell line models allow the assessment of 
the underlying cellular and molecular mechanisms. In this thesis SH-
SY5Y and NT2 cell lines were used due to their extensive 
representativeness for neuronal differentiation studies [48]–[51], 
[64]–[69], [163]. Nonetheless, they are tumour cells having mutagenic 
and oncogenic potential, being less representative of physiological 
conditions [48], [164], thus hMVbcl-xL cell line was also studied. 
Although hMVbcl-xL cells are derived from midbrain tissue, 
presenting genuine characteristics of their regional identity, they 
have been genetically modified in order to be cultured in vitro by 
over-expressing the anti-apoptotic protein Bcl-XL [46], [47]. 
(ii) Hippocampal organotypic slice cultures (HOSCs) were used 
for validation of cell line generated data, because they represent a 
valuable model of adult neurogenesis, including neural stem cell 
proliferation, differentiation and migration within an intact neuronal 
















The hypothesis that CO may play a role in modulating neuronal 
differentiation is based on three main correlations (Fig. 1.10). First, 
ROS are signaling molecules in several CO-induced pathways [166] 
and are also key players in neuronal differentiation [167]. Secondly, 
mitochondrial biogenesis is an important process during cell 
differentiation [93], [102] and CO promotes mitochondrial biogenesis 
[132], [141]. Third, CO has been described as anti-proliferative 
molecule in different cell types, namely smooth muscle, cancer and T 
cells [124], which can be involved in the balance between 
differentiation and proliferation that occurs during neurogenesis. 
 
 
Figure 1.10 - The main hypothesis of this thesis. Correlation between adult 
neurogenesis process and carbon monoxide effect which were on the basis 






A schematic representation of the main questions of this thesis and 
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Cerebral ischemia and neurodegenerative diseases lead to 
impairment or death of neurons in the central nervous system. Stem 
cell based therapies are promising strategies currently under 
investigation. Carbon monoxide (CO) is an endogenous product of 
heme degradation by heme oxygenase (HO) activity. Administration 
of CO at low concentrations produces several beneficial effects in 
distinct tissues, namely anti-apoptotic and anti-inflammatory. Herein 
the CO role on modulation of neuronal differentiation was assessed. 
Three different models with increasing complexity were used: human 
neuroblastoma SH-S5Y5 cell line, human teratocarcinoma NT2 cell 
line and organotypic hippocampal slice cultures (OHSC). Cell lines 
were differentiated into post-mitotic neurons by treatment with 
retinoic acid (RA) supplemented with CO-releasing molecule A1 
(CORM-A1). CORM-A1 positively modulated neuronal differentiation, 
since it increased final neuronal production and enhanced the 
expression of specific neuronal genes: Nestin, Tuj1 and MAP2. 
Furthermore, during neuronal differentiation process, there was an 
increase in proliferative cell number (ki67 mRNA expressing cells) 
and a decrease in cell death (lower propidium iodide (PI) uptake, 
limitation of caspase-3 activation and higher Bcl-2 expressing cells). 
CO supplementation did not increase the expression of RA receptors. 
In the case of SH-S5Y5 model, small amounts of reactive oxygen 
species (ROS) generation emerges as important signaling molecules 















during CO-promoted neuronal differentiation. CO’s improvement of 
neuronal differentiation yield was validated using OHSC as ex vivo 
model. CORM-A1 treatment of OHSC promoted higher levels of cells 
expressing the neuronal marker Tuj1. Still, CORM-A1 increased cell 
proliferation assessed by ki67 expression and also prevented cell 
death, which was followed by increased Bcl-2 expression, decreased 
levels of active caspase-3 and PI uptake. Likewise, ROS signaling 
emerged as key factors in CO’s increasing number of differentiated 
neurons in OHSC.In conclusion, CO’s increasing number of 
differentiated neurons is a novel biological role disclosed herein. CO 
improves neuronal yield due to its capacity to reduce cell death, 
promoting an increase in proliferative population. However, one 
cannot disregard a direct CO’s effect on specific cellular processes of 
neuronal differentiation. Further studies are needed to evaluate how 
CO can potentially modulate cell mechanisms involved in neuronal 
differentiation. In summary, CO appears as a promising therapeutic 
molecule to stimulate endogenous neurogenesis or to improve in 
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Adult neurogenesis, which consists of generation of neurons from 
neural stem/precursor cells, occurs in specific brain regions called 
neurogenic zones. These niches are mostly located in the 
subventricular zone (SVZ), on the border of the lateral ventricle and 
striatum, and the subgranular zone of the dentate gyrus (DG) in the 
hippocampus [1]. At least five steps appear to be involved in the 
neurogenesis process: (i) proliferation of stem/progenitor cells, (ii) 
migration of newborn neurons, (iii) neuronal differentiation and 
maturation, (iv) integration into neuronal circuits and (v) survival of 
cells [2]. 
Programmed cell death is an important developmental cell process 
that occurs during neural development: from early embryonic 
proliferation stages until adult stages [3]–[5]. In the central nervous 
system (CNS), the majority of neuronal apoptosis is caused by an 
intrinsic program independent of external cues [6]. About half of the 
cortical interneurons are eliminated from CNS during neurogenic 
development [3]. It is possible that the terminal division of the 
interneuron progenitors gives rise to a pair of cells that have different 
propensity to initiate apoptosis [3]. Actually, cell death of 
differentiating neurons during embryonic development has been 
intensively studied [3]–[5], whereas cell death affecting adult neural 
stem cells is much less characterized. Adult stem cell proliferation 
and cell death appear to be coupled in many systems to control cell 















number, patterning and lineages.  Indeed, in genetically modified 
mouse models, where executor or regulatory apoptotic genes 
(caspase-3, caspase-9, Bak, Bax, among others) are knock out, 
resulted in supernumerary neurons in the brain [4].  
Carbon monoxide (CO) is an endogenous product of heme 
degradation by heme oxygenase (HO), among with free iron and 
biliverdin, which is rapidly converted into the anti-oxidant bilirubin 
[7]. Administration of CO at low concentrations produces several 
beneficial effects in distinct tissues, such as anti-inflammatory, anti-
proliferative, vasodilator and anti-apoptotic [7], [8]. In CNS, the anti-
apoptotic capacity of CO has been described in neurons and 
astrocytes, using in vitro and in vivo models [8]–[13], for further 
review [14] . Many CO-induced effects are dependent on generation 
of small amounts of reactive oxygen species (ROS), which can signal 
different pathways [8], [15]–[18] and can promote tissue tolerance by 
stimulation of preconditioning [12], [19]–[21]. Although few data 
report CO as a factor involved in stem cell differentiation, several 
studies describe modulation of HO activity in different models of cell 
differentiation, such as T cells and mesenchymal stem cells [11], 
[22]–[29]. Recently endogenous CO was shown to stimulate 
differentiation of myeloid cells into functional macrophages [30] and 
CORM-A1 was used to modulate T-cell proliferation and 
differentiation [31]. The hypothesis that CO may play a role in 
modulating neuronal differentiation is based on two correlations. 
Chapter II 
 
First, ROS are signalling molecules in several CO-induced pathways 
[32] and are also key players in neuronal differentiation [33]. 
Secondly, mitochondrial biogenesis is an important process during 
cell differentiation [34], [35] and CO promotes mitochondrial 
biogenesis [9], [17]. 
Accumulating evidence of beneficial CO effects and its potential 
therapeutic application led to the development of CO releasing 
molecules, which can be clinically more relevant approach to 
administer CO. In this study it was used CORM-A1 (carbon-monoxide 
releasing molecule A1), which is a boronocarbonate compound 
containing a carboxylic acid for delivering CO [36]. CORM-A1 releases 
CO in a temperature and pH dependent manner, presenting a half-life 
of approximately 21 minutes for transfer of CO to myoglobin in vitro 
at pH of 7,4 and 37ºC [36], [37].  
The main purpose of the present study was to assess the potential 
role of CO in modulating neuronal differentiation. Three different in 
vitro models with increasing complexity were used: (i) human 
neuroblastoma SH-SY5Y cell line [38]–[40], (ii) human teratocarcinoma 
NT2 cell line [41] and (iii) organotypic hippocampal slice cultures 
(OHSC). Cell lines are simpler models to study the neuronal 
differentiation process, allowing the assessment of the involved 
cellular mechanisms. Thus cell lines are good models for studies 
requiring a more controlled setting. SH-SY5Y cells are derived from 
neural crest [38], [40] and represents a rapid and representative 















model for studying neuronal differentiation processes [39]. NT2 
lineage is derived from human testicular embryonic teratocarcinoma 
and differentiates into functional post-mitotic neurons, which express 
many neuronal markers [41] and produce a variety of 
neurotransmitter phenotypes [42]–[44]. Moreover, NT2-derived 
neurons can form functional synapses [45] have also been used in 
several transplantation studies in experimental animals [46], [47] and 
in human patients[48].  Both immortal cell lines provide unlimited 
supply of cells capable of proliferating in culture for long periods and 
of differentiating into several cell types, including post-mitotic 
neurons upon treatment with retinoic acid (RA)[38]–[41], [49]–[51]. RA 
is a derivative of vitamin A, which is essential for promoting normal 
patterning and neurogenesis during development. RA signalling 
pathway leading to neuronal differentiation is dependent on retinoic 
acid binding proteins (CRABP)-I and II, which in turn deliver RA into 
the nuclear RA receptors (RARs). Then RARs directly regulate the 
expression of specific RA-inducible genes and neuronal 
differentiation[49]–[51].  
Despite all previously described advantages of using NT2 and SH-
SY5Y cell lines, the human origin of both used cell lines is a clear 
advantage to study human neuronal processes and cell manipulation 
for potential therapy. Furthermore, these cell lines have similar 
characteristics of human cells expressing a number of specific 
proteins, contrary to primary cultures of rodent precursor cells. 
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Nonetheless, they are tumour cells having mutagenic and oncogenic 
potential, being less representative of physiological neuronal 
differentiation [38], [52]. Therefore, for data validation we also 
studied the effect of CO supplementation in OHSC, which represent a 
valuable model of adult neurogenesis, including neural stem cell 
proliferation, differentiation and migration within an intact neuronal 
circuitry [53]–[55].  
This study demonstrated that CO does increase the final yield of 
post-mitotic neurons in both human cell models of neuronal 
differentiation and improves neurogenesis in the ex vivo model of 
OHSC. In fact, during neuronal differentiation process, CO partially 
inhibits apoptosis in a ROS-dependent manner and simultaneously 
increases the number of proliferating precursor cells. Thus, a novel 
promising therapeutic role for CO can emerge: improvement of in 





















MATERIAL AND METHODS 
Materials  
All chemicals used were of analytical grade and were obtained from 
Sigma unless stated otherwise. The mass spectrometry derivatization 
reagents MTBSTFA (N-methyl-N- (tert - Butyldimethylsilyl) 
trifluoroacetamide), MSTFA (N-Methyl-N-(trimethylsilyl) 
trifluoroacetamide) and the t-BDMS-Cl (tert-butyldimethylchlorosilane) 
were purchased from Regis Technologies, Inc. (Morton Grove, IL, 
USA).  
Plastic tissue culture dishes were acquired from Sarstedt (Germany); 
foetal bovine serum (FBS), penicillin/streptomycin solution 
(Pen/Strep), and Dulbecco’s minimum essential medium (high 
glucose, L-glutamine and pyruvate) (DMEM-HG) were obtained from 
Invitrogen (United Kingdom); and BALB/c mice pups were purchased 
from Instituto Gulbenkian de Ciência (Oeiras, Portugal). 
 
NT2 human teratocarcinoma cell line 
Maintenance of undifferentiated cells 
Undifferentiated NT2 cells from American Type Culture Collection 
(ATCC) were grown in DMEM-HG supplemented with 10%(v/v) FBS and 
1%(v/v) Pen/Strep (growth medium). Cells were maintained in a 
humidified atmosphere of 5%(v/v) CO2 at 37ºC.  Undifferentiated cells 
per vial were grown in 75cm
2
 T-flasks and subcultured with fresh 
Chapter II 
 
growth medium whenever high cell confluence was achieved (about 
90-100% cell confluence). Cells were rinsed with phosphate-buffered 
saline (PBS) and then incubated with trypsin for 2 minutes at 37ºC for 
trypsinization and resuspended in growth medium in a 1:4 cell 
passage. Growth medium was changed every 2 to 3 days. 
 
Neuronal differentiation protocol 
Following trypsinization and resuspension in growth medium, cells 





Neuronal differentiation was induced 24 hours after plating 
undifferentiated cells to ensure settle and attachment to flask surface 
and attain appropriate density. The NT2 cell line neuronal 
differentiation was induced in DMEM-HG with 10%(v/v) FBS and 
1%(v/v) Pen/Strep, supplemented with 10µM all-trans RA 
(differentiation medium). CO effect was studied by using the same 
composition of differentiation medium supplemented with 25µM 
CORM-A1. Differentiation medium was replaced three times a week 
until reach 10 differentiation treatments (24 days). After neuronal 
differentiation and before neuronal enrichment, cells were collected 
for analysis. Protein from cell extracts was quantified using BCA 






















 differentiation treatment, cells were replated at lower 
density to disperse the dense multilayer cell culture and start 
neuronal enrichment. On the following day, the culture medium was 
exchanged with fresh growth medium supplemented with mitosis 
inhibitors: 1µM Cytosine Arabinoside, 10µM Floxuridine and 10µM 
Uridine for neuronal enrichment. Growth medium supplemented with 
mitosis inhibitors was replaced, twice a week, for 10 days, making a 
total of 3 to 4 treatments. On the 10
th
 day of neuronal enrichment, 
enriched culture was collected for different analysis. Protein from cell 
extracts proteins was quantified using BCA assay (Pierce, Illinois). The 
used protocol is schematically represented in Fig.2.1A. 
 
SH-SY5Y neuroblastoma cell line 
Maintenance of undifferentiated cells 
The SH-SY5Y cell line was cultured in DMEM/F-12 supplemented with 
10%(v/v) FBS and 2%(v/v) Pen/Strep (growth medium). Cells were 
maintained in a humidified atmosphere of 5%(v/v) CO2 at 37ºC. 
Undifferentiated cells were grown in 75cm
2
 T-flasks and subcultured 
with fresh growth medium whenever cell confluence achieved (about 
80-90% cell confluence). Cells were detached by trypsinization at 
room temperature (R.T.) and slight shaking and hitting to drain down 
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cells with trypsin and resuspended in growth medium in a 1:4 cell 
passage. Growth medium was changed twice a week. 
 
Neuronal differentiation protocol 
Following trypsinization and resuspension in growth medium, cells 
were plated on 75cm
2
 T-flasks in a 1:2 cell passage. Neuronal 
differentiation was induced 24 hours after plating undifferentiated 
cells to ensure settle and attachment to flask surface and attain 




Neuronal differentiation was induced with DMEM/F-12 medium, 
reduced serum to 1%(v/v) FBS, 2%(v/v) Pen/Strep and supplemented 
with 10µM of all-trans RA (differentiation medium). CO effect was 
studied by using the same composition of differentiation medium 





 days) of the 7 days of treatment. On the 7
th
 
day, cells were collected for analysis. Protein from cell extracts 
proteins was quantified using BCA assay (Pierce, Illinois). Whenever it 
is the case, neuronal differentiation of SH-SY5Y cells was 





 day of differentiation, cells were replated at lower density 
to disperse the cell culture for neuronal enrichment. On the following 















day, the culture medium was exchanged with fresh growth medium 
supplemented with mitosis inhibitors: 1µM Cytosine Arabinoside, 
10µM Floxuridine and 10µM Uridine for neuronal enrichment. Growth 
medium supplemented with mitosis inhibitors was replaced after 2 
days. On the 5
th
 day of neuronal enrichment, enriched cultures were 
collected for different analysis. The used protocol is schematically 
represented in Fig.2.1B. 
 
Organotypic Hippocampal Slice Cultures (OHSC) 
For mouse tissue collection, mice were rapidly decapitated with 
minimizing suffering procedures. The procedure was approved by the 
National Institutional Animal Care and Use Committee (Direção Geral 
de Alimentação e Veterinária with reference number 
0421/000/000/2013) and accordingly with relevant national and 
international guidelines. 
OHSC were prepared from eight days old BALB/c mice pups. Mice 
were decapitated and the brains were removed. The brain was cut 
along the midline and the hemispheres separated for the hippocampi 
to be exposed. The hippocampi were dissected out, cut in 350μm 
thick transverse slices on a McIlwain tissue chopper and transferred 
to a petri dish containing a balanced salt solution with 25mM 
glucose. The slices were separated under the stereomicroscope and 
placed in inserts with semipermeable membranes (Millipore, France), 
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six slices culture arranged in a circle per insert. The inserts were 
placed in 6-well culturing plates, each well containing culture medium 
(25% heart inactivated horse serum, 25% Hank’s balanced salt 
solution, 50% OptiMEM medium and 25mM glucose). The plates were 
maintained in a humidified atmosphere of 5%(v/v)% CO2 at 33ºC. 
Medium was changed twice a week throughout the growth period. 
Cultures were mature at 11 days in vitro (DIV)[54], [56]–[58]. After 
11DIV, the culture medium was exchanged by a differentiation 
medium (98% Neurobasal medium, 2% B-27 supplement and 1mM L-
glutamine) and slices were treated with 25μM CORM-A1 twice a 
week[57]–[60]. Whenever it is the case, OHSC was also supplemented 
with 0.5 or 5mM of N-acetyl-cysteine (NAC). To investigate effects on 
cell proliferation, cultures were fixed after 3 days of CORM-A1 
treatment (at 14 DIV, ki67 was used as a marker for cell 
proliferation). To study on neuronal differentiation, matured OHSC 
were maintained for 12 days longer (until 26 DIV) to investigate the 
expression of neuronal markers (Tuj1). The effect of CORM-A1 
treatments was assessed at the various time points by 
immunohistochemistry, cell counting and propidium iodide uptake 





























Figure 2.1 – Scheme of the different models for neuronal differentiation 
assessment. (A) Neuronal differentiation of NT2 cells was performed 
throughout 3 weeks, with medium exchanges three times a week in 
alternated days. After 24 days of differentiation (d24), the obtained mixed 
(undifferentiated and neuronal) cell population was treated with anti-mitotic 
compounds for neuronal enrichment during 10 days (d34). B) SH-SY5Y cells 
were induced to differentiate during 7 days (d7), subjected to a 
differentiation medium exchange at day 4. After 7 days of differentiation 
(d7), a mixed population of undifferentiated cells and post-mitotic neurons 
was obtained. In order to obtain an enriched neuronal population, cultures 
are treated with anti-mitotic compounds for 5 days (d12). C) After 11 days of 
in vitro culture, the differentiation medium is added to the OHSC (11 DIV). 
The medium is exchanged twice a week during 2 weeks. Then, fully mature 





Preparation of CORM-A1  
The solution of CORM-A1 was prepared in milli-Q water with a final 
concentration of 5mM. Then, the solution was filtrated using a 0,2µM 
filter and stored at -20ºC. CORM-A1 reconstituted and stored at -20ºC 
was compared with iCORM-A1 and CO gas saturated solutions (Fig.2, 
S1 Fig. and S2 Fig.) and no evidences of loss of CO due to storage 
were found. Thus, for each use, a pre-prepared aliquot was thawed 
and immediately used.  
 
Preparation of inactivated CORM-A1 
CO-depleted inactive form (iCORM-A1) was generated to be used as 
negative control by initially dissolving CORM-A1 in 0.1 M HCl and 
then bubbling pure N2 through the solution for 10 min in order to 
remove the residual CO gas [36]. The solution of iCORM-A1 was 
finally adjusted to pH 7.4.  Then, the solution was filtrated using a 
0,2µM filter and stored at -20ºC. For each use, an aliquot was thawed 
and immediately used.  
 
 
Preparation of CO Solutions 
Fresh stock solutions of CO gas were prepared each day and sealed 
carefully. PBS was saturated by bubbling 100% of CO gas for 30 min 
to produce 10e-3 M stock solution. The concentration of CO in 















solution was determined spectrophotometrically by measuring the 
conversion of deoxymyoglobin to carbon monoxymyoglobin as 
described previously [61]. 100% CO was purchased as compressed 
gas (Linde, Germany). 
 
Cell counting and viability 
Cell cultures were visualized using an inverted microscope with phase 
contrast (DM IRB, Leica, Germany). Total cell number was determined 
by counting cell nuclei using a Fuchs-Rosenthal hemacytometer, after 
digestion with 0,1M citric acid/1% Triton X-100 (wt/wt)/0,1% crystal 
violet (wt/v). 
After differentiation treatments cells were harvested and the 
assessment of cell viability was performed using 1µM PI (15 minutes 
at 37ºC). Data acquisition was obtained in FACSCalibur and Cell 
Quest Software (BD Biosciences, San Jose, CA, USA). Flow cytometry 
data was analyzed by FlowJo software version 10.1.  
 
PI uptake evaluation in OHSC  
A final concentration of 2μM PI was added to the medium 24 hours 
before starting the differentiation process of the OHSC[54], [60]. PI 
uptake on the whole culture was assessed by fluorescent microscopy, 




NT2 and SH-SY5Y cells were plated at a density of 2x10
6 
cells/well in 
24-well plates coated with Poly-D-lysine in 0,15M sodium borate 
buffer solution pH 8,4. Cells were fixed with 4%(v/v) PFA and 4%(w/v) 
sucrose solution (20 minutes at R.T.) and then permeabilized with 
0,3%(v/v) Triton X-100 solution (15 minutes at R.T.). Later, cells were 
incubated 2 hours at R.T. with primary antibody: Tuj1 (Sigma-Aldrich, 
T8660); MAP2 (Sigma-Aldrich, M1406); ki67 (Millipore, AB9260) or 
active caspase-3 (Cell Signaling, #9664), following incubation for 1 
hour at R.T. with secondary antibody: AlexaFluor 488 anti-mouse 
(A11001) or AlexaFluor 594 anti-rabbit (A11012). Primary and 
secondary antibodies were dilute in 1%(v/v) BSA and 0,1%(v/v) Triton 
X-100 solution. Cultures were mounted on Prolong mounting media 
(with DAPI - Invitrogen) and images were captured with Zeiss Axiovert 
40 CFL microscope. All solutions were prepared in PBS (1X). Washes 
with PBS (1X) solution were performed between each step. 
In a 6-well plate OHSC were washed with PBS and fixed with 4% (w/v) 
paraformaldehyde in PBS with 4% (w/v) sucrose for 30 minutes. After 
fixation, OHSC were washed and stored in PBS. The insert membrane, 
containing the cultures of interest, was cut and transferred to a 12-
well plate well containing Tris-buffered saline buffer with 0,1-0,3% 
Triton X-100 (TBS+TX-100) for cell permeabilization. Then slices were 
pre-incubated for 30 minutes at R.T. in 0,05M TBS containing 10% 
serum to block non-specific binding sites. Afterwards, cultures were 















incubated with primary antibody (Tuj1 (Sigma-Aldrich, T8660); MAP2 
(Sigma-Aldrich, M1406); ki67 (Millipore, AB9260); active caspase-3 
(Cell Signaling, #9664)) for 2 days at 4ºC, followed by incubation for 
2 hours at R.T. with secondary antibody (AlexaFluor 488 anti-mouse, 
A11001; AlexaFluor 594 anti-rabbit, A11012). Whole mount samples 
were transferred to high adherence microscope slides and the insert 
membrane was removed.  Slices were mounted using ProLong 
mounting (Invitrogen) medium with DAPI and visualized afterwards in 
a fluorescence microscpe (Leica). 
 
Immunoblotting 
Cell extracts were separated under reducing electrophoresis on a 
1mm of NuPAGE Novex Bis-Tris gel (Invitrogen) and transferred to a 
nitrocellulose membrane (HybondTMC extra, Amersham Biosciences). 
Tuj1, Actin and cleaved caspase-3 proteins were stained with α-Tuj1 
(Sigma-Aldrich, T8660), α-cleaved caspase-3 (Cell Signaling, #9664) 
and α-actin (Sigma-Aldrich, A4700) at 1/1000 dilution for 2h at room 
temperature. Blots were developed using the ECL (enhanced 
chemiluminescence) detection system after incubation with HRP-
labeled anti-mouse IgG anti- body (Amersham Biosciences 




Quantitative-Polymerase chain reaction (Q-PCR)  
For evaluation of gene expression, mRNA was extracted from NT2 
and SH-SY5Y cells using High Pure RNA isolation kit (Roche 
Diagnostics) and cDNA synthesis was performed using the 
Transcriptor High Fidelity cDNA synthesis kit (Roche Diagnostics). 
PCR was performed using specific forward and reverse primers 
designed for the Nestin gene (5′-CTGTGAGTGTCAGTGTCCCC-3′ and 
5′-CTCTAGAGGGCCAGGGACTT-3′), Tuj1 gene (5′-
GCAAGGTGCGTGAGGAGTAT-3′ and 5′-GTCTGACACCTTGGGTGAGG-
3′), MAP2 gene (5′-GGAGCTGAGTGGCTTGTCAT-3′ and 5′-
CTAGCTCCAGACAGACGCAG-3′), ki67 gene (5′-
GAAGTCCCTGAAGACCTGGC-3′ and 5′-GTCTGGCTGTGAAGCTCTGT-3′), 
Bcl2 gene (5’-TCATGTGTGTGGAGAGCGTC-3’ and 5’-
TCAGTCATCCACAGGGCGAT-3’), Bcl-XL gene (5’-
ACTCTTCCGGGATGGGGTAA-3’ and 5’-TTGTCTACGCTTTCCACGCA-
3’), CRABP1 gene (5’-CCAGGACGGGGATCAGTTCT-3’ and 5’-
CTAAACTCCTGCACTTGCGT-3’), CRABP2 gene (5’-
CTCAAAGTGCTGGGGGTGAA-3’ and 5’-TGATCTCCACTGCTGGCTTG-
3’), RARα gene (5’-CCTGGACATCCTGATCCTGC-3’ and 5’-
CATCATCCATCTCCAGGGGC-3’), RARβ gene (5’-
TGACAGCTGAGTTGGACGAT-3’ and 5’-AGCACTGGAATTCGTGGTGT-
3’), RARγ gene (5’-CTGTGCGAAATGACCGGAAC-3’ and 5’-
CTGCACTGGAGTTCGTGGTA-3’) and RPL22 gene (5’-
CACGAAGGAGGAGTGACTGG-3’ and 5’-TGTGGCACACCACTGACATT-















3’), respectively. Fast Start DNA Master Plus SYBR Green I (Roche 
Diagnostics) was used with the experimental run protocol: 
denaturation program was 95 °C for 10 minutes, followed by 45 
cycles of 95 °C for 10 seconds, 60°C for 10 seconds and 72 °C for 10 
seconds. 
 
Gas Chromatography-Mass Spectrometry (GC-MS) 
For analysis of 
13
C percent enrichment in intracellular 
neurotranmitters, cell extracts obtained from total mixed populations 
of NT2 and SH-SY5Y cell lines were lyophilized and resuspended in 
0.01M HCl followed by pH adjustment to pH<2 with HCl 6 M. Samples 
were dried under atmospheric air (50 °C), and metabolites were 
derivatised with MTBSTFA in the presence of 1% t-BDMS-Cl [62], [63]. 
The samples were analyzed on an Agilent 6890 gas chromatograph 
connected to an Agilent 5975B mass spectrometer (Agilent 
Technologies, Palo Alto, CA, USA). The parent ion (M) and atom 
percent excess for one 
13
C atom (M+1) values for glutamate and GABA 
were calculated from GC-MS data using MassHunter software supplied 
by Agilent (Agilent Technologies, Palo Alto, CA, USA) and correcting 
for the naturally abundant 
13
C by using non-enriched standards [64]. 




Measurement of ROS Generation 
ROS generation was followed by the conversion of 5μM 2’,7’-
dichlorofluorescein diacetate (H2DCFDA) (Invitrogen) to fluorescent 
2’,7’-dichlorofluorescein (DCF). While superoxide anion formation 
was quantified using 5μM MitoSOX Red mitochondrial superoxide 
indicator (Life Technologies, Scotland). After differentiation process, 
cells were incubated for 20 min with 5μM H2DCFDA or MitoSOX 
prepared in PBS. Cells were washed twice, and fluorescence was 
measured ( λex 485 nm/λem 530 nm and λex 510 nm/λem 580 nm, 
respectively) using a TECAN infinite F200 PRO spectrofluorimeter. 
ROS generation was measured at the end of neuroranl differentiation 
process 24 days for NT2 cells and 7 days for SH-SY5Y cells. For SH-
SY5Y cell ROS were also quantified 1h following RA treatment (with or 
without CORM-A1) for assessing CO-induced ROS generation and 
signaling. N-acetyl-cysteine (NAC) 5mM was added during all the 
neuronal differentiation (7 days for SH-SY5Y cell lines). ROS 
generation was calculated as an increase over base-line levels, 
determined for untreated cells (100%) and normalized by total cell 
count for each condition.  
 
Statistical analysis 
Data concerning cell culture were carried out at least in three 
independent culture preparations. For every immunocytochemistry 















and immunohistochemistry assay a representative image is showed. 
All values are mean ± SD (standard deviation), n≥3. Error bars, 
corresponding to standard deviation, are represented in the figures. 
Statistical comparisons between two groups were made with an 
independent two-tailed Student’s t-test. Between multiple groups, 
statistical comparisons were performed using one-way ANOVA single 
factor with replication and Bonferroni’s multiple comparisons test for 
confidence intervals and significance correction. For all the data, p-




CO increases the final neuronal differentiated cell population  
The effect of CO on modulation of neuronal differentiation was tested 
in both NT2 and SH-SY5Y cell lines. These cells were differentiated in 
the presence of RA supplemented with CORM-A1 (Fig.2.1A and B). Of 
note, CO cannot induce neuronal differentiation per se since NT2 and 
SH-SY5Y cells were not able to differentiate into neurons without RA. 
Actually, NT2 cells treated only with CORM-A1 did not differentiate 
and died following 7 days of procedure (data not shown). Thus, CO 
increased the RA-induced neuronal differentiation, but this 
gasotransmitter is not a differentiating factor. 
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After differentiation process and neuronal enrichment procedure, 
cells were harvested and their nuclei were counted. It was observed 
that RA treatment supplemented with CORM-A1 at 25μM yielded a 
duplication of the final number of NT2 post-mitotic neurons (Fig. 
2.2A) and a 6-fold increase on SH-SY5Y post-mitotic neuronal 
population when compared to RA treatment without supplementation 
(Fig. 2.2B). Immunocytochemistry analysis was performed in order to 
evaluate neuronal morphology and the expression of neuronal 
specific protein Tuj1 in post-mitotic NT2 (Fig. 2.2C) and SH-SY5Y 
neurons (Fig.2.2D). Neurons obtained from treatment with RA 
supplemented with CORM-A1 were comparable to neurons obtained 
from RA treatment only (Fig. 2.2C-D). Furthermore, neuronal 
functionality was assessed by quantification of two 
neurotransmitters, glutamate and GABA, in cell extracts at the end of 
neuronal differentiation process. For NT2 model, the levels of 
glutamate were similar in the presence or absence of CORM-A1 (Fig. 
2.2E), while GABA was too low for precise quantification in both 
treatments. In SH-SY5Y cells, the intracellular levels of GABA and 
glutamate were comparable (Fig. 2.2F). In conclusion CORM-A1 
increased neuronal yield production. Co-treatment with CORM-A1 did 
not cause (i) any cell morphology alteration, (ii) any change on the 
expression of neuronal specific protein Tuj1 nor (iii) any change on 
intracellular neuronal transmitters’ level. 


















Figure 2.2 – CORM-A1 increases final yield of enriched neurons. (A) 
Neuronal yield is calculated based on nuclei count per volume of NT2 derived 
post-mitotic neurons (neuron/mL) after 24 days of differentiation and 10 
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days of neuronal enrichment; (B) Nuclei count per volume of SH-SY5Y derived 
post-mitotic neurons (neuron/mL) after 7 days of differentiation and 5 days 
of neuronal enrichment (C) Characterization of NT2 derived post-mitotic 
neurons by immunocytochemistry (green staining: Tuj1; blue staining: DAPI; 
magnification 200x); (D) Characterization of SH-SY5Y derived post-mitotic 
neurons by immunocytochemistry (green staining: Tuj1; blue staining: DAPI; 
magnification 100x); (E,F) Characterization of neuronal functionality by 
neurotransmitter quantification (glutamate and GABA) in mixed cell 
populations of NT2 and SH-SY5Y cells after 24 and 7 days of differentiation, 




In order to validate that CORM-A1 effect is dependent on CO release, 
NT2 cells were also differentiated using CO gas supplementation via 
CO-saturated PBS solutions (Fig. 2.3A). CO gas also increased the 
final yield of post-mitotic neurons in a dose-dependent manner (Fig. 
2.3A). Thus, CORM-A1 improvement of final neuronal production is 
due to its CO molecule and not due to CORM-A1 chemical structure.  
 
 















Figure 2.3 – Effect of CO gas saturated solution supplementation on NT2 
cells neuronal differentiation. (A) Post-mitotic neurons total cell count after 
24 days of differentiation and 10 days of neuronal enrichment; (B) Total 
mixed population cell count after 24days of differentiation; (C) Tuj1 protein 
analysis in total mixed cell population after 24 days of differentiation 
(specific Tuj1 expression quantification normalized by Actin expression). 
 
 
CO increases total cellular population during differentiation 
process: precursor cells, early stage neurons and mature neurons 
The CO enhancement of neuronal production yield indicates that this 
gasotransmitter might modulate the differentiation process. CO’s 
modulation of neuronal differentiation process can be due to three 
main hypotheses: (i) increased cell proliferation, (ii) protection 
against cell death and/or (iii) by facilitating the neuronal 
differentiation per se. In order to clarify these hypotheses, the mixed 
cell populations (containing progenitor cells and post-mitotic 
neurons) were evaluated at the end of differentiation process and 
before neuronal enrichment. 
In the beginning of the differentiation process, the inoculated cell 
number was the same for RA treatment and RA treatment 
supplemented with CORM-A1 for both NT2 and SH-SY5Y cell lines. At 
day 24, the total number of cells in the mixed population of NT2 cells 
treated with CORM-A1 and RA was higher than only with RA 
supplementation (Fig.2.5A), whereas inactive CORM-A1 (iCORM-A1) 
rendered a lower total number of cells in the mixed population (Fig. 
2.4 A). The same effect was observed in the SH-SY5Y cells, whose cell 
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growth increase was higher than 50% (Fig. 2.4B) and CO’s effect was 
lost when cells were differentiated with iCORM-A1 as supplement 
(Fig. 2.4 C and D). Therefore, CO increased total cellular population 
(including precursor proliferating cells, early stage neurons and 
mature neurons) at the end of differentiation procedure. Moreover, 
CORM-A1 effect is due to the release CO gas and not to its chemical 
structure, since the cell population increase was not observed when 
inactive CORM-A1 was applied.  
 















Figure 2.4 – Effect of iCORM-A1 supplementation neuronal 
differentiation. (A) NT2 total mixed population cell count (total cell number 
after 24days of differentiation); (B) NT2 cells Tuj1 expression of total mixed 
cell population after 24 days of differentiation; (C) SH-SY5Y total mixed 
population cell count (cell concentration after 7 days of differentiation); (D) 
SH-SY5Y neuronal cell count (cell concentration after 7 days of differentiation 
followed by 5 days of anti-mitotic treatment); (E) mRNA expression 
quantification of specific neuronal differentiation markers (Nestin for 
neuronal precursors, Tuj1 for early differentiated neurons and MAP2 for 
mature neurons) for SH-SY5Y mixed cell population after 7 days of 
differentiation. 
 
For characterization of mixed cell population at the end of neuronal 
differentiation process, the expression of specific genes (Nestin, Tuj1 
and MAP2) was assessed by mRNA quantification using RT-Q-PCR. 
Neuronal precursor cells express Nestin, while Tuj1 is expressed in 
early stage of neuronal differentiation and MAP2 is expressed by 
mature neurons. Cells obtained from neuronal differentiation of NT2 
cells upon supplementation with CORM-A1 present some increased 
expression of Nestin, Tuj1 and MAP2 (Fig. 2.5C). In other hand, SH-
SY5Y presented higher levels of Nestin, Tuj1 and MAP2 mRNA, when 
cultured in the presence of CORM-A1 (Fig. 2.5D).  
In contrast, NT2 cell neuronal differentiation process supplemented 
with iCORM-A1 did not increase Tuj1 expression. Indeed, its levels 
were similar to the ones obtained from cells that were differentiated 
only in presence of RA (Fig. 2.5B). Accordingly, NT2 cells treated with 
CO gas saturated solutions presented the same effects already 
described for CORM-A1: increased mixed cell population with higher 
expression of Tuj1 per cell (Fig. 2.5B and C). Taking all together, we 
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can claim that CORM-A1 role on neuronal differentiation is due to CO 
gas that is released from CORM-A1. 
Moreover, the increased expression of specific marker of neuronal 
precursor cells (Nestin) indicates that population of neuronal-
committed proliferative cells is positively modulated by CORM-A1. At 
this point one can speculate that CORM-A1 increases the number of 
cells to be differentiated into neurons, expressing Tuj1 and MAP2 
proteins. Nevertheless, it cannot be excluded that CO can also 
modulate cell death and/or increasing number of differentiated 
neurons process per se. 
 
 
Figure 2.5 – CO increases total mixed cellular population during 
differentiation process: precursor cells, early stage neurons and mature 
neurons. Characterization of mixed cell population was assessed following 
neuronal differentiation and before neuronal enrichment. (A) Nuclei count of 
NT2 mixed population after 24 days of differentiation; (B) Nuclei count of SH-
SY5Y mixed population after 7 days of differentiation. mRNA expression of 
specific neuronal differentiation markers (Nestin for neuronal precursors, 















Tuj1 for early-differentiated neurons and MAP2 for mature neurons) was 




CORM-A1 does not increase the expression of retinoic acid 
receptors  
As showed above, CO improved the RA-induced neuronal 
differentiation. RA signalling pathway leading to neuronal 
differentiation is dependent on retinoic acid binding proteins 
(CRABP)-I and II, which in turn deliver RA into the nuclear RA 
receptors (RARs). Then RARs directly regulate the expression of 
specific RA-inducible genes and neuronal differentiation [49]–[51]. 
Once CO is not a differentiating factor per se, but a modulator of 
neuronal differentiation, CO effect in RA signaling pathway was 
assessed in both NT2 and SH-SY5Y cell lines (Fig.2.6). 
 
Figure 2.6 – CORM-A1 does not increase the expression of retinoic acid 
receptors in mixed cell population (after neuronal differentiation 
procedure). (A) mRNA expression of cellular and nuclear retinoic acid 
receptors were measured in NT2 mixed population after 24 days of 
differentiation; (B) Quantification of mRNA of cellular and nuclear retinoic 




CORM-A1 did not cause any significant difference in expression of 
RA’s receptors in total mixed population, after 24 days of 
differentiation of NT2 cells (Fig. 2.6A). On other hand, for SH-SY5Y 
total mixed population, there was a decrease in RAR α and CRABP1 
expression (Fig. 2.6B). Because mixed population obtained from SH-
SY5Y differentiation for 7 days is mainly composed of post-mitotic 
cells (Fig. 2.2 and 2.5), one can speculate that the diminished 
expression of RAR α and CRABP1 is due to the decreased need of this 
kind of receptors. In conclusion, improved number of differentiated 
neurons by CO is not due to a positive modulation of retinoic acid 
receptors in the cells. 
 
CO and cell proliferation 
CO’s effect on modulation of cell proliferation can be partially 
assessed by mRNA ki67 expression [65], which was quantified by RT-
Q-PCR in mixed cell populations of NT2 and SH-SY5Y cells (Fig. 2.7A 
and B). Concerning NT2 cell line (Fig.2.7A), ki67 mRNA quantification 
was done during differentiation process at two different time points. 
It was observed that CORM-A1 supplementation highly increased ki67 
mRNA expression at day 17, while at the end of differentiation 
process (day 24), the amount of ki67 expressing cells decreased 
significantly in the presence of CORM-A1. Thus, these data indicate 
that CO might increase the number of cells with activate cell cycle 















during the neuronal differentiation process. However this effect 
decreases by the end of neuronal differentiation procedure.  
 
 
Figure 2.7 – CORM-A1 promotes cell proliferation. (A) Ki67 mRNA 
expression was assessed in NT2 mixed cell population at two distinct time 
points, day 17 and day 24, during neuronal differentiation process; (B) 
quantification of ki67 mRNA expression in SH-SY5Y mixed population after 7 
days of differentiation. 
 
The levels of ki67 mRNA expression in SH-SY5Y cells (Fig.2.7B) were 
higher in the case of CORM-A1 supplementation at the end of 
differentiation process (day 7). Taking all together, these data 
suggest that CORM-A1 treatment enhanced proliferative cell 
population, although further experiments are needed to effectively 
assess cell proliferation. Both cell lines presented different patterns 
of ki67 expression at the end of differentiation process, which can be 
due to the intrinsic differences between cell models. Indeed, NT2 
cells yield a mixed population at day 24 that contains higher levels of 
Tuj1 and MAP2, both specific markers for neurons (Fig. 2.7C). While, 
SH-SY5Y cells have a shorter procedure of differentiation, which can 
be the reason for the relative high levels of ki67 and Nestin 
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expression, and low levels of Tuj1 at day 7 (Fig. 2.5D). Hence, CORM-
A1 supplementation increased the proliferative population of both 
cell models during differentiation process.  
 
CO prevents cell death during neuronal differentiation 
Still, one cannot disregard that CO is a well-accepted anti-apoptotic 
molecule in several distinct tissues [7]–[9], [12], [32], [66]. Based on 
the work developed by Boya and colleagues, proliferation and cell 
death appear to be coupled in many systems, in particular during cell 
differentiation for controlling cell number, patterning and lineages 
[4]. Taking these facts into account, one can speculate that the 
CORM-A1 increases mixed cell population and final neuronal 
population by also inhibiting cell death in a ROS dependent manner 
via a preconditioning effect. 
To disclose the anti-apoptotic effect of CO during neuronal 
differentiation, cellular viability of NT2 and SH-SY5Y cell lines were 
analyzed by flow cytometry using propidium iodide (PI) at the last day 
of differentiation (day 24 and 7, respectively)  (Fig.2.8A and B). Cells 
treated with CORM-A1 presented slightly but significant less 
incorporation of PI, meaning that there was less cell death in culture 
at the end of differentiation process for both cell models.  
Furthermore, the expression of the anti-apoptotic gene Bcl-2 was 
quantified by RT-Q-PCR (Fig.2.8C and D). CORM-A1 increases Bcl-2 















mRNA expression during the differentiation process (day 17) in NT2 
cells (Fig. 2.8C). These data directly correlate with the results for ki67 
expression presented in the previous section (Fig.2.7A). Therefore it 
seems that because CORM-A1 prevents cell death by increasing the 
expression of anti-apoptotic Bcl-2, there is a robust cell proliferation 
process ongoing, which is reflected by the increased levels of ki67. 
On the other hand, at day 24, NT2 cells express as much Bcl-2 with or 
without CORM-A1 supplementation (Fig.2.8C). Also, this can be 
correlated with ki67 mRNA amount since the levels of proliferation is 
lower in this point of the process (Fig.2.7A). CORM-A1 treated SH-
SY5Y cells displayed an increased level of Bcl-2 expression in the last 
day of differentiation (Fig. 2.8D). Once more, this correlates with the 
increased ki67 mRNA expression at the same time point (Fig.2.7B).  
For further investigate cell death modulation by CORM-A1, 
expression of the pro-apoptotic gene Bax and activation of caspase-3 
were also assessed. In the case of NT2 cell line, the total mixed 
population at day 24 of differentiation presented lower levels of Bax 
mRNA expression. Bax is a pro-apoptotic protein that interacts with 
BCL-2 family leading to cytochrome c release from mitochondria, and 
posterior initiation of caspase cascade. Increased levels of Bcl-2 
expression and decreased Bax expression are corroborated by the 
lower amount of cleaved and activated caspase-3 protein present in 
NT2 cell extract after 24 days of differentiation (Fig. 2.8G). In SH-
SY5Y cell model, despite the increased level of Bcl-2 mRNA 
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expression in the presence of CORM-A1, non-significant difference in 
Bax mRNA expression was found due to CORM-A1 treatment after 7 
days of differentiation process (Fig. 2.8F). Also, a decrease on 
caspase-3 activation was found in SH-SY5Y cells (Fig.2.8H).  
Taking all together, it seems that CORM-A1 improved neuronal yield 
by limiting cell death during neuronal differentiation process. Thus, 
higher amounts of post-mitotic generated neurons are achieved in 
the presence of CORM-A1.  
 
















Figure 2.8 – CORM-A1 prevents cell death in mixed cell population 
(following neuronal differentiation procedure). (A) NT2 PI incorporation 
evaluation after 24 days of differentiation; (B) SH-SY5Y PI incorporation 
evaluation after 7 days of differentiation; (C) NT2 mixed population’s Bcl-2 
expression at two distinct time points, day 17 and day 24, during neuronal 
differentiation process; (D) SH-SY5Y mixed population’s Bcl-2 expression 
after 7 days of differentiation; (E) NT2 mixed population’s Bax expression 
after 24 days of differentiation; (F) SH-SY5Y mixed population’s Bax 
expression after 7 days of differentiation; (G) cleaved caspase-3 protein 
quantification by western blot analysis of cell extracts obtained after 24 days 
of NT2 neuronal differentiation; (H)  cleaved caspase-3 protein quantification 
by western blot analysis of cell extracts obtained after 7 days of SH-SY5Y 
neuronal differentiation.  
 
 
Reactive oxygen species role in CORM-A1 modulation of neuronal 
differentiation  
Small amounts of CO stimulate endogenous mechanisms of cellular 
defense and maintenance of tissue homeostasis in a ROS dependent 
manner [12], [15], [19]–[21], [32]. Furthermore, ROS signaling also 
modulates neuronal differentiation. Thus, ROS generation was 
quantified in mixed cell populations following neuronal 
differentiation process (Fig. 2.9). For NT2 cell line, no significant 
difference was observed in the levels of ROS generation (Fig. 2.9A). In 
contrast, for SH-SY5Y cells there was an increase on ROS levels in the 
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presence of CO treatment. At day 1 of neuronal differentiation 





















Figure 2.9 – Role of reactive oxygen species (ROS) in CORM-A1 
modulation of neuronal differentiation. (A) Quantification of intracellular 
ROS in NT2 mixed cell populations after 24 days of neuronal differentiation 
(values normalized by total cell count); (B) Intracellular ROS quantification in 
SH-SY5Y mixed population 1h after treatment with RA 10μM ± CORM-A1 
25μM and after 7 days of differentiation (values normalized by total cell 
count); (C) Phase contrast images of SH-SY5Y cells after 7 days of 
differentiation under different conditions (including N-acetylcysteine 
treatment); (D) Quantification of cell number and protein levels of SH-SY5Y 
cells after 7 days of differentiation under different conditions. 
 
These data are in accordance with the fact that CO generates ROS as 
signaling molecules at short periods after treatment [8], [12], [15]. 
Furthermore, at the end of neuronal differentiation process, CO-
treated SH-SY5Y cells presented higher levels of ROS, compared to 
the levels of cell population treated only with RA, which suggests an 
increase on cellular oxidative state in the presence of ROS (Fig. 2.9B). 
Moreover, when SH-SY5Y differentiation procedure was done in the 
presence of the anti-oxidant N-acetyl-cysteine (NAC), CORM-A1 
positive modulation (increased yield) of neuronal differentiation is 
lost (Fig. 2.9C). Indeed, total amount of cell population at day 7 of 
neuronal differentiation procedure was lower in the presence of NAC 
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compared to RA and CORM-A1 treatment, cell population was 
quantified by cell counting and total protein amounts (Fig. 2.9D). 
Thus, CO modulation of neuronal differentiation is a ROS dependent 
process, at least for SH-SY5Y cell model.  
 
In vivo-like validation of CO modulation of neuronal 
differentiation 
In order to validate the in vitro data (NT2 and SH-SY5Y cell lines), 
CORM-A1 modulation of neuronal differentiation was also assessed in 
OHSC. This is an advantageous ex vivo model for assessing cell 
proliferation, differentiation and migration in a tissue context, since 
it mimics the in vivo cerebral tissue structure [53]–[55]. Continuous 
formation of new neurons can be evaluated using this ex vivo model 
of adult neurogenesis, which occurs, particularly in both Subgranular 
region of the Dentate Gyrus and in Cornu Ammonis region 1 [1], [55], 
[67]. Cultures were mature at 11 days in vitro (DIV) [54], [56]–[58]. 
After that, the culture medium was exchanged by a differentiation 
medium and slices were treated with 25μM CORM-A1 twice a week 
[57]–[60]. To investigate effects on cell proliferation, cultures were 
fixed after 3 days of CORM-A1 treatment (at 14 DIV, ki67 was used as 
a marker for cell proliferation). To study neuronal differentiation, 
matured OHSC were maintained for 12 days longer (until 26 DIV) to 
investigate the expression of neuronal markers (Tuj1) (Fig.2.1C). 















In OHSC, no difference in cell morphology was found in the slices 
supplemented or not with CORM-A1. CORM-A1 treatment increased 
Tuj1 expression following the differentiation process at 18DIV (Fig. 
2.10A).  Interestingly at 26DIV it is visible a shrinkage in the control 
hippocampal slices that is abolished in the case of CORM-A1 
supplemented cultures (Fig.2.10B), indicating a cytoprotective effect 
of CORM-A1. Furthermore, in OHSC expression of ki67 was assessed 
by immunohistochemistry for following proliferative cell fate. It was 
observed that CORM-A1 promoted increased expression of ki67 
among whole hippocampal slice (Fig. 2.10D), in particular in dentate 
gyrus (Fig. 2.10C), indicating an improvement on proliferative cell 
population by CO. In conclusion, CORM-A1 stimulates increasing 
number of differentiated neurons in OHSC without causing any 
morphological alteration in hippocampal tissue, consolidating the 






















Figure 2.10 – Validation of CORM-A1 role in neuronal differentiation in 
ex-vivo model of OHSC. (A)OHSC immunohistochemistry at 26 DIV (green 
staining: Tuj1; blue staining: DAPI; magnification 50x); (B) phase contrast 
images during neuronal differentiation process (magnification 40x); (C) OHSC 
immunohistochemistry at 14 DIV (red staining: ki67; blue staining: 
Hoechst33342; magnification 50x); (D) Proliferative cells (ki67 positive cells) 
per slice. Ratio calculated taking in account the area positively stained for 
ki67 and Hoechst33342; (E) OHSC PI uptake (red staining) at 26 DIV 
(magnification 50x); (F) PI uptake per slice – count of the positively marked 
cells in each slice; (G) OHSC Active caspase-3 and Bcl-2 expression at two 
distinct time points, 18 DIV and 26 DIV, during neuronal differentiation 
process (red staining: active caspase-3; blue staining: Hoescht33342; green 
staining: Bcl2) (magnification 40x); Area per slice. Ratio calculated taking in 
account the area positively stained for active caspase-3 and Bcl2 at two 
distinct time points, 18 DIV and 26 DIV, during neuronal differentiation 
process; (H) Immunohistochemistry quantification of active caspase-3 
positive cells in HOSC after 26DIV, treated with N-acetyl-cysteine and CORM-
A1 during neuronal differentiation process.  
 
For assessing cell death in this model, PI uptake was measured in 
OHSC after 26 DIV accordingly with Noraberg [60] and it was 
observed that CORM-A1 supplementation prevented the uptake of 
this dye in the internal part of the slice (Fig. 2.10E-F). Concerning 
apoptosis assessment, it was observed by immunohistochemistry, an 
increase in Bcl-2 expression in slices treated with CORM-A1, both in 
early (18 DIV) and late (26 DIV) differentiation stages. Likewise, the 
occurrence of cleaved and active caspase3 was lower in CORM-A1 
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treated slices at late differentiation stage (Fig. 2.10G). Moreover, 
whenever HOSC differentiation procedure was done in the presence 
of the anti-oxidant NAC, CORM-A1 modulation of cell death (assessed 
by decreased active caspase 3 positive cells) during neuronal 
differentiation was lost (Fig. 2.10H). Thus, CO inhibition of cell death 
and consequently its modulation of neuronal differentiation is a ROS 
dependent process in HOSC model. 
The data obtained in OHSC validate CO’s increasing number of 
differentiated neurons in a more physiological model. Furthermore, 
these results reinforce the hypothesis that CO increases number of 
differentiated neurons by (i) limiting apoptosis in a ROS signaling 
dependent manner and by (ii) enhancing cell proliferation. 
 
DISCUSSION  
The increasing prevalence of aging related diseases, such as 
neurodegenerative diseases and ischemic stroke, boosts the 
investigation of stem cell based therapies. Better understanding the 
molecular mechanisms underlying neuronal differentiation opens new 
windows for potential replacement therapies against neuronal 
impairment or death in the CNS. Regarding this, our aim was to study 
whether low doses of CO can improve neuronal production yields in 
three models with different complexity levels: human neuroblastoma 















SH-SY5Y cell line, human teratocarcinoma NT2 cell line and mice 
organotypic hippocampal slice culture (OHSC). SH-SY5Y and NT2 cell 
lines are derived from neural crest and embryonic carcinoma cells, 
thus the stem cell characteristics are preserved. RA treatment 
stimulates neuronal differentiation, giving rise to neurons expressing 
neuronal markers [43], neurotransmitters [42], [44] and also able to 
form synapsis [47], [48]. However, one cannot disregard the fact that 
they also maintain some mutagenic and oncogenic potential [38], 
[52]. These issues can reduce the physiological representativeness of 
these cell line models concerning neuronal differentiation. Therefore 
CO modulatory effect was also validated in OHSC, which represents a 
more physiological model for studying adult neurogenesis, where its 
neuroanatomy and cell-to-cell interactions are partially preserved. In 
OHSC model, neurogenesis is stimulated by addition of growth 
factors [53]–[55]. In all studied models, CORM-A1 supplementation 
during neuronal differentiation procedures yielded higher levels of 
neuronal cell population and preserved tissue structure and 
homeostasis in the particular case of HOSC. 
It is increasingly accepted that CO acts in a ROS-dependent manner; 
activating endogenous mechanisms of defense and maintaining 
tissue homeostasis, either via a rapid boost of CO (such as the use of 
CO saturated solutions) or slower administration of CO (for instance 
CORM-A1 presenting a half-life of 21 minutes) [8], [15], [16], [18], 
[68]. Actually, there are several examples that CO acts by activation 
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of a preconditioning state via ROS signaling [12], [19]–[21]. 
Furthermore, CO is intimately related to cell metabolism modulation 
[9], [69], which is also a sort of conditioning of cells to a oxidative 
metabolic profile, which is tightly connected to cell differentiation 
process. Thus, in the tested models, only two CORM-A1 treatments 
per week (amongst with RA or growth factors supplementation) can 
in fact change cell fate and promote increased number of 
differentiated neurons by boosting cell survival that, in turn, promote 
the continuous improvement of neuronal differentiation yield. One 
cannot disregard that different expositions of CO could change its 
biological effect. Indeed, it can be speculated that continuous CO 
treatment, even at low concentrations, could become cytotoxic. 
Further studies are necessary to clarify this issue. 
Furthermore, ROS generation appear to be key signaling factors in 
CO-induced neuronal differentiation in SH-SY5Y cell line and in HOSC 
model. Increased levels of ROS were found in the presence of CORM-
A1. Most importantly, the use of the anti-oxidant molecule (N-acetyl-
cysteine) reverted the CO-induced prevention of cell death and 
improvement on differentiated neurons number.  
There are three hypotheses for the mechanisms underlying CO-
induced improvement of neuronal yield: (i) increased proliferative cell 
population, (ii) protection against cell death and/or (iii) direct 
facilitation of neuronal differentiation process. Our data indicate that 
CO increase proliferative cell population; nevertheless there is a great 















amount of literature demonstrating that CO has an anti-proliferative 
role. In the late 90’s Morita and colleagues found that CO had the 
capacity to decrease proliferation of vascular smooth muscle cells 
[70]. Since then, several studies pointed out the anti-proliferative 
ability of CO in different models: airway smooth muscle, pancreatic 
cancer cells, breast cancer cells and human umbilical vein endothelial 
cells [71]–[74]. Furthermore, Chen and colleagues were the first 
correlating the well-established anti-apoptotic capacity [8], [9], [12], 
[14], [21], [37] of HO-1/CO pathway with the increased proliferation 
of olfactory receptor neurons [75]. Also, it is known that cellular 
proliferation and programmed cell death are directly related with 
neuronal differentiation from early embryonic proliferating stages 
until late adult stages [3], [4]. The incidence and role of cell death in 
the different stages are yet not well understood. For instance, death 
of neuronal cells during development is much better characterized 
than the cell death occurring during adult neurogenesis. 
Furthermore, a fine-tuning of neuronal population is dependent on 
the balance between proliferation/differentiation and cell death [4], 
[76]–[79]. Thus, we have shown the importance of cell death 
modulation during adult neuronal differentiation.
 
Our data 
demonstrate that CO improvement of neuronal differentiation yield is 
clearly related to the control of cell death in a ROS signaling 
dependent manner. CORM-A1 treatment increased cell viability in the 
three tested models. CORM-A1 increased the expression of anti-
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apoptotic gene Bcl2, while limited caspase-3 activation. In the 
particular case of NT2 cells, CORM-A1 decreased the expression of 
pro-apoptotic gene Bax. Because there are strong evidences showing 
CO as anti-proliferative factor and our data are apparently 
controversial since CO increased proliferative cell population; one can 
speculate that this increase might be a consequence of a 
cytoprotective role of CO. Indeed by limiting cell death, CO would 
increase the amount of proliferating cells, which in turn generates 
more neuronal precursors and mature neurons, as it was observed in 
NT2 and SH-SY5Y models.
 
CO emerges as a promising therapeutic molecule that increases the 
number of differentiated neurons by preventing cell death during the 
proliferation of stem/progenitor cells.  Although the apparent 
increase on proliferating cell population might be due to the anti-
apoptotic capacity of CO, the hypothesis of CO-improved proliferative 
capacity cannot be excluded since proliferation was not deeply 
studied. Also, one cannot disregard that CO can also facilitate 
neuronal differentiation per se, by modulating cellular processes 
involved in neurogenesis. Nevertheless, it can be excluded any CO’s 
involvement on the increased expression of retinoic acid receptors. 
Further studies are needed to clarify CO mode of action in stem cells 
differentiation, namely through cell metabolic adaptations, during 
neuronal differentiation and maturation. Migration of newborn 















neurons, integration into neuronal circuits and subsequent cell 
survival should be addressed using organotypic brain slice cultures.  
Finally, the novelty of this work consists in establishing CO as a 
promising cytoprotective molecule for neuronal differentiation 
processes. Potentially two scenarios can be envisaged for the use of 
CO: (i) improving in vitro neuronal production for cell therapies, such 
as transplantation or (ii) modulation of endogenous neurogenesis via, 
for instance, systemic effect of CO or direct perfusion through blood-
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Exploratory studies using human fetal tissue have suggested that 
intrastriatal transplantation of dopaminergic neurons may become an 
effective treatment for patients with Parkinson’s disease (PD). 
However, the use of human fetal tissue is compromised by ethical, 
regulatory and practical concerns. Human stem cells constitute an 
alternative source of cells for transplantation in PD patients. 
Nevertheless, efficient protocols for controlled dopaminergic 
differentiation need to be developed.  
Short-term low-level carbon monoxide (CO) exposure has been shown 
to affect cell signaling in several tissues, resulting in both 
cytoprotection and anti-inflammation. The present study investigated 
the role of CO on dopaminergic differentiation of human neural stem 
cells (NSCs). In addition, a new system for CO production and delivery 
was used, based on decarbonylation reaction of 
methyldiphenylsilacarboxylic acid, a novel CO-releasing molecule. 
Short-term cell exposure to 25 parts per million (ppm) CO at days 0 
and 4 significantly increased the relative content of β-tubulin III 
immature neurons and tyrosine hydroxylase (TH) expressing 
catecholaminergic neurons, as assessed 6 days after differentiation. 
Also the number of microtubule associated protein 2 (MAP2) mature 
neurons had increased significantly. Moreover, the content of 
apoptotic cells (active Caspase 3 positive cells) was reduced, whereas 
the expression of a cell proliferation marker (Ki67) was left 
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unchanged. Increased VEGF in cultures exposed to CO may suggest a 
mechanism involving mitochondrial alterations and metabolic 
modulation. In conclusion, the present procedure using controlled, 
short-term CO exposure allows efficient dopaminergic differentiation 
of human NSCs at low cost and may as such contribute to the future 
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Parkinson’s disease (PD) is a neurodegenerative disorder 
affecting more than six million people worldwide [1]. The disease is 
associated with a progressive loss of midbrain dopaminergic neurons 
and subsequent depletion of striatal dopamine. Cardinal symptoms 
include bradykinesia, rigidity, tremor and postural instability, but 
non-motor symptoms also occur, such as loss of sense of smell, 
constipation and sleep disturbances [2].  
Several explorative clinical studies using human fetal ventral 
mesencephalic tissue have indicated that intrastriatal transplantation 
may become a future treatment for PD [3]–[8]. However, the use of 
human fetal tissue is hampered by ethical concerns, suboptimal 
survival of grafted dopaminergic neurons, development of 
postgrafting dyskinesias in some patients, and the complex logistics 
related to collection and storage of the donor tissue [3], [7], [9]–[13].  
Pre-differentiated induced pluripotent stem cells, embryonic stem 
cells and neural stem cells (NSCs) represent potential alternative 
sources of cells for cell replacement therapy in PD. NSCs are self-
renewable multipotent cells that can be isolated from the developing 
and mature nervous system. Such cells may have significant 
advantages compared to human fetal tissue as they can be 
propagated to almost unlimited numbers of relatively homogenous 
cells in vitro and can be frozen without significant loss of viability 
[14], [15]. Nevertheless, efficient, simple and cost-effective protocols 
















for controlled generation of functional dopaminergic neurons are still 
not available.  
Carbon monoxide (CO) is an endogenous product of heme 
degradation, a reaction catalyzed by the enzyme heme oxygenase 
(HO) [16]. This gasotransmitter shows several beneficial biological 
activities and has been the target of extensive studies related to 
cardiovascular diseases, inflammatory disorders and organ 
transplantation [17]. The great potential of CO in biomedical 
applications has prompted development of several delivery strategies 
of CO for therapeutic or research purposes. Gas inhalation is the 
most simple strategy and has been greatly used in pre-clinical in vivo 
experiments [18]–[20]. Cell cultures can also be exposed to CO in gas 
chambers as described for neurons [21] and macrophages [22]. 
Another possible strategy for in vitro application of CO gas is the use 
of CO-saturated solutions [23], [24]. Nevertheless, for all these 
approaches CO gas bottles are handled with the potential risk of 
leaking the odorless and highly toxic gas. Furthermore, gas 
inhalation is not the most appropriate method for CO administration 
in a clinical context, since it promotes increased carboxyhaemoglobin 
levels, as well as CO delivery occurs to both healthy and diseased 
tissues. Therefore, CO-releasing molecules (CORMs) have been 
developed for providing controlled CO delivery [25]. The most 
studied non-metal based CORM is boranocarbonate [H3BCO2]Na2 
(CORM-A1), which has been shown to modulate cytoprotection, 
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hormesis and inflammation in several studies [26]–[28]. There are 
also many metal-based compounds studied in biological systems, and 
the most explored is the water-insoluble dimer [Ru(CO)3Cl2]2 (CORM-2) 
and its water soluble derivative Ru(CO)3Cl(κ2-H2NCH2CO2) (CORM-3). 
CORM-2 and CORM-3 have been tested in pre-clinical studies of 
cardioprotection [29], [30], inflammation [31]–[33], neuroprotection 
[34], transplantation [35] and pain [36].  
In the CNS, the CO/HO axis is a key player in processes 
involved in cytoprotection, vasomodulation, neuroinflammation, 
neural cell death, metabolism and cellular redox responses [37]. CO 
was first recognized as a neurotransmitter by Verma and colleagues 
in 1993 [38], and their work led to extensive research on CO and HO 
in the nervous system. Interestingly, both HO activation or induction 
and exogenous administration of CO were reported to stimulate 
neuroprotection and maintenance of tissue homeostasis in response 
to various pathophysiological conditions; including cerebral ischemia 
[19], [39]–[41], cerebrovasodilation [27], [42], [43], 
neuroinflammatory [20], [44], [45] and neurodegenerative diseases 
[46]–[48].  
The CO-induced pathways and putative targets are a matter of 
debate. Nevertheless, it is well accepted that CO activates soluble 
guanylyl cyclase and nitric oxide synthase, increasing the cGMP and 
nitric oxide (NO) levels respectively, whose best described effects are 
modulation of vasodilation [49]. In neurons, CO-induced cGMP 
















production is involved in protection against cell death [21], [50].  
In the present study two major novelties are approached. 
Firstly, it is assessed the role and the molecular mechanisms of CO 
on modulation of dopaminergic differentiation of human NSCs. 
Secondly, a new strategy for delivering CO gas is tested. In this new 
system, CO is generated by a decarbonylation reaction using the new 
CORM methyldiphenylsilacarboxylic acid (MePh2SiCO2H), along with 
the non-transition-metal activator potassium fluoride and dimethyl 
sulfoxide [51]. This strategy avoids the use of CO gas bottles, thus 
being safer and more cost-effective than previously described 
methods.  
 
MATERIAL AND METHODS 
Carbon monoxide releasing molecules (CORMs) 
Crystalline silacarboxylic acid was synthesized from the 
corresponding chlorosilane via reduction with metallic lithium, and 
allowed it to react with CO2 [51]. By mixing 
methyldiphenylsilacarboxylic acid (MePh2SiCO2H) with the non-
transition-metal activator potassium fluoride (KF; Sigma) and the 
solvent dimethyl sulfoxide (DMSO; Sigma) a decarbonylation reaction 
results in CO-release (Fig. 3.1A) [51]. For the present study, a 
plexiglass chamber was developed (Fig. 3.1B). The amount of solids 
required to achieve a predefined level of CO (12,5-100 ppm) were 
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placed in a glass vial (Supelco) and transferred to the exposure 
chamber together with the culture plates/flasks and a CO monitor 
(Dräger). The chamber was placed at 36 ºC, 5% CO2 and 95% 
humidified air. To start CO release, DMSO was lead through a 
separator in the wall of the chamber and into the vial with 
silacarboxylic acid/KF. A ventilator homogenized the concentration of 
gas in the closed atmosphere (Fig. 3.1B). The CO concentration was 
measured throughout all experiments (Fig. 3.2).  
 
Culturing and passaging of NSCs 
Two human ventral mesencephalic (VM) stem cell lines generated in 
previous studies were used (hVMbclXL). In brief, VM cells were derived 
from a 10-week-old foetus and immortalized using a retroviral vector 
coding for v-myc (LTR-vmyc-SV40p-Neo-LTR), creating a multipotent 
cell line (hVM1) [52]. The hVM1 cells were genetically modified (MLV-
based retroviral vector) to over-express the anti-apoptotic gene BclXL 
(LTR-Bcl-XL-IRES-rhGFP-LTR), essentially as described by Liste et al. 
[53].  
Cells were propagated in poly L-lysine (PLL/10 µg/ml; Sigma)-coated 
culture flasks containing HNSC100 medium (DMEM/F12 w. Glutamax 
(Gibco), 2% (v/v) 30% glucose (Sigma), 0.5% (v/v) 1 M Hepes (Gibco), 
2.5% (v/v) AlbuMAX-I (Gibco), 1% (v/v) N2 supplement (Gibco), 1% 
(v/v) NEAA (Sigma) and 1% penicillin/streptomycin (Gibco)) 
















supplemented with 20 ng/ml epidermal growth factor (EGF, R&D 
Systems) and 20 ng/ml basic fibroblast growth factor (bFGF, R&D 
Systems) at 36 °C, 5% CO2/95% humidified air. Medium was changed 
every third day, and cells passaged at 80% confluence.  
 
Neuronal differentiation protocols 
NSCs were passaged and plated into PLL-coated 24-/96-well trays or 
T75 culture flasks (Nunc, Sigma) with HNSC100 medium. hVMbclXL 
cells were exposed to CO for 30 min. Untreated cultures served as 
controls. hVMbclXL cultures received CO treatment at day 0 followed 
by differentiation for 1, 6 and 10 days or were exposed to CO at days 
0 and 4 and differentiated until day 6 or 10 (Fig. 3.1C).  
 
Fixation and immunocytochemistry 
Monolayer cultures were fixed (20 min) in 4% 
paraformaldehyde/0.15M phosphate buffer. For 
immunocytochemistry cultures were washed in 0.05M tris-buffered 
saline (TBS) containing 0.1% triton X-100 (Sigma) and pre-incubated 
(30 min) in TBS/10% donkey or sheep serum (Gibco). Primary 
antibodies (24 hrs; 4 °C) were diluted in TBS/10% donkey or sheep 
serum: Tyrosine hydroxylase (TH; polyclonal rabbit; Chemicon) 
1:600; β-tubulin III (β-tubIII; monoclonal mouse; Sigma) 1:2000; 
human nuclei (HN; monoclonal mouse; Chemicon) 1:500; microtubule 
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associated protein 2ab (MAP2; monoclonal mouse; Sigma) 1:2000; 
Ki67 (monoclonal mouse; BD Pharmigen) 1:500; Caspase3 (Casp3; 
polyclonal rabbit; R&D Systems) 1:5000.  
Cultures were then incubated for 1 hr with biotinylated anti-rabbit or 
anti-mouse antibodies (GE Healtcare) diluted 1:200 in TBS/10% 
donkey or sheep serum followed by 1 hr with horseradish 
peroxidase-conjugated streptavidin (GE Healthcare) diluted 1:200 in 
TBS/10% donkey or sheep serum. For development/visualization 
3,3´-diaminobenzidine (DAB; Sigma) was used.  
 
Western blotting 
Western blotting was performed as described by Krabbe et al. [54]. 
Membranes were incubated (overnight/4 ºC) with anti-TH (1:2000; 
monoclonal mouse; Chemicon) or anti-β-tubIII antibody (1:2000; 
monoclonal mouse; Sigma) diluted in TBS/Tween-20, washed, 
incubated (1 hr) with HRP-conjugated anti-mouse antibody (1:2000; 
DAKO) diluted in TBS/Tween-20, developed with chemiluminiscence 
(SuperSignal®Extended duration substrate; Thermo Scientific), and 
visualized using a CCD camera. Loading control: alpha-actin antibody 
(1:6000; mouse; Chemicon). 
 
 
















Quantitative-Polymerase chain reaction  
Messenger RNA was extracted using the High Pure RNA isolation kit 
(Roche Diagnostics), and cDNA synthesis was performed using the 
Transcriptor High Fidelity cDNA synthesis kit (Roche Diagnostics). 
PCR was performed using specific forward and reverse primers 




TTCCTCAACTCCCAGTGTGC-3′ and 5′-AGGATGAGCTCCACCTCCTT-3′), 
DBH (5′-CTTCCTGGTCATCCTGGTGG-3′ and 5′-
TCCAGGGGGATGTGATAGGG-3′), Glut1 (5’- 
TTATAGGACCCCGGCCATTG-3′ and 5′-CTGAGCGAGGCAGTGGTTA-3′) 
and RPL22 (5’-CACGAAGGAGGAGTGACTGG-3’ and 5’-
TGTGGCACACCACTGACATT-3’). Fast Start DNA Master Plus SYBR 
Green I (Roche Diagnostics) was applied using the following protocol: 
denaturation program, 95 °C for 10 min followed by 45 cycles of 95 
°C for 10 sec, 60 °C for 10 sec and 72 °C for 10 sec. 
 
MTS cell viability assay 
Cell viability was determined using a MTS kit (CellTiter 96®AqueousOne 
Solution; Promega) according to the manufacturer’s instructions and 
a Vmax kinetic microplate reader with SoftMax®Pro software 
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(Molecular Devices).  
 
High-performance liquid chromatography (HPLC)  
Dopamine and homovanillic acid (HVA) were assessed in culture 
medium/extracts derived from cells differentiated (14 days) 
according to our standard protocol supplemented by 25 ppm CO (30 
min) at days 0 and 4.  
Sample preparation; medium: Cells were washed twice in Hank’s 
balanced salt solution (HBSS; Life Technologies), followed by 
incubation (2 hrs/36 
o
C) in 200 µl of HBSS containing 10µM 
nomifensine (Research Biochemicals International). A 100 µl sample 
was transferred to HPLC vials containing 50 µl of mobile phase (10% 
methanol (v/v), 20 g/l citric acid monohydrate, 100 mg/l octane-1-
sulfonic acid sodium salt, 40 mg/l EDTA dissolved in Milli-Q water 
and pH adjusted to 4.0; all from Merck/VWR Chemicals) and stored at 
-20
o
C until HPLC analysis with electrochemical detection [55], [56].  
Sample preparation; extracts: After removing the culture medium, 
150 µl/well of 0.1 M perchloric acid (PCA; Merck) with antioxidants 
(0.2 g/L Na2S2O5, 0.05g/L Na2-EDTA; Merck) was added. Cells were 
resuspended in PCA, transferred to dark eppendorf vials on ice, 
briefly sonicated and centrifugated (20.000 x g/20 min/4 
o
C). The 
supernatant was stored at -20 °C until analysis.  
 
















Multi cytokine array 
Conditioned culture medium was frozen (-20 
o
C), and cells were 
collected as described for Western blotting but with the cell pellets 
dissolved in RayBio® Cell Lysis Buffer (RayBioech). Protein 
concentrations were determined using a protein assay (BioRad). Four 
membranes (Human Cytokine Antibody Array-5; RayBiotech) were 
incubated (30 min/RT) with Blocking Buffer (BB) (RayBiotech), and 1 
ml conditioned culture medium or 160 µg cell lysate (diluted to 1 ml 
in BB) was added (incubation; 1 hr/RT followed by 12 hrs/4 ºC). After 
washing, membranes were incubated with biotin-conjugated antibody 
diluted in BB (2 hrs/RT and 12 hrs/4 ºC). Membranes were then 
incubated with HRP-conjugated streptavidin diluted in BB (2 hrs/RT), 
washed, developed with chemiluminiscence (RayBiotech), and 
visualized using a CCD camera (Carestream). Densitometric analysis 
was performed using Image J software (NIH). Changes >50% relative 
to control were taken into consideration.  
 
Lactate/Glucose Ratio 
Total glucose and lactate concentrations in the culture supernatant 
were determined with automated enzymatic assays (YSI 7100 
Multiparameter Bioanalytical System; Dayton, OH). The rate between 
lactate production and glucose consumption was obtained by linear 
regression of the metabolites concentrations. The ratio between 
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lactate production and glucose consumption rate was determined for 
each time point. 
 
Cell counting 
Quantification of cells was performed using bright field microscopy 
(Olympus). Cells with an extensive immunostaining and a well-
preserved cellular structure were counted in 16 randomly selected 





Statistical analysis was performed using Prism GraphPad Software. 
Cell numbers were compared by one way analysis of variance 
followed by Dunnett’s multiple comparisons test. Student’s t-test was 
used when comparing only two groups. p<0.05 (*), p<0.01 (**) and 
p<0.001 (***).   

















Carbon monoxide release system 
To characterize and validate decarbonylation reaction from the new 
CO-releasing molecule (CORM) MePh2SiCO2H (Fig. 3.1A), the CO 
concentration was measured in the gas chamber every minute 
throughout a 30 min exposure period (Fig. 3.1B). The CO level 
increased rapidly after mixing MePh2SiCO2H, potassium fluoride and 
dimethyl sulfoxide, reaching the required concentrations after 5 min 





Figure 3.1 - Chemical reaction releasing carbon monoxide (CO) and 
experimental setup. (A) The chemical reaction releasing CO when mixing 
MePh2SiCO2H, KF and DMSO. (B) Illustration of the CO gas chamber. (C) 
Human neural stem cells were plated at day 0, cultured for 4 hrs followed by 
one or two 30 min CO treatments. All culture medium was changed at days 
4, 6 and 9. For experiments with hVMbclXL cells: 1) cultures received CO 
treatment at day 0 followed by immunocytochemistry at days 1, 6 and 10, or 
2) cultures received CO treatment at days 0 and 4 and were used for cytokine 
profiling (day 5), immunocytochemistry (day 6 and 10), Western blotting (day 
6) or MTS assay (day 6). Untreated control cultures were included in all 







Figure 3.2 - Repeated measure of carbon monoxide (CO) levels in the CO 
chamber during the 30 min exposure period.  Measurements visualized in 
the figure represent data from the analysis of 4 different CO concentrations 






















Effect of CO on stem cell differentiation 
To investigate the effect of CO on the dopaminergic differentiation, 
hVMbclXL cells were differentiated for 6 days and received CO at days 
0 and 4 (Fig. 3.1C). At the end of the differentiation process, the 
density of neurons increased significantly, when the cells were 
exposed to CO at 25 and 100 ppm compared to control (Fig. 3.3A). 
Moreover, the percentage of TH neurons relative to human nuclei 
cells (total cells) was significantly higher for cultures exposed to CO 
at 25 and 100 ppm compared to control (Fig. 3.3E). Representative 
digital images visualizing the content and morphology of neurons are 
shown in Fig. 3.3H.  
The density of β-tubulin III neurons increased significantly in cultures 
treated with 25-100 ppm CO compared to control (Fig. 3.3B). 
Furthermore, the percentage of β-tubIII-expressing neurons of total 
cells was significantly higher (Fig. 3.3F). No differences in total cells 
were detected (Fig. 3.3C). Representative images of these cells are 
shown in Fig. 3.3H.  
TH and β-tubIII expression was also investigated by Western blotting 
(WB) showing increased TH expression at 25 and 100 ppm CO 
compared to control. Moreover, there was indication of increased β-
tubIII expression in all CO treated groups (Fig 3.3G). In summary, 
short-term CO exposure during stem cell differentiation has the 
capacity to increase both density and relative content of cells 

























Figure 3.3 - Dose response effects of short-term carbon monoxide (CO) 
treatment on neuronal differentiation of human neural stem cells 
(hVMbclXL). Quantitative analysis of total cells (human nuclei cells), cells 
differentiated into TH and β-tubIII neurons in 6-day-old cultures. (A) 
Quantification of TH neurons showed a significant increase for 25 and 100 
ppm CO compared to control; (B) Quantification of β-tubIII neurons revealed a 
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significant increase for cells treated with 25, 50 and 100 ppm CO; (C) No 
differences between numbers HN cells were seen; (D) The percentage of TH 
neurons of β-tubIII neurons did not differ between the groups; (E) Exposure 
to 25 and 100 ppm CO resulted in a significant increase in the percentage of 
TH neurons of total cells, and (F) 25-100 ppm CO resulted in a significant 
increase in the percentage of β-tubIII neurons of total cells as compared to 
untreated controls. Data are based on four independent experiments and 
expressed as mean±SEM (*p<0.05, **p<0.01, ***p<0.001); (G) Western 
blotting for β-tubIII showed an increase in signal intensities for all CO 
treatment groups compared to control; (H) Digital images of cultures treated 




Influence of cell differentiation time 
To address if the effect of CO was transient or long-lasting hVMbclXL 
cells received CO treatment (25 ppm; 30 min) at days 0 and 4 and 
were differentiated for 6 or 10 days (Fig. 3.4). At day 6 and 10, the 
content of TH neurons relative to β-tubIII neurons had increased 
significantly in the CO treated groups (Fig. 3.4B). Furthermore, the 
relative yields of TH neurons of total cells had increased (Fig. 3.4C). 
At day 6 and 10, WB analysis indicated increased signal intensities for 
β-tub III, and at day 10 TH expression was slightly increased for 
cultures exposed to CO compared to control (Fig. 3.4A). In summary, 
CO-induced improvement on neuronal differentiation lasts up to 10 
days. Representative photomicrographs of TH and β-tubIII neurons 
are shown in Figs. 3.4D and E.  
 
 

















Figure 3.4 - Effects of carbon monoxide (CO) on neuronal and 
dopaminergic differentiation. Quantitative analysis of 6- and 10-day-old 
cultures (hVMbclXL) differentiated into dopaminergic neurons by exposure to 
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25 ppm CO at days 0 and 4. Control cells followed the same protocol but 
received no CO treatment. (A) Western blotting for β-tubIII and TH showed a 
slight increase in band intensities after CO treatment compared to controls; 
(B) At day 10, the percentages of TH neurons of total neurons (β-tubIII) were 
significantly higher for the CO treatment groups compared to control; (C) At 
days 6 and 10 also the percentages of TH neurons of total cells (HN cells) 
were significantly increased for the CO treatment groups. Data are expressed 
as mean±SEM (*p<0.05, **p<0.01, ***p<0.001); (D, E) Representative digital 
images of TH neurons displaying a mature neuronal morphology with long 




To investigate whether a single dose of CO would be sufficient to 
elevate the content of TH cells, a group of cultures were exposed to 
25 ppm CO at day 0 followed by differentiation for 1, 6 and 10 days. 
No difference was found between CO treatment and control cultures 
at day 1, whereas a significant increase in TH neurons was seen at 6 
and 10 days after CO treatment (data not shown). The number of HN 
cells did not differ between CO treatment and control cultures at any 
time point. Consequently, the relative content of TH neurons had 
increased significantly at day 6 and 10 in CO exposed cultures 
compared to controls. In summary, the positive effect of CO on the 
relative content of TH cells was not transient, and it could be 
obtained even with a single dose of CO. 
  
Effect of CO on neuronal maturation and dopaminergic capacity  
To investigate the potential effect of CO on neuronal maturation, the 
amount of mature MAP2 neurons were quantified in 6-day-old 
















cultures (25 ppm CO; 30 min; day 0 and 4 versus control). The 
percentage of MAP2 neurons of total cells was significantly higher for 
CO-treated cultures (Fig. 3.5A). Moreover, CO treated cells displayed 
a more mature morphology with longer and branching processes. 




Figure 3.5 - Characterization of neuronal cells in differentiated cultures. 
Assessment of neuronal maturation of hVMbclXL cells receiving 25 ppm CO 
treatment at days 0 and 4 and differentiated for 6, 10 and 14 days. Control 
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cultures followed the same protocol but received no CO treatment. (A) 
Percentage of MAP2 neurons of total cells showed a significant increase for 
cultures treated with CO compared to controls; (B) Digital images of MAP2 
neurons showing mature neuronal morphology with long processes. Scale 
bar = 50 µm; (C) Quantitative mRNA analysis of hVMbclXL cells receiving 25 
ppm CO treatment at days 0 and 4 and differentiated for 10 days. Control 
cells followed the same protocol but received no CO treatment. Quantities of 
mRNA were compared with mRNA levels at day 0. TH mRNA levels were 
significantly increased for cultures treated with CO compared to controls; 
(D,E) HPLC analysis for DA in cell extracts (**p<0.01) and the DA metabolite 
HVA in culture medium (***p<0.001) from untreated controls and cultures 
receiving 25 ppm CO at days 0 and 4 and differentiated for 14 days. The 
analyses revealed significant elevations in both DA and HVA for cultures 




The expression of catecholaminergic/midbrain-specific genes (TH, 
Nurr1 DAT and DBH) was assessed by mRNA quantification using 
real-time Q-PCR. TH and Nurr1 (Fig. 3.5C) were increased significantly 
after CO treatment, whereas DAT levels were lower. DBH mRNA levels 
were also increased after CO treatment (not shown). In addition, HPLC 
analysis revealed a significant elevation of dopamine levels in cell 
extracts (Fig. 3.5D) and significantly increased homovanillic acid 
(HVA) levels in culture medium from cells exposed to CO compared 
to controls (Fig. 3.5E). However, noradrenaline could not be detected 
under the chromatographic conditions used. In summary, CO 
treatment stimulates neuronal maturation and formation of neurons 
from hVMbclXL present catecholaminergic/midbrain-specific gene 
expression.  
 
















Molecular mechanisms of action: Effects of CO on cell 
proliferation, apoptosis and cytokine profile 
To address the effect of CO on cell proliferation, hVMbclXL cells 
received a single dose of CO at day 0 (25 ppm; 30 min) and were 
differentiated for 1, 6 or 10 days. The relative content of proliferative 
cells did not differ between the groups at any time-point (Fig. 3.6). 
However, the overall percentage of Ki67 cells was found to increase 
during the differentiation from day 1 to 10 (Fig. 3.6A). Representative 
photomicrographs of Ki67 cells are shown in Fig. 3.5B. Further 
evaluation of cell proliferation was performed by measuring MTS 
reduction in 6-day-old cultures receiving CO treatment compared to 
control. The analysis revealed no difference between the groups (Fig. 
3.6C). To evaluate the potential effect of CO on apoptosis, 6-day-old 
cultures receiving CO treatment at days 0 and 4 were immunostained 
for active Caspase3 (Casp3). The relative content of Casp3 cells was 
significantly reduced after CO treatment (Fig. 3.6D). In summary, CO 
is not increasing hVMbclXL proliferation but, by preventing cell death, 













Figure 3.6 - Effects of carbon monoxide (CO) treatment on proliferation 
and apoptosis. Assessment of proliferation in hVMbclXL cells receiving 25 
ppm CO at day 0 (30 min) and differentiated for 1, 6 and 10 days and 
apoptosis in cultures receiving 25 ppm CO treatment (30 min) at days 0 and 
4 and differentiated for 6 days. Control cells followed the same protocol but 
received no CO treatment. (A) The percentage of Ki67 cells of HN cells 
showed no difference between CO treatment and control cultures at any 
time-point; (B) Representative digital images of Ki67 cells receiving 25 ppm 
CO treatment at day 0 and differentiated for 1, 6 and 10 days; (C) Analyses of 
MTS reduction in cultures receiving 25 ppm CO treatment at days 0 and 4 
and differentiated for 6 days did not differ between the groups; (D) The 
percentage of Casp3 apoptotic cells of total cells was significantly reduced 
for cultures receiving CO compared to controls. Data are expressed as 




















To address whether CO had an effect on cytokine profiles 
(conditioned culture medium/cell lysates), multi-cytokine analysis was 
performed using hVMbclXL cells receiving 25 ppm CO (30 min) at 
days 0 and 4 and differentiated for 5 days versus untreated controls 
(Fig. 3.7). Densitometric analysis revealed a reduction in the release 
of neurotrophin-3 (NT-3) and an increase in neurotrophin-4 (NT-4) 
and vascular endothelial growth factor (VEGF) in cells receiving CO 
(Fig. 3.7). The culture medium revealed a reduction in interleukin-15 
(IL-15) and interferon-γ (IFN-γ) levels and an increase in insulin-like 







Figure 3.7 - Effects of CO treatment on cytokine profiles. Semi-quantitative 
expression profile of cytokines in cells (hVMbclXL) and medium from cultures 
receiving 25 ppm CO treatment (30 min) at days 0 and 4 and differentiated 
for 5 days compared to untreated controls. (A) Digital images of signal 
intensities of 80 different cytokines plus positive and negative staining 
controls; (B) Schematic overview illustrating the different cytokines. 
Comparison of intensities revealed an increase for VEGF, NT-4 and ostepontin 
and a relative reduction for NT-3 in cells receiving CO compared to controls. 
The semi-quantitative expression of cytokines in the medium revealed an 
increase for IGFBP-4 and a reduction in IFN-γ and IL-15 for cultures treated 
with CO compared to control. 
 
 
Glucose Metabolism Assessment 
CO increases VEGF, a cytokine described to be responsible for 
metabolism regulation [57], [58]. For instance, both in vivo and in 
endothelial cell line, Domigan and colleagues showed that whenever 
knocking-out VEGF occurs an alteration in mitochondrial homeostasis 
[58]. Also, a complete ablation of VEGF in brown adipocytes 
decreases oxidative capacity of mitochondria [57]. Thus, it is 
important to evaluate metabolic status of hVMbclXL cells during 
dopaminergic differentiation (Fig. 3.8). 
Characterization of cell metabolism, in particular the balance 
between glycolytic and oxidative metabolism, can be assessed by 
















extracellular quantification of lactate production and glucose 
consumption, whose ratio is calculated over time. Whenever this ratio 
(lactate concentration/glucose concentration) is close to 2, it means a 
fully glycolytic metabolism, since through glycolysis one molecule of 
glucose gives rise to two molecules of lactate. Thus, as much as this 
ratio decreases higher levels of oxidative phosphorylation might 
occur. In order to assess how CO modulates glucose metabolism, 
culture supernatants were collected during differentiation (days 3, 6 
and 9) and the levels of glucose and lactate were quantified. In Table 
3.1, one can find the values for lactate production per glucose 
consumption, for hVMbclXL cells exposed to CO and control cells. In 
both cases during the differentiation process cells progressively 
change their metabolism, as ratios increase over time. However, cells 
exposed to CO present a decreased ratio of qLac/qGlc, thus one can 
conclude that CO exposure stimulates oxidative phosphorylation 
during neuronal differentiation, comparing to control conditions 
(Table 3.1).  
 
Table 3.1 – Metabolic characterization of glucose utilization during 
differentiation of hVMbclXL. Lactate production per glucose consumption 





3 0.91 0.80 
6 1.46 1.14 
9 1.86 1.32 
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In summary, the complex mechanisms underlying the observed 
effects of CO on stem cell differentiation into dopaminergic neuronal 
cells involve a reduction of apoptotic cell death, a changed cytokine 




To our knowledge, this is the first study demonstrating a positive 
effect of CO on dopaminergic neuronal differentiation of human 
NSCs. In brief, hVMbclXL cell line was exposed to low levels of CO 
during their differentiation. Short-term CO treatment significantly 
increased both the numbers and relative yields of β-tubIII neurons, 
suggesting that CO treatment stimulates neurogenesis. Moreover, the 
relative content of TH neurons was significantly increased after CO 
exposure (Fig. 3.3), which indicates that CO treatment favors 
induction or survival of the catecholaminergic phenotype. Exposure 
of hVMbclXL cells to CO also increased the number of MAP2 neurons 
(Fig. 3.5A), indicating that CO promotes generation of mature 
neurons. Control experiments confirmed that the observed effects 
were due to the release of CO and not the reagents used to initiate 
the chemical reaction (data not shown). 
In our study, CO treatment did not alter the total number of cells. 
Furthermore, the MTS analysis used to assess cell proliferation and 
















viability revealed no change after CO treatment, which was in line 
with the unchanged content of HN cells (Fig. 3.6). Thus, it is unlikely 
that the applied CO concentrations influenced cell proliferation or 
were toxic to the cells. This is to some extent in accordance with 
studies showing an anti-proliferative effect of CO in other tissues, 
including vascular smooth muscle cells and T-lymphocytes, through 
activation of mitogen-activated protein kinases and the cell cycle 
inhibitor p21 [16], [67], [68]. Interestingly, studies exposing NSCs to 
low oxygen tension have reported both increased cell proliferation 
and dopaminergic differentiation [15], [69]. In the present study 
using CO exposure under normoxia, dopaminergic differentiation 
was increased without an improvement of cell proliferation, which 
suggests other underlying mechanisms than those triggered by low 
oxygen. 
Many biological effects of CO are associated with generation of low 
levels of reactive oxygen species (ROS), which act as signaling 
molecules [21], [59]–[63]. CO-induced ROS generation is mainly due 
to partial inhibition of cytochrome C oxidase [64]–[66]. Interestingly, 
stimulation of ROS production is also important for cell signaling 
during neuronal differentiation and/or survival of embryonic stem 
cells, mesenchymal stem cells and neuronal progenitor cells [21], 
[23], [64], [65].  
Previous studies have shown an anti-apoptotic effect of CO treatment 
on fibroblasts, endothelial cells, astrocytes, cerebellar granule cells 
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and neural stem cells [21], [24], [60], [70]–[72]. To address whether a 
similar effect was present in hVMbclXL cells, cultures were 
immunostained for active Casp3. The relative content of Casp3 cells 
was significantly reduced after CO, indicating that CO has an anti-
apoptotic effect. However, the number of Casp3 positive cells was 
very low most likely due to the over-expression of the anti-apoptotic 
protein BclXL, which should be also taken into account. 
For characterization of the catecholaminergic cell population 
obtained after CO treatment, the expression of 
catecholaminergic/midbrain-specific genes (TH, Nurr1, DAT and DBH) 
was assessed by real-time Q-PCR (Fig. 3.5C). Nurr1 is involved in 
maintenance of midbrain dopaminergic activity and is related to 
dopaminergic differentiation since Nurr1-null mouse-derived NSCs 
fail to differentiate and express TH [73], [74]. In the present study, 
Nurr1 expression was increased after CO exposure, which is in 
accordance with the observed increase in TH expression and release 
of dopamine and HVA. This could indicate that a substantial fraction 
of the neurons were dopaminergic.  
The levels of dopamine in neuronal cells can be modulated by the 
activity of DAT and DBH. DAT is responsible for dopamine transport 
from the synaptic cleft, and surprisingly it was down-regulated after 
CO treatment. This may be due to the significant increase in the pool 
of free dopamine after CO treatment and/or due to the artificial in 
vitro conditions. The observed increase in DBH following CO 
















treatment, which catalyses the conversion of dopamine into 
noradrenaline, may simply reflect the rise of intracellular dopamine 
levels as a result of TH up-regulation.  
Interestingly, a reduction in NT-3 and an increase in NT-4 expression 
levels were found in cell lysates from cultures receiving CO 
treatment. No studies have investigated the effect of CO treatment on 
NT-3 and NT-4, but both neurotrophins have been reported to be 
involved in neuronal growth, synapse formation, maturation and 
plasticity. Moreover, NT-3 is expressed in NSCs, stimulating their 
neuronal differentiation and survival [75]–[77]. The down-regulation 
of NT-3 may reflect the observed stimulatory effect of CO on 
neurogenesis and cell maturation leading to a reduction in the pool 
of NSCs. On the other hand the observed up-regulation of NT-4 could 
potentially stimulate further maturation and growth of cells, which, at 
day 5, are still undergoing differentiation.  
The cytokine profiling of conditioned culture medium revealed 
changes for IL-15, IFN-γ and IGFBP-4 after CO treatment (Fig. 3.7). The 
decrease in IL-15 observed for CO-treated cultures could indicate that 
CO exhibit an anti-inflammatory effect on NSCs. Indeed, previous 
studies have demonstrated that IL-15 is a pro-inflammatory cytokine 
present in both NSCs and differentiated neurons during 
inflammation. Nevertheless,  it has also been reported that decreased 
levels of IL-15 in vivo lead to an increase in cell differentiation and 
reduction in cell proliferation [78]–[80]. Interestingly, a study 
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culturing rat NSCs showed that IL-15 treatment reduced the number 
of MAP2 neurons, thus inhibiting neuronal maturation [81]. The 
observed decrease of IL-15 found in our study may therefore have 
contributed to increased cell maturation as shown by the increased 
number of MAP2 neurons found after treatment. The reduction in 
IFN-γ in cultures receiving CO also suggests an anti-inflammatory role 
of CO since existing literature describe pro-inflammatory 
characteristics of IFN-γ [82].  
Previous studies have shown that IGFBP-4 plays a role in the 
developing brain by stimulating neuronal differentiation of NSCs. In 
the present study the increase in IGFBP-4 in cultures receiving CO 
could indicate that CO signals through IGFBP-4 to promote cell 
differentiation [83], [84].  
Also, semi-quantitative cytokine profiling of cell lysates and 
conditioned culture medium showed an increase in VEGF for CO-
treated cultures (cell lysates) compared to controls (Fig. 3.7). This is 
consistent with other studies demonstrating that CO elevates VEGF 
levels in astrocytes and cardiomyocytes [85]–[87].Moreover, VEGF is 
described to be responsible for metabolism regulation [57], [58]. 
Thus, metabolic status of hVMbclXL cells was evaluated during 
dopaminergic differentiation (Fig. 3.8). Lower ratios of lactate 
production per glucose consumption in cells differentiated after CO 
exposition suggest an increase in glucose oxidation, which lead one 
to speculate that CO pushes cell metabolism towards oxidative 
















phosphorylation. In conclusion, one possible mechanism for CO to 
promote neuronal differentiation is by metabolism modulation and 
reinforcement of oxidative phosphorylation, however further studies 
are needed. 
One of the novelties of this study consists in the new strategy for 
delivering CO gas. In this new system, CO is generated by a 
decarbonylation reaction using the new CORM MePh2SiCO2H, along 
with potassium fluoride and DMSO [51]. This strategy avoids the use 
of CO gas bottles, being safer and easier to use in the benchtop.  
Also, it is more cost-effective than previously described methods and 
a great strategy for the laboratory scale studies, however one cannot 
disregard the lack of potential to be used in human therapeutics.  
Short-term treatment of human NSCs during neuronal differentiation 
process with a low dose of CO, represents an efficient, simple and 
safe method for in vitro derivation of dopaminergic neurons with 
midbrain characteristics that may as such contribute to the future 
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The process of cell differentiation goes hand-in-hand with 
metabolic adaptations, which are needed to provide energy and new 
metabolites. Carbon monoxide (CO) is an endogenous cytoprotective 
molecule able to inhibit cell death and improve mitochondrial 
metabolism. Neuronal differentiation processes were studied using 
the NT2 cell line, which is derived from human testicular embryonic 
teratocarcinoma and differentiates into post-mitotic neurons upon 
retinoic acid treatment. CO-releasing molecule A1 (CORM-A1) was 
used do deliver CO into cell culture. CO treatment improved NT2 
neuronal differentiation and yield, since there were more neurons 
and the total cell number increased following the differentiation 
process. CO supplementation enhanced the mitochondrial population 
in post-mitotic neurons derived from NT2 cells, as indicated by an 
increase in mitochondrial DNA. CO treatment during neuronal 
differentiation increased the extent of the classical metabolic change 
that occurs during neuronal differentiation, from glycolytic to more 
oxidative metabolism, by decreasing the ratio of lactate production 
and glucose consumption. The expression of pyruvate and lactate 
dehydrogenases was higher, indicating an augmented oxidative 
metabolism. Moreover, these findings were corroborated by an 
increased percentage of 
13
C incorporation from [U-
13
C]glucose into the 
tricarboxylic acid cycle metabolites malate and citrate, and also 















glutamate and aspartate in CO-treated cells. Finally, under low levels 
of oxygen (5%), which enhances glycolytic metabolism, some of the 
enhancing effects of CO on mitochondria were not observed. In 
conclusion, our data show that CO improves neuronal and 
mitochondrial yield by stimulation of tricarboxylic acid cycle activity, 
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Embryonic and adult stem cells have the capability to produce 
at least one daughter stem cell upon division (self-renewal) and the 
ability to generate differentiated cells (potency). Thus stem cells can 
proliferate into an increasingly, undifferentiated stem cell population, 
or they can originate all tissues during embryonic and postnatal 
development, which is crucial for tissue repair. This process of cell 
differentiation goes hand-in-hand with metabolic alterations needed 
to provide new bioenergetic, synthetic and catabolic requirements 
important for cell identity. In 2013, Göttle and colleagues 
demonstrated the role of purine metabolism and purine pools during 
neuronal differentiation [1]. Actually, they show that dysfunctions in 
purine metabolism can lead to specific abnormalities, such as 
decreased dopamine levels [1]. Thus, regulation of stem cell’s 
metabolic pathways must be considered in what regards stem cell 
fate, namely promotion and regulation of cell differentiation [2]–[8]. 
The modulation of stem cell differentiation is dependent on cell 
metabolic shifts, mitochondrial function and oxygen levels [9]–[14]. 
Stem cells appear to rely to a greater extent on glycolysis than on 
oxidative phosphorylation to generate ATP [15]–[17]. Consistently, 
there is lower levels of mitochondrial population in human ESCs than 
in their differentiated progeny [18]–[21]. Furthermore neuronal 
differentiation process promotes mitochondrial biogenesis. 
Accordingly to Cho and colleagues, the increase of mitochondrial 
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population during differentiation might permit more cellular 
respiration and, therefore, an increase of cellular ATP production 
[18], which is needed for cell differentiation from progenitor to fully 
mature and functional cell. Stem cell dependency on glycolysis raises 
as an adaptation to the low oxygen levels, which indeed are present 
in vivo during development and in an adult stem cell 
microenvironment or ‘niche’. Adult neural stem cells (NSCs) reside in 
niches that are characterized by low oxygen levels (1–6%) [23], [24]. 
Accumulating evidence supports the idea that the fate of embryonic 
and adult stem cells can be controlled by oxygen signaling [5], [25]–
[30]. For instance, oxygen gradients in the niche might help to direct 
stem cells to differentiate into specific cell lineages. Likewise, low 
oxygen levels can specify the fate of differentiating NSCs, promoting 
the production of dopaminergic neurons and oligodendrocytes [29], 
[30]. 
NT2 cell line is derived from human testicular embryonic 
teratocarcinoma and is able to differentiate into neurons upon 
retinoic acid treatment. NT2 cells differentiate into functional post-
mitotic neurons, which express many neuronal markers [31] and 
produce a variety of neurotransmitter phenotypes [32]–[34]. 
Moreover, NT2-derived neurons can form functional synapses [35] 
and have also been used in several transplantation studies in 
experimental animal models [36], [37] and in human patients [38].   















CO is mostly known as a silent-killer due to its great affinity to 
hemoglobin, which compromises oxygen delivery and promotes high 
levels of intoxication and death. Furthermore, high concentrations of 
CO are cytotoxic by inhibition of cytochrome c oxidase (COX), 
excessive ROS generation or uncoupling effect [39]. Nevertheless, CO 
is an endogenously produced gasotransmitter generated by the 
cleavage of heme group via the enzymatic activity of heme-oxygenase 
(HO)[40]. HO is a stress-related enzyme, whose expression or activity 
increases in response to several stresses, namely: oxidative stress, 
hypoxia, hyperoxia, hyperthermia, inflammation, UV, misfolded 
protein response, among others [40]–[42]. Likewise, it has been 
demonstrated that low levels of exogenous CO promote 
cytoprotection, limit inflammation and prevent cell death [40], [41], 
[43]–[46]. Moreover, CO-induced cytoprotection can be dependent on 
generation of low amounts of ROS, which function as signaling 
molecules [43], [47]–[50]. Likewise, low concentrations of CO 
promote mitochondrial biogenesis [51], [52], increase COX activity 
[44], [53]–[56], improve oxidative metabolism [51], [57] and induce 
mild mitochondrial uncoupling that protects mitochondria from 
oxidative stress [58], [59]. For further reading, please read the 
following reviews [51], [60], [61]. 
Recently we have shown that CO improves neuronal 
differentiation by preventing cell death [62]. Because modulation of 
cell metabolism and oxygen signaling are involved in neuronal 
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differentiation, the main purpose of the present work is to assess the 
role of CO in promoting neuronal differentiation through metabolism 
modulation, in particular oxidative phosphorylation. This study 
demonstrated that CO increases NT2 neuronal yield production 
through stimulation of oxidative metabolism. 
  















MATERIAL AND METHODS 
Materials  
All chemicals were of analytical grade and were obtained from Sigma 
unless stated otherwise. Plastic tissue culture dishes were from 
Sarstedt (Germany); fetal bovine serum, penicillin/streptomycin 
solution, and Dulbecco’s minimum essential medium (high glucose, 
L-glutamine and pyruvate) were obtained from Invitrogen (United 
Kingdom). 
13
C-labelled glucose was obtained from Cambridge Isotope 
Laboratories (Tewksbury, MA, USA).  
The mass spectrometry derivatization reagents MTBSTFA (N-methyl-N- 
(tert - Butyldimethylsilyl) trifluoroacetamide), MSTFA (N-Methyl-N-
(trimethylsilyl) trifluoroacetamide) and the t-BDMS-Cl (tert-
butyldimethylchlorosilane) were purchased from Regis Technologies, 
Inc. (Morton Grove, IL, USA). All other chemicals were of the purest 
grade available from regular commercial sources.  
NT2 human teratocarcinoma cell line 
Maintenance of undifferentiated cells 
Undifferentiated NT2 cells from American Type Culture Collection 
(ATCC) were grown in DMEM-HG supplemented with 10%(v/v) FBS and 
1%(v/v) Pen/Strep (growth medium). Cells were maintained in a 
humidified atmosphere of 5%(v/v) CO2 at 37ºC.  Undifferentiated cells 
per vial were grown in 75cm
2
 T-flasks and subcultured with fresh 
growth medium whenever high cell confluence was achieved (about 
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90-100% cell confluence), cells were rinsed with phosphate-buffered 
saline (PBS) and then incubated with trypsin for 2 minutes at 37ºC for 
trypsinization and resuspended in growth medium in a 1:4 cell 
passage. Growth medium was changed every 2 to 3 days. 
 
Neuronal differentiation protocol 
Following trypsinization and resuspension in growth medium, cells 





Neuronal differentiation was induced 24 hours after plating 
undifferentiated cells to ensure that they settle and attach to flask 
surface and attain appropriate density. The NT2 cell line neuronal 
differentiation was induced in DMEM-HG with 10%(v/v) FBS and 
1%(v/v) Pen/Strep, supplemented with 10µM all-trans retinoic acid 
(RA), which is the differentiation medium. CO effect was studied by 
using the same composition of differentiation medium supplemented 
with 25µM CORM-A1. Differentiation medium was replaced three 
times a week until reaching 10 differentiation treatments (24 days). 
For hypoxic experiments, cells were maintained in a humidified 





 differentiation treatment, cells were replated at lower 
density to disperse the dense multilayer cell culture and start 
neuronal enrichment for obtaining neurons. On the following day, the 















culture medium was exchanged for fresh growth medium 
supplemented with mitosis inhibitors: 1µM Cytosine Arabinoside, 
10µM Foxuridine and 10µM Uridine for neuronal enrichment. Growth 
medium supplemented with mitosis inhibitors was replaced twice a 
week for 10 days, making a total of 3 to 4 treatments. On the 10
th
 day 
of neuronal enrichment, enriched neurons were collected for different 




Figure 4.1 – Scheme of NT2 cells neuronal differentiation. Neuronal 
differentiation of NT2 cells is performed over 3 weeks, with medium 
exchanged three times a week on alternate days. After 24 days of 
differentiation, the obtained mixed (undifferentiated and neuronal) cell 
population is treated with anti-mitotic compounds for neuronal enrichment 
during 10 days.  
 
 
Carbon monoxide releasing molecule A1 (CORM-A1)  
The solution of CORM-A1 (Sigma, Germany) was prepared in milli-Q 
water with a final concentration of 5mM. Then, solution was filtrated 
with 0,2µM filter and stored at -20ºC. For each use, an aliquot was 
thawed and immediately used. CO-depleted inactive form (iCORM-A1) 
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was generated to be used as negative control by initially dissolving 
CORM-A1 in 0.1 M HCl and then bubbling pure N2 through the 
solution for 10 min in order to remove the residual CO gas. The 
solution of iCORM-A1 was finally adjusted to pH 7.4 [63].  Then, the 
solution was filtrated using a 0,2µM filter and stored at -20ºC. For 
each use, an aliquot was thawed and immediately used.  
Cell counting and viability 
Cell cultures were visualized using an inverted microscope with phase 
contrast (DM IRB, Leica, Germany). Total cell number was determined 
by counting cell nuclei using a Fuchs-Rosenthal hemacytometer, after 
digestion with 0.1M citric acid/1% Triton X-100 (wt/wt)/0.1% crystal 
violet (wt/v). 
 
Quantitative-Polymerase chain reaction (Q-PCR) 
Mitochondrial population assessment 
Genomic DNA was extracted from cells after differentiation using the 
High Pure PCR Template preparation kit (Roche Diagnostics, 
Mannheim, Germany). PCR was performed using specific forward and 
reverse primers designed for the mitochondrial COXII gene (5’-
ACAGACGAGGTCAACGATCC-3’ and 5’-AGATTAGTCCGCCGTAGTCG-
3’) and for the nuclear GAPDH gene (5’-GCATCCTGGGCTACACTGAG-
3’ and 5’-GTCAAAGGTGGAGGAGTGGG-3’), respectively. GAPDH gene 
was used as housekeeping for mitochondrial DNA quantification. Fast 















Start DNA Master Plus SYBR Green I (Roche Diagnostics) was used 
with the experimental run protocol: denaturation program was 95° C 
for 10 min, followed by 45 cycles of 95° C for 15’’, 60 °C for 6’’ and 
72° C for 20’’.  
 
Evaluation of gene expression (mRNA quantification) 
For evaluation of gene expression, mRNA was extracted from NT2 
cells using High Pure RNA isolation kit (Roche Diagnostics), and cDNA 
synthesis was performed using the Transcriptor High Fidelity cDNA 
synthesis kit (Roche Diagnostics). PCR was performed using specific 
forward and reverse primers:  
 






























































Fast Start DNA Master Plus SYBR Green I (Roche Diagnostics) was 
used with the experimental run protocol: denaturation program was 
95 °C for 10 min, followed by 45 cycles of 95 °C for 10’’, 60°C for 10’’ 
and 72 °C for 10’’. 
 
Immunoblotting 
Cell extracts were separated under reducing electrophoresis on a 
1mm of 10% sodium dodecyl sulfate-polyacrylamide (SDS-PAGE) gel, 
for 1 hour under 130-150V.  Samples were transferred to a 
nitrocellulose membrane (HybondTMC extra, Amersham Biosciences) 
for 1 hour under 500mA. PDH or Actin protein was stained with α-
PDH (abcam, ab110330) or α-actin (Sigma-Aldrich, A4700) at 1/1000 















dilution for 2h at room temperature. Blots were developed using the 
ECL (enhanced chemiluminescence) detection system after incubation 
with HRP-labeled anti-mouse IgG anti- body (Amersham Biosciences 
Bioscience), 1/5000, 1h of room temperature incubation.  
 
Lactate/Glucose Ratio 
Total glucose and lactate concentrations in the culture supernatant 
were determined with automated enzymatic assays (YSI 7100 
Multiparameter Bioanalytical System; Dayton, OH). The rate between 
lactate production and glucose consumption was obtained by linear 
regression of the metabolites concentrations, then the ratio between 
lactate production and glucose consumption rate was determined for 
each time point. 
 
Gas Chromatography-Mass Spectrometry (GC-MS) 
For analysis of 
13
C percent enrichment in intracellular metabolites, 
NT2 cells differentiated for 24 days were incubated with [U-
13
C]glucose for 24 hours. After the incubation period, cells were 
washed twice with cold PBS and the intracellular metabolites 
extracted with 70% ethanol and lyophilized. Cell extracts were 
resuspended in 0.01M HCl followed by pH adjustment to pH<2 with 
HCl 6 M. Samples were dried under atmospheric air (50 °C), and 
metabolites were derivatised with MTBSTFA in the presence of 1% t-
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BDMS-Cl (Mawhinney et al. 1986) (see Amaral et al. 2014 for further 
details). The samples were analyzed on an Agilent 6890 gas 
chromatograph connected to an Agilent 5975B mass spectrometer 
(Agilent Technologies, Palo Alto, CA, USA). The parent ion (M) and 
atom percent excess for 
13
C atoms (M+1, M+2 and M+3) values for 
citrate, malate, aspartate and glutamate were calculated from GC-MS 
data using MassHunter software supplied by Agilent (Agilent 
Technologies, Palo Alto, CA, USA) and correcting for the naturally 
abundant 
13
C by using non-enriched standards [64].  
 
Statistical analysis 
The data concerning cell culture were carried out at least in three 
independent preparations. All values are mean ± SD, n≥3. Error bars, 
corresponding to standard deviation, are represented in the figures. 
Statistical comparisons between multiple groups were performed 
using ANOVA single factor with replication and between two groups 
were made with an independent two-tailed Student’s t-test. For all the 





















CORM-A1 modulates neuronal differentiation 
In order to characterize the effect of CORM-A1 in neuronal 
differentiation of NT2 cell line, cells were differentiated with retinoic 
acid (RA) supplemented with CORM-A1 (Fig. 4.1). RA is the factor that 
allows these cells to differentiate into post-mitotic neurons and 
CORM-A1 is only capable of modulating the process when 
administered jointly with RA. CO per se is not an inducer of neuronal 
differentiation, since NT2 cells died whenever treatment was done 
only with CORM-A1 without RA supplementation (data not shown). 
During the differentiation process, culture supplementation with 
25µM CORM-A1 yielded a duplication of the final number of post-
mitotic neurons (Fig.3.2A). Likewise, in the first two columns of Table 
3.1 the kinetic parameters for cell growth demonstrated an increase 
on growth rate (μ), doubling time (td) and fold increase (FI) in the 
presence of CORM-A1.  
Furthermore, neuronal morphology and expression of the neuronal 
protein Tuj1 (assessed by immunocytochemistry) are similar between 
neurons derived from RA treatment alone and derived from RA 
supplemented with CORM-A1 (Fig. 4.2B). Moreover, supplementation 
with inactivated CORM-A1 did not increase total mixed cell 




Table 4.1 - Growth rate (μ), doubling time (td) and fold increase (FI) 
values of NT2 cells differentiated in normoxic conditions (21% O2) and 
hypoxic conditions (5% O2). 
 




RA 10μM + CORM-
A1 25μM 






0,08±0,03 0,09±0,03 0,07±0,01 
DT 
(day) 
9,62±3,44 8,27±2,91 10,23±1,29 






















Figure 4.2 – CORM-A1 improves the neuronal differentiation process. (A) 
Relative quantification of neuronal cells obtained after 34 days of neuronal 
differentiation and enrichment processes; (B) Immunocytochemistry of NT2 
derived post-mitotic neurons (green staining: Tuj1; blue staining: DAPI; 
magnification 200x); (C) Relative quantification of cells obtained in the mixed 
cell population after 24 days of neuronal differentiation; (D) mRNA 
expression of specific neuronal differentiation markers (Nestin for neuronal 
precursors, Tuj1 for early differentiated neurons and MAP2 for mature 




The enhancement in the final yield of post-mitotic neurons 
promoted by CORM-A1 supplementation can be due to increased 
precursor cell proliferation or a facilitation of neuronal differentiation 
per se. To clarify this issue, the total mixed cell population 
(composed of progenitor cells and post-mitotic neurons) was 
evaluated before neuronal enrichment with anti-mitotic agents. For 
the same number of inoculated undifferentiated NT2 cells, the total 
number of cells in the mixed population after 24 days of 
differentiation was higher in the presence of CORM-A1 (Fig. 4.2C). 
The mixed cell population obtained by treatment with only RA and RA 
supplemented with CORM-A1 were characterized by mRNA 
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quantification of neuronal related genes. The neuronal precursor cell 
marker Nestin, as well as Tuj1 and MAP2, which are expressed in the 
early stage of neuronal differentiation and by mature neurons, 
respectively, presented higher levels of mRNA in the presence of 
CORM-A1 (Fig. 4.2D). In summary, accordingly to our previously our 
data [62], CO released by CORM-A1 improves the neuronal 
differentiation process in the NT2 cell model. 
 
Mitochondrial population assessment 
Cellular differentiation leads to mitochondrial biogenesis [18], 
[22]. According to Cho and colleagues, the increase of mitochondrial 
population during differentiation should permit more cellular 
respiration and, therefore, an increase in ATP concentration [18], 
which is needed for cell differentiation to progress from progenitor to 
fully functional cell.  Mitochondrial population of NT2 cells under 
differentiation was assessed by mitochondrial DNA quantification by 
Q-PCR. It was observed that during neuronal differentiation with RA, 
as expected, there was a significant increase in mitochondrial 
population compared to undifferentiated cells (data not shown). 
However, CORM-A1 supplementation did not increase mitochondrial 
DNA content in the mixed cell population obtained after 24 days of 
differentiation (Fig. 4.3A).  In order to understand whether progenitor 
and neuronal cells had different levels of mitochondrial population, 















mitochondrial DNA was quantified in the post-mitotic NT2 derived 
neurons following neuronal enrichment (Fig. 4.3B). Indeed, post-
mitotic neurons obtained from the differentiation medium 
supplemented with RA and CORM-A1 presented higher levels of 
mitochondrial DNA than post-mitotic neurons derived from 
differentiation medium supplemented only with RA (Fig. 4.3B). Thus, 
CORM-A1 enhances the mitochondrial population of post-mitotic 
neurons. Because CO is known as the modulator of cell metabolism 
[44], [57], one can speculate that CORM-A1 supplementation 
increases neuronal yield due to its capacity to raise mitochondrial 





Figure 4.3 – Mitochondrial population assessment.  
Mitochondrial DNA quantification by Q-PCR in (A) mixed population of NT2 
cells after 24 days of differentiation; (B) post-mitotic neurons obtained from 





Cellular metabolism assessment 
In order to understand more deeply whether CORM-A1-
increased mitochondrial population reflects a change in cell 
metabolism, the expression of some metabolic enzymes and 
transporters was evaluated at the end of the neuronal differentiation 
process (Fig. 4.4A). Glucose transporter 1 (Glut1) is a transporter 
responsible for the glucose entrance in the cell, while MCT2 is the 
monocarboxylate transporter present in neurons, in particular lactate. 
Pyruvate dehydrogenase (PDH) is involved in the conversion of 
pyruvate to acetyl-CoA that then enters into Tricarboxylic Acid Cycle 
(TCA), and is an irreversible reaction. Finally, lactate dehydrogenase 
(LDH) is the enzyme catalyzing pyruvate into lactate. There is a 
tendency of CORM-A1 to increase oxidative metabolism: the 
expression of both membrane transporters (Glut1 and MCT2) mRNA 
is increased. Likewise, there are higher levels of mRNA expression of 
PDH and LDH (Fig. 4.4A). PDH protein levels were also quantified by 
immunoblot, presenting a significant increase in its expression in the 
presence of CORM-A1 (Fig. 4.4B). 
 
 















Figure 4.4 – Oxidative metabolism from glucose assessment. (A) mRNA 
expression of specific metabolic markers (PDH for pyruvate dehydrogenase, 
LDH for lactate dehydrogenase, MCT2 for monocarboxylate transporter 2 and 
GLUT1 for glucose transporter 1) in NT2 mixed cell population after 24 days 
of neuronal differentiation; (B) PDH protein quantification by immunoblotting. 
 
 
Characterization of cell metabolism, in particular the balance 
between glycolytic and oxidative metabolism, can be assessed by 
extracellular quantification of lactate production and glucose 
consumption, whose ratio is calculated over time. Whenever this ratio 
(lactate concentration/glucose concentration) is close to 2, it means a 
fully glycolytic metabolism, since through glycolysis one molecule of 
glucose gives rise to two molecules of lactate. Thus, as much as this 
ratio decreases oxidative phosphorylation might occur. In order to 
understand how CORM-A1 modulates oxidative metabolism, 
supernatants of NT2 cells during differentiation were collected and 
glucose and lactate levels were quantified. In Table 3.2, one can 
observe the ratios of lactate production per glucose consumption in 
the case of cells treated with RA only and cells treated with RA 








Table 4.2 - Metabolic characterization of NT2 neuronal differentiation. 
Lactate production per glucose consumption (qLac/qGlc) ratios were 





RA 10µM RA 10µM + CORM-A1 25µM 
2 2,00 ± 0,19 2,00 ± 0,19 (p=0,96)  
4 1,97 ± 0,18 1,80 ± 0,16 (p=0,41) 
7 1,56 ± 0,14 1,40 ± 0,06 (p=0,17) 
13 1,34 ± 0,05 1,26 ± 0,03 (p=0,03) 
17 1,27 ± 0,12 0,90 ± 0,08 (p=0,08) 
24 1,05 ± 0,03 0,92 ± 0,08 (p=0,08) 
 
 
 In both cases it is clear that during the differentiation process 
cells progressively change their metabolism from glycolytic to 
oxidative, as the ratios decrease over time, which is fully in 
accordance with the shift between more proliferative to differentiated 
cells. Furthermore, when neuronal differentiation process occurs in 
the presence of CORM-A1, the decrease in the ratio occurs early on 
and is always lower for the cultures supplemented with CORM-A1. 
Thus, we can conclude that CORM-A1 supplementation stimulates 




















Mitochondrial metabolism was assessed by measuring % 
13
C 
enrichment above the natural 1.1% using GC-MS. To study 
13
C 
enrichment in intracellular metabolites, NT2 cells differentiated for 
24 days were incubated with [U-
13
C]glucose for 24 hours in the 
presence and absence of  CORM-A1 supplementation and cell 
extracts were prepared for GC-MS analysis. % 
13
C enrichment in TCA 
cycle metabolites (citrate and malate) and aspartate and glutamate 









Figure 4.5 – Metabolic profile. (A) Labelling patterns derived from [U-
13
C]glucose metabolism; The % enrichment with 
13
C leading to the formation 
of molecules with masses: M+1, M+2 and M+3 for (B) citrate, (C) glutamate, 
(D) malate and (E) aspartate, determined by GC-MS analysis of NT2 cell 









C]pyruvate which is 
then converted into [1,2-
13
C]acetyl CoA. This molecule condenses with 
non-labelled oxaloacetate to form double-labelled (M+2) compounds 
in the first turn of the TCA cycle (Fig. 4.5A) and monolabeled (M+1) 
isotopologues in the second turn if mono labeled oxaloacetate 
condenses with unlabeled acetyl CoA. Furthermore, in a combination 
of the first and second turn of the TCA cycle, [1,2-
13
C]acetyl CoA can 
condense with labelled oxaloacetate and give rise to the formation of 















diversely labelled compounds (Fig. 4.5A). GC-MS analysis of NT2 cell 
extracts incubated with [U-
13
C]glucose showed that % 
13
C labelling of 
glutamate, aspartate, malate and citrate was increased for M+1, M+2 
(Fig. 4.5B-E). These increases in labelling corroborate our hypothesis: 
CO improves neuronal differentiation through stimulation of 
mitochondrial metabolism. 
 
CORM-A1 supplementation under hypoxic conditions 
Oxygen levels are extremely important for oxidative 
phosphorylation, thus the assessment of CORM-A1 effect on neuronal 
differentiation under hypoxia is important to validate CO modulation 
of cell metabolism during differentiation. NT2 cells were 
differentiated under 5% O2 levels and it was observed that, although 
there were no morphological differences in the final post-mitotic 
neurons (Fig. 4.6B), some of the reported effects of CORM-A1 during 
neuronal differentiation are lost under hypoxia. The number of post-
mitotic neurons obtained is lower under hypoxia, but still higher than 
neurons differentiated with RA alone (Fig. 4.6A). In addition, the 
number of total mixed cell population following 24 days of 
differentiation is decreased to the levels of control, RA 
supplementation only (Fig. 4.6C). Hypoxia partially reverted the 
increased mRNA expression of the specific neuronal genes (Nestin 
and Tuj1) due to the presence of CORM-A1 (Fig. 4.6D). Under 
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hypoxia, the CORM-A1-increased mitochondrial population of the 
post-mitotic enriched neurons is reverted to control levels (Fig. 4.6E). 
Furthermore, growth rates (μ), doubling times (DT) and fold-increase 
(FI) of NT2 cell cultures during neuronal differentiation were 
calculated and compared (Table 4.1).  
















Figure 4.6 – Effect of hypoxia (5% O2) on CORM-A1 modulation of 
neuronal differentiation. (A) Relative quantification of neuronal cells 
obtained after 34 days of neuronal differentiation and enrichment; (B) 
Immunocytochemistry of NT2 derived post-mitotic neurons (green staining: 
Tuj1; blue staining: DAPI; magnification 200x); (C) Relative quantification of 
neuronal cells obtained in the mixed cell population after 24 days of 
neuronal differentiation; (D) mRNA expression of specific neuronal 
differentiation markers (Nestin for neuronal precursors and Tuj1 for early 
differentiated neurons) in NT2 mixed cell  population after 24 days of 
neuronal differentiation; (E) Mitochondrial DNA quantification by Q-PCR in 





CORM-A1 supplementation increased cellular growth rate and 
decreased doubling time, which translates into higher fold-increase 
after the neuronal differentiation process under normoxic conditions. 
Upon hypoxia, CORM-A1 effect in growth rate and doubling time is 
reverted. Thus, one can speculate that, under lower levels of oxygen, 
CORM-A1 partially loses some capacities to positively modulate 
neuronal differentiation, namely: lower levels of post-mitotic neurons; 
mixed cell population after differentiation process presents lower 
levels of neuronal markers (mRNA expression of Nestin and Tuj1) and 
decreased mitochondrial population in post-mitotic neurons. Thus, in 
low levels of oxygen, CO is not able to improve neuronal 





Emerging evidence suggests that molecular regulators of 
energy metabolism play essential roles in stem cell fate, particularly 
in the decision to self-renew or differentiate [4], [5]. Due to the 
increasing prevalence of neurodegenerative diseases and ischemic 
stroke, modulation of neurogenesis is a promising strategy to 
regenerate tissue and improve the outcome of those devastating 
disorders related to aging. It is extremely important to understand 
the molecular mechanism underlying neuronal differentiation and 
also how these mechanisms can be modulated in order to stimulate 















an efficient replacement of impaired neurons in the central nervous 
system. Therefore, cell metabolism manipulation can be a key tool for 
neurogenesis modulation. In the present study, our aim was to assess 
the metabolic regulation achieved by CO supplementation during the 
neuronal differentiation process, which in turn can improve neuronal 
production.  
CO is intimately related to cell metabolism modulation [51], 
[65] by reinforcing oxidative phosphorylation: (i) in the context of 
cancer cells, which present an anti-Warburg effect [66] and (ii) in the 
primary cultures of astrocytes for promoting cytoprotection [44]. 
Furthermore, CO rescues mice from dying in the context of sepsis by 
supporting mitochondrial energy metabolism and promoting 
mitochondrial biogenesis [49], [67]. Actually, in the present study it 
was shown that CO improved neuronal differentiation rates by 
modulating cell metabolism, in particular reinforcing oxidative 
metabolism. In the presence of CORM-A1, there is an increase on 
mitochondrial population in post-mitotic neurons derived from NT2 
cells. Increased glucose oxidation is also supported by decreased 
ratios of lactate production per glucose consumption upon 
supplementation with CORM-A1, which suggests that CO pushes cell 
metabolism towards oxidative phosphorylation. Neuronal metabolism 
is mostly oxidative and neurons also use glucose for maintaining 
their anti-oxidant status by generation of reduced glutathione via 
pentose-phosphate pathway (PPP). Moreover, whenever glycolysis is 
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forced in neurons (gene overexpression or inhibition), there is a great 
reduction PPP and consequently of anti-oxidant defence  [68]. 
Therefore, for further study, the role of PPP must be taken into 
account during CO manipulation of neuronal differentiation. 
New insights into the modulation of metabolic pathways have 
challenged the long-held assumption that all metabolic enzymes 
performing housekeeping functions, are being expressed at constant 
levels, in all cells [69]. During neuronal differentiation of NT2 cells 
supplemented with CORM-A1, mRNA expression of the enzymes PDH 
and LDH and the transporters Glut1 and MCT2 were higher than 
control, indicating an increased oxidative metabolism. Furthermore, 
it cannot be disregarded that neurons can take up and use lactate as 
oxidative substrate [70]. In particular under physiological conditions, 
there is the astrocyte-neuron lactate shuttle (ANLS) [70]–[72]. Because 
of their glycolytic metabolism, astrocytes produce and release lactate, 
which can be taken up and consumed by neurons. Although there are 
no astrocytes present in the neuronal differentiation culture, the 
differentiation process is not synchronized, and there are cells with 
different levels of maturation. Thus, it can also be speculated that the 
remaining progenitor cells could function as astrocyte-like cells by 
releasing lactate, since they have more glycolytic metabolism. 
Therefore, the increased expression of MCT2 in the presence of CO 
can also be related to an improved oxidative consumption of lactate 
by neurons. Likewise, the increase of PDH expression (mRNA and 















protein) is coupled to a higher entrance of pyruvate into the TCA 
cycle and oxidative metabolism, which can be synthesized from both 
glucose and lactate. Finally, conversion of pyruvate into lactate by 
LDH is a reversible reaction, thus the higher levels of oxidative 
metabolism can also explain the increased expression of LDH. In 
conclusion, these data indicate that CORM-A1 positively modulates 
oxidative metabolism. The increased expression of Glut1 in the total 
mixed populations after 24 days of neuronal differentiation leads to a 
global increased oxidative metabolism [73]. Of note, Glut1 is 
expressed only in vitro neuronal cultures, while for in vivo models 
Glut3 must also be considered. Due to some residual mutagenic and 
oncogenic potential of the NT2 cells [74], one cannot disregard that 
aerobic glycolysis (Warburg effect) is more efficient in supporting 
rapid cell growth when compared with normal glycolysis linked to the 
TCA cycle and oxidative phosphorylation [69]. Thus, CO seems to 
favour neuronal differentiation at different levels: (i) supplying 
glucose needs for cellular growth and (ii) pushing metabolism from 
glycolytic to oxidative in order to stimulate differentiation. MCT2 is a 
proton symporter responsible for the transmembrane transport of 
mono-carboxylates in neurons [75], [76]. CORM-A1 also increased the 
expression of the monocarboxylate transporter MCT2, which is 
mostly present in neurons, more specifically in glutamatergic 
synapses [76], indicating the potential link between MCT2 function 
and glutamatergic transmission in functional neurons. These data 
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correlate with the fact that NT2-derived neurons are mostly 
glutamatergic [34]. Thus, upon supplementation with CORM-A1, 
differentiating NT2 cells yield a higher number of post-mitotic 
neurons that are metabolically more active. Moreover, one can 
speculate that these cells are more prepared to survive episodes of 
energy deprivation, such as stroke, in the re-oxygenation phase when 
they can take up lactate to support their mitochondrial activity. PDH 
and LDH were also quantified and, upon supplementation with CORM-
A1, neuronal differentiation yielded cells with increased expression of 
both enzymes. Thus, the overexpression of LDH in differentiating 
neuronal cells induces an improved feeding of TCA cycle and 
consequently oxidative phosphorylation. The improvement in 
mitochondrial metabolism during NT2 neuronal differentiation was 
corroborated by isotopic enrichment studies, which showed that 
13
C 
labelling of TCA cycle metabolites and amino acids derived for TCA 
cycle metabolites glutamate and aspartate was increased in the 
presence of CO. Finally, under hypoxic conditions (5% O2), CORM-A1 
supplementation did not yield the same beneficial effects on 
mitochondria as observed during normoxia (21% O2). Thus, one can 
speculate that, under hypoxia the lack of oxygen impaired the ability 
of CO to increase mitochondrial metabolism and oxidative 
phosphorylation.  
In summary, these data validate: (i) the role of cell 
metabolism, in particular oxidative metabolism, during the neuronal 















differentiation process and (ii) that CO-improvement of neuronal 
differentiation is dependent on cell metabolism modulation. This 
study contributes to clarify the pathways involved in neurogenesis, 
promoting the establishment of new strategies to stimulate neuronal 
differentiation. The increasing knowledge of stem cell biochemistry 
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Over the last decades, the silent-killer carbon monoxide (CO) has 
been shown as an endogenous cytoprotective molecule able to inhibit 
cell death and to modulate mitochondrial metabolism. Neuronal 
metabolism is mostly oxidative and neurons also use glucose via 
pentose-phosphate pathway (PPP) for maintaining their anti-oxidant 
status by generation of reduced glutathione. Moreover, whenever 
glycolysis is forced in neurons (gene overexpression or inhibition), 
there is a great reduction PPP and consequently of anti-oxidant 
defence. It is well known that neuronal differentiation process is 
related to ROS generation and signalling, however there is a lack of 
information about modulation of PPP during adult neurogenesis. 
Thus, the main goal of this study is to disclose CO modulation of 
neuronal differentiation and how it can be related with PPP regulation 
for increasing antioxidant defence. 
 It was used human neuroblastoma SH-S5Y5 cell line, which 
differentiate into post-mitotic neurons by treatment with retinoic acid 
(RA), as model for adult neurogenesis. CO-releasing molecule A1 
(CORM-A1) was used do deliver CO into cell culture. SH-SY5Y cell 
differentiation process supplemented with CORM-A1 prompted an 
increase in neuronal yield. However, this improvement was not 
related to the classical metabolic shift that occurs during 
differentiation: (i) CORM-A1 did not alter glycolytic metabolism since 
Chapter V 
 
levels of lactate produced per glucose consumed was not altered and 
(ii) oxidative metabolism slightly decreased upon CORM-A1 
supplementation as verified by the levels of labeled metabolites. 
Nevertheless, due to the fact that lactate dehydrogenase expression 
was increased by CORM-A1 but without any apparent effect on 
glycolysis, pentose phosphate pathway was assessed. The expression 
of PPP key enzymes (phosphogluconate dehydrogenase and 
transketolase) increased in the presence of CORM-A1. Furthermore, 
the ratio between reduced and oxidized glutathione increased, which 
is an indirect evaluation of this pathway. Moreover, CORM-A1 
promotes the modulation of glutathione metabolism, once it 
increases protein glutathionylation levels. In summary, CO improves 
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Stem cell fate can be regulated by various factors, namely 
cellular energy metabolism, which is capable of modulating the 
decision of stem cells to self-renew or to differentiate [1], [2]. Thus, 
manipulation of cell metabolism can be a key tool for neurogenesis 
modulation, in order to stimulate a replacement of impaired neurons 
in central nervous system (CNS), particularly in cases of 
neurodegenerative diseases and ischemic stroke.  
CO is mostly known as a silent-killer due to its great affinity to 
hemoglobin, which compromises oxygen delivery and promotes high 
levels of intoxication and death. Nevertheless, CO is an endogenously 
produced gasotransmitter generated by the cleavage of heme group 
via the enzymatic activity of heme-oxygenase (HO)[3]. HO is a stress-
related enzyme, whose expression or activity increases in response to 
several stressful stimuli, namely: oxidative stress, hypoxia, 
hyperoxia, hyperthermia, inflammation, UV and misfolded protein 
response, among others [3]–[5]. Likewise, it has been demonstrated 
that low levels of exogenous CO promote cytoprotection, limit 
inflammation, prevent cell death and improve neuronal differentiation 
[3], [4], [6]–[11]. Moreover, CO-induced cytoprotection can be 
dependent on generation of low amounts of ROS, functioning as 
signaling molecules [6], [12]–[15]. Low concentrations of CO promote 
mitochondrial biogenesis [16], [17], increase COX activity [7], [18]–
[21], improve oxidative metabolism [16], [22] and induce mild 
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mitochondrial uncoupling that protects mitochondria from oxidative 
stress [23], [24]. For further reading, please consult the following 
reviews [16], [25], [26]. Herein, it was used CORM-A1 (carbon-
monoxide releasing molecule A1), which able to release CO in a 
temperature and pH dependent manner, presenting a half-life of 
approximately 21 minutes for transfer of CO to myoglobin in vitro at 
pH of 7,4 and 37ºC [27], [28].  
Pentose Phosphate Pathway (PPP) is an important route of 
glucose oxidation, divided in two branches, the oxidative and non-
oxidative phase, where, by multiple reactions, sugar phosphates are 
interconverted. The oxidative phase of PPP is linked to glycolysis at 
the level of glucose-6-phosphate and catalyses its conversion into 
ribulose-5-phosphate and CO2. Also, in this phase there is the 
reduction of NADP
+
 into NADPH, the major reducing compound, 
which is required for regeneration of reduced glutathione (GSH) from 
its oxidized form (GSSG). On the other hand, the non-oxidative phase 
converts pentose phosphates into phosphorylated aldoses and 
ketones. This branch is linked to glycolysis by their common 
intermediates glyceraldehyde-3-phosphate and fructose-6-phosphate 
and it also produces ribose-5-phosphates, which are precursors for 
nucleotide synthesis [29], [30]. The activity of this non-oxidative 
phase of PPP is mainly used to support the active cellular proliferation 
during neurogenesis [31]. Moreover, modulation of PPP flux can allow 
cells to obtain the same amount of energy per glucose molecule, 














when compared to glycolysis, but with an associated increase in 
nucleotide synthesis and in availability of electron donors, such as 
NADPH.  
For assessing PPP modulation by CO, human neuroblastoma 
SH-S5Y5 cell line was chosen as cell model. This is a simple model to 
study neuronal differentiation process [32], allowing the assessment 
of the involved cellular mechanisms, which requires more controlled 
settings. SH-SY5Y cells are derived from neural crest [33], [34] and 
present the ability to differentiate into neuron-like cells that fulfil the 
morphological, biochemical and functional neuronal criteria [32], 
[34], [35], constituting a valuable model for neuronal toxicity studies 
[36]–[39]. 
Also, GSSG/GSH recycling is dependent on PPP and it has been 
already described that CO modulates GSH recycling [6]. Thus, one can 
speculate that CORM-A1 can stimulate PPP flux, which in turn can 
facilitate the cellular machinery rearrangement needed during 
neuronal differentiation.  
The main goal of this study was to assess metabolic 
regulation of neuronal differentiation achieved by CO, in particular at 
the level of PPP. CORM-A1 supplementation increases neuronal yield 
of SH-SY5Y neuronal differentiation and it was observed that the 
presence of CORM-A1 increases PPP flux and modulates GSH 
metabolism, favouring protein glutathionylation. Herein was proved 
that adult neurogenesis may be differently metabolically modulated 
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accordingly to the characteristics of the different in vitro model 
chosen, which open routes to improved strategies to overcome 
neurodegenerative scenarios.  
 
 
MATERIAL AND METHODS 
Materials  
All chemicals were of analytical grade and were obtained from 
Sigma unless stated otherwise. Plastic tissue culture dishes were from 
Sarstedt (Germany); fetal bovine serum, penicillin/streptomycin 
solution, and Dulbecco’s minimum essential medium (high glucose, 
L-glutamine and pyruvate) were obtained from Invitrogen (United 
Kingdom). 
The mass spectrometry derivatization reagents MTBSTFA (N-
methyl-N- (tert-Butyldimethylsilyl) trifluoroacetamide), MSTFA (N-
Methyl-N-(trimethylsilyl) trifluoroacetamide) and the t-BDMS-Cl (tert-
butyldimethylchlorosilane) were purchased from Regis Technologies, 
Inc. (Morton Grove, IL, USA). All other chemicals were of the purest 
grade available from regular commercial sources.  
 
 














SH-SY5Y human neuroblastoma cell line 
Maintenance of undifferentiated cells 
The SH-SY5Y cell line was cultured in DMEM/F-12 
supplemented with 10%(v/v) FBS and 2%(v/v) Pen/Strep (growth 
medium). Cells were maintained in a humidified atmosphere of 
5%(v/v) CO2 at 37ºC. Undifferentiated cells were grown in 75cm
2
 T-
flasks and subcultured with fresh growth medium whenever cell 
confluence achieved (about 80-90% cell confluence). Cells were 
detached by trypsinization at room temperature (R.T.) and slight 
shaking and hitting to drain down cells with trypsin and resuspended 
in growth medium in a 1:4 cell passage. Growth medium was 
changed twice a week. 
 
Neuronal differentiation protocol 
Following trypsinization and resuspension in growth medium, 
cells were plated on 75cm
2
 T-flasks in a 1:2 cell passage. Neuronal 
differentiation was induced 24 hours after plating undifferentiated 
cells to ensure settle and attachment to flask surface and attain 




Neuronal differentiation was stimulated using DMEM/F-12 
medium, reduced serum to 1%(v/v) FBS, 2%(v/v) Pen/Strep and 
supplemented with 10µM of all-trans RA (differentiation medium). CO 
effect was studied by using the same composition of differentiation 
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medium supplemented with 25µM CORM-A1. Differentiation medium 




 days) during 7 days of treatment. On 
the 7
th





 day of differentiation, cells were replated at lower 
density to disperse cell culture for neuronal enrichment. On the 
following day, the culture medium was exchanged with fresh growth 
medium supplemented with mitosis inhibitors: 1µM Cytosine 
Arabinoside, 10µM Floxuridine and 10µM Uridine for neuronal 
enrichment. Growth medium supplemented with mitosis inhibitors 
was replaced after 2 days. On the 5
th
 day of neuronal enrichment, 
enriched cultures were collected for different analysis. The used 
protocol is schematically represented in Figure 5.1B. 
 
Carbon monoxide releasing molecule A1 (CORM-A1)  
The solution of CORM-A1 was prepared in milli-Q water with a 
final concentration of 5mM. Then, solution was filtrated with 0,2µM 
filter and stored at -20ºC. For each use, an aliquot was thawed and 
immediately used.  
 














Preparation of inactivated CORM-A1 
CO-depleted inactive form (iCORM-A1) was generated to be 
used as negative control by initially dissolving CORM-A1 in 0.1 M HCl 
and then bubbling pure N2 through the solution for 10 min in order 
to remove all residual CO gas [28]. The solution of iCORM-A1 was 
adjusted to pH 7.4, filtrated using a 0,2µM filter and stored at -20ºC. 
For each use, an aliquot was thawed and immediately used.  
Cell counting and viability 
Cell cultures were visualized using an inverted microscope 
with phase contrast (DM IRB, Leica, Germany). Total cell number was 
determined by counting cell nuclei using a Fuchs-Rosenthal 
hemacytometer, after digestion with 0.1M citric acid/1% Triton X-100 
(wt/wt)/0.1% crystal violet (wt/v). 
 
Quantitative-Polymerase chain reaction (Q-PCR) 
Genomic DNA was extracted from cells after differentiation 
using the High Pure PCR Template preparation kit (Roche Diagnostics, 
Mannheim, Germany). PCR was performed using specific forward and 
reverse primers designed for the mitochondrial COXII gene (5’-
ACAGACGAGGTCAACGATCC-3’ and 5’-AGATTAGTCCGCCGTAGTCG-
3’) and for the GAPDH gene (5’-GCATCCTGGGCTACACTGAG-3’ and 
5’-GTCAAAGGTGGAGGAGTGGG-3’), respectively. Fast Start DNA 
Master Plus SYBR Green I (Roche Diagnostics) was used with the 
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experimental run protocol: denaturation program was 95 °C for 10 
min, followed by 45 cycles of 95 °C for 15’’, 60 °C for 6’’ and 72 °C 
for 20’’. 
For evaluation of gene expression, mRNA was extracted from 
NT2 and SH-SY5Y cells using High Pure RNA isolation kit (Roche 
Diagnostics), and cDNA synthesis was performed using the 
Transcriptor High Fidelity cDNA synthesis kit (Roche Diagnostics). 
PCR was performed using specific forward and reverse primers 
designed for the Phosphogluconate dehydrogenase gene (5’-
ACCAGCAGACAATGCACGTA-3’ and 5’- AGGGATGAAGACAGCCACAC-
3’), Transketolase gene (5’- CATGCCAGTGACCGCATCAT-3’ and 5’- 
ATGCGAATCTGGTCAAAGGC-3’), Pyruvate Dehydrogenase gene (5′-
AGGGTGGTTTCTATCTGTCTTGT-3′ and 5′-
TCATGCTTCTTTTATCCTCTTGCT-3′), Lactate Dehydrogenase gene (5′-
GGCTATTCTTGGGCAACCCT-3′ and 5′-
TGGAAGTGGTACCAATACAACTCA-3′) and RPL22 gene (5’-
CACGAAGGAGGAGTGACTGG-3’ and 5’-TGTGGCACACCACTGACATT-
3’), respectively. Fast Start DNA Master Plus SYBR Green I (Roche 
Diagnostics) was used with the experimental run protocol: 
denaturation program was 95 °C for 10 min, followed by 45 cycles of 
95 °C for 10’’, 60°C for 10’’ and 72 °C for 10’’. 















Total glucose and lactate concentrations in the culture 
supernatant were determined with automated enzymatic assays (YSI 
7100 Multiparameter Bioanalytical System; Dayton, OH). The rate 
between lactate production and glucose consumption was obtained 
by linear regression of the metabolites concentrations. 
  
Gas Chromatography-Mass Spectrometry (GC-MS) 
For analysis of 
13
C percent enrichment in intracellular 
metabolites cell extracts were lyophilized and resuspended in 0.01M 
HCl followed by pH adjustment to pH<2 with HCl 6 M. Samples were 
dried under atmospheric air (50 °C), and metabolites were derivatised 
with MTBSTFA in the presence of 1% t-BDMS-Cl (Mawhinney et al. 
1986) (see Amaral et al. 2014 for further details). The samples were 
analyzed on an Agilent 6890 gas chromatograph connected to an 
Agilent 5975B mass spectrometer (Agilent Technologies, Palo Alto, 
CA, USA). The parent ion (M) and atom percent excess for one 
13
C 
atom (M+1) values for 3PG, PEP, alanine, aspartate, lactate, citrate 
and glutamate were calculated from GC-MS data using MassHunter 
software supplied by Agilent (Agilent Technologies, Palo Alto, CA, 
USA) and correcting for the naturally abundant 
13
C by using non-




High Performance Liquid Chromatography (HPLC) 
Cell extracts were performed by lysing cells with 250 μL of 
Triton X-100 (0.01 %) in PBS 1× (v/v) followed by centrifugation at 
13000 rpm for 5 min, 4 °C. The aminothiols in cell extracts and 
culture media (supernatants) (50 μL) were reduced with tris(2-
carboxyethyl)phosphine (TCEP); the proteins were precipitated with 
trichloroacetic acid; and reduced thiols were derivatized with 
ammonium 7- fluoro-2,1,3-benzoxadiazole-4-sulfonate (SBD-F), 
according to Nolin et al. [41]. Samples were analyzed by HPLC system 
(Shimadzu) with a RF 10AXL fluorescence detector, operating at 385 
nm (λ excitation) and 515 nm (λ emission). The aminothiols CYS, 
CysGly, and GSH were separated on a LiChrospher 100 RP-18 (250×4 
mm, 5 μm; Merck), with a mobile phase consisting on a mixture of 
0.1 M acetate buffer (pH 4.5, adjusted with acetic acid): methanol 
(99:1v/v) at a flow rate of 0.8 mL/min at 29 ° C. The run time was 20 
min. 
Immunofluorescence microscopy 
SH-SY5Y cells were plated at a density of 2x10
6 
cells/well in 
24-well plates coated with Poly-D-lysine in 0,15M sodium borate 
buffer solution pH 8,4. Cells were fixed with 4%(v/v) PFA and 4%(w/v) 
sucrose solution (20 minutes at R.T.) and then permeabilised with 
0,3%(v/v) Triton X-100 solution (15 minutes at R.T.). Later, cells were 
incubated 2 hours at R.T. with primary antibody: Tuj1 (Sigma-Aldrich, 














T8660) and ki67 (Millipore, AB9260), following incubation for 1 hour 
at R.T. with secondary antibody: AlexaFluor 488 anti-mouse (A11001) 
or AlexaFluor 594 anti-rabbit (A11012). Primary and secondary 
antibodies were dilute in 1%(v/v) BSA and 0,1%(v/v) Triton X-100 
solution. Cultures were mounted on Prolong mounting media (with 
DAPI - Invitrogen) and images were captured with Zeiss Axiovert 40 
CFL microscope. All solutions were prepared in PBS (1X). Washes with 
PBS (1X) solution were performed between each step. 
 
Statistical analysis 
The data concerning cell culture were carried out at least in 
three independent preparations. All values are mean ± SD, n≥3. Error 
bars, corresponding to standard deviation, are represented in the 
figures. Statistical comparisons between multiple groups were 
performed using ANOVA single factor with replication and between 
two groups were made with an independent two-tailed Student’s t-










CORM-A1 increases neuronal differentiation yield  
CORM-A1 modulatory effect on neuronal differentiation was 
assessed using SH-SY5Y cells, which have the ability to differentiate 
into neurons upon treatment with retinoic acid (RA) (Fig. 5.1A). 
CORM-A1 was used as a supplement of the classical differentiation 
procedure. Treatment with only CO without RA is not enough to 
induce neuronal differentiation, since there was no neuronal 
differentiation (data not shown). The neuronal differentiation process 
of SH-SY5Y cells takes 7 days, followed by 5 days of neuronal 
enrichment with anti-mitotic agent treatment (Fig. 5.1A). 
After 7 days of differentiation, it was obtained a mixed cell 
population composed of fully differentiated neurons and precursors 
cells that did not differentiate. This occurs mainly because cells are 
not synchronized in the beginning of the process. When SH-SY5Y cells 
were differentiated for 7 days in the presence of 25µM CORM-A1, the 
total number of cells of the mixed cell population increased 
significantly (Fig. 5.1B). As expected, this population was composed 
of neurons and proliferative cells, expressing Tuj1 and ki67 proteins, 
respectively, as assessed by immunocytochemistry (Fig. 5.1B). In 
order to understand whether this increase was due to an effect on 
cellular proliferation or differentiation, the mixed SH-SY5Y cell 
population was treated with anti-mitotic agents for neuronal 














enrichment, and it was characterized by immunocitochemistry (Fig. 
5.1C). For the same amount of cells in the beginning of neuronal 
differentiation process, enriched neuronal population increased about 
4,5 times in the presence of CORM-A1 (Fig. 5.1C). Thus, CO released 
by CORM-A1 presents a positive modulatory role in the neuronal yield 
of SH-SY5Y cell line differentiation, as already demonstrated in 
Almeida et al 2016 [10].  
 
 
     
 
Figure 5.1 – CORM-A1 improves neuronal differentiation yield. (A) SH-
SY5Y neuronal differentiation procedure: SH-SY5Y cells were induced to 
differentiate during 7 days (d7), subjected to a differentiation medium 
exchange at day 4. After 7 days of differentiation (d7), a mixed population of 
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undifferentiated cells and post-mitotic neurons was obtained. In order to 
obtain an enriched neuronal population, cultures are treated with anti-mitotic 
compounds for 5 days (d12); Characterization of SH-SY5Y cells by 
immunocytochemistry (green staining: Tuj1; blue staining: DAPI; red staining: 
ki67; magnification 100x) and nuclei count per volume of SH-SY5Y cells (B) 
after 7 days of differentiation and (C) after anti-mitotic treatment during 5 
days. All values are mean ± SD, n≥3 and p-value is indicated in each panel. 
  
 
CORM-A1 effect on glycolytic metabolism 
Because neuronal differentiation involves modulation of 
glycolytic metabolism [42]–[44] and CO also regulates cell 
metabolism [22], CORM-A1 effect on glycolysis was assessed (Fig. 
5.2A). It was observed that the levels of lactate production per 
glucose consumption remain unchanged with or without CORM-A1 
supplementation during neuronal differentiation process (Fig. 5.2A), 
which indicates that there might be no change on glycolysis due to 
CO presence.  
During glycolysis, glucose is converted into pyruvate which 
can follow two distinct pathways: it can be transformed (i) in lactate 
by lactate dehydrogenase (LDH) or (ii) in acetyl-CoA, by pyruvate 
dehydrogenase (PDH) action followed by coenzyme A ligation, which 
will feed tricarboxylic acid cycle (TCA). Thus, glycolysis progression 
in the presence of CORM-A1 was evaluated using labelled glucose 
(
13
C) and measuring the percentage of 
13
C enrichment using GC-MS. 
To study 
13
C enrichment in intracellular metabolites, SH-SY5Y cells 
differentiated for 7 days in the presence and absence of CORM-A1 
supplementation were incubated with [U-
13
C]glucose for 24 hours and 














cell extracts were prepared for GC-MS analysis. The percentage of 
13
C 
enrichment was quantified in lactate, in glutamine and glutamate and 






C]pyruvate. As shown in 
Fig. 5.2C, there is no significant difference of M+3 lactate levels 
between control cells and CORM-A1 supplemented ones. This data 
corroborate the ratios of lactate production per glucose consumption 
presented in Fig. 5.1A, meaning that there is no increase on 
glycolysis. In turn, [U-
13
C]pyruvate is then converted into [1,2-
13
C]acetyl CoA. This molecule condenses with non-labelled 
oxaloacetate to form double-labelled (M+2) compounds in the first 
turn of the TCA cycle (Fig. 5.2B). Furthermore, in a combination of 
the first and second turn of the TCA cycle, [1,2-
13
C]acetyl-CoA can 
condense with labelled oxaloacetate and give rise to the formation of 
diversely labelled compounds (Fig. 5.2B). GC-MS analysis of SH-SY5Y 
cell extracts incubated with [U-
13
C]glucose showed that the 
percentage of 
13
C labelling of citrate, aspartate, glutamine and 
glutamate was decreased for M+2 (Fig. 5.2D-H) in the presence of 
CORM-A1. In summary, CORM-A1 supplementation of SH-SY5Y cells 
neuronal differentiation seems to not interfere with glycolysis but 
leads to a slight decrease in mitochondrial metabolism. Moreover, 
mRNA expression of pyruvate dehydrogenase (PDH) and lactate 
dehydrogenase (LDH) were quantified. CORM-A1 induces a decrease 
in PDH and an increase in LDH expression. This result correlates with 
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the decreased mitochondrial metabolism observed in CORM-A1 
supplemented cells (Fig. 5.2 D-H) and with the unaltered ratio and 
quantity of lactate obtained during differentiation in the presence of 
CORM-A1 (Fig. 5.2 A and C). Consequently, one may speculate that, 
upon CORM-A1 supplementation, glucose is going to feed other 
pathways than glycolysis, such as PPP, which is parallel but 






















Figure 5.2 – Glycolytic metabolism profile. (A) Lactate production per 
glucose consumption (qLac/qGlc) ratios calculated between treatments (n≥3); 
(B) Labelling patterns derived from [U-
13
C]glucose metabolism; The % 
enrichment with 
13
C leading to the formation of molecules with masses: M+1, 
M+2 and M+3 for (C) lactate, (D) citrate, (E) aspartate, (F) glutamine and (G) 
glutamate, determined by GC-MS analysis of SH-SY5Y cell extracts 
differentiated for 7 days and subjected to 24h incubation with medium 
containing [U-
13
C]glucose; (H) mRNA expression of specific metabolic markers 
(PDH for pyruvate dehydrogenase and LDH for lactate dehydrogenase) in SH-
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SY5Y mixed cell population after 7 days of neuronal differentiation. All values 




CORM-A1 modulates Pentose Phosphate Pathway  
To study PPP, two key enzymes were assessed. mRNA 
expression of phosphoglucoronate dehydrogenase (PGDH) and 
transketolase (TKT), from oxidative and non-oxidative phases of PPP 
respectively (Fig. 5.3A). Actually, the expression of both enzymes 
increased in the presence of CORM-A1 in neuronal differentiated 
cells. Moreover, PPP assessment can be indirectly done by glutathione 
quantification using HPLC because PPP is coupled to GSSG/GSH 
recycling system, which is crucial for cellular anti-oxidant defense. 
Note that GSH reacts directly with radicals and it is an electron donor 
in reactions catalysed by glutathione peroxidases, generating, in 
turn, glutathione disulphide (GSSG). GSH is regenerated from GSSG in 
the reaction catalysed by glutathione oxidases, which transfers 
electrons from NADPH to GSSG [45], [46]: GSH recycling coupled to 
PPP.  
Cell extracts of differentiated SH-SY5Y cells with or without 
CORM-A1 supplementation were analysed at 2h following the first 
treatment (Fig. 5.3B). Intracellularly, CORM-A1 supplementation 
leaded to a slight increase in the ratio GSH/GSSG. Although the 
difference between treated and non-treated cells with CORM-A1 is not 














statistically relevant, one may speculate that the increase in 
GSH/GSSG ratio directly correlates with more quantity of NADPH. This 
electron donor is mainly provided by PPP, thus the increase of NADPH 
can be related with an increased PPP flux. In summary, the increase in 
GSH/GSSG ratio corroborates the result obtained from mRNA 





Figure 5.3 – CO modulation of pentose phosphate pathway. (A) mRNA 
expression of specific PPP enzymes (PGDH for phosphogluconate 
dehydrogenase and TKT for transketolase) in SH-SY5Y mixed cell population 
after 7 days of neuronal differentiation; (B) GSSG/GSH ratios 2 hour after 
CORM-A1 supplementation; (C) Reactive oxygen species (ROS) quantification 
2hour after CORM-A1 supplementation (day 1) and in the end of neuronal 
differentiation (day 7). 
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Moreover, it is already known that CO effect occurs via ROS 
signaling [6], [7], [10] which promotes the oxidation of GSH into GSSG 
[6]. Thus, the reinforcement of PPP (Fig. 5.3A) and improvement of 
GSH recycling (Fig. 5.3B), can be a response to ROS production during 
CORM-A1 supplementation. ROS intracellular levels were quantified 
2h after CORM-A1 supplementation and after 7 days of neuronal 
differentiation (Fig. 5.3C). It was observed that CORM-A1 increases 
ROS levels, immediately after its supplementation, and the increased 
levels are maintained at the end of neuronal differentiation process 
(Fig. 5.3C). Hence, CORM-A1 effect on neuronal differentiation of SH-
SY5Y cells might be mediated by ROS as signaling molecules, which 
would require an improvement of GSSG recycling in order to control 
the redox state of the cell that is only possible due to an increase in 
NADPH levels. The electron donor NADPH is obtained by a boost in 
PPP. However, the contribution of anabolic and catabolic pathways of 
glutathione also should be taken in account. 
 
CORM-A1 modulates Glutathione metabolism 
An increase in the ratio GSH/GSSG can occur by three 
processes: (i) increase in glutathione catabolism; (ii) decrease in 
glutathione anabolism and/or (iii) increase of protein 
glutathionylation (Fig. 5.4A). In order to evaluate these processes, 
three different strategies were adopted: (i) quantification of Cys-Gly 














peptide in extracellular environment [47]; (ii) quantification of the 
intracellular aminoacid Cysteine, which is the rate-limiting factor for 
GSH synthesis [47], [48]; and (iii) estimation of bound glutathione by 
difference in the quantification of total glutathione in the cell and 
free glutathione in the cell [48]. 
Glutathione is synthetized intracellularly through the 
condensation of three aminoacids: cysteine, glutamate and glycine 
(Fig. 5.4A). In Fig. 5.4A is schematized glutathione metabolism and 
recycling coupled to PPP. In the previous section (Fig. 5.3B) it was 
observed a tendency of CORM-A1 to improve the recycling of GSSG in 
GSH, however one cannot disregard that the proportion of 
glutathione within the cell can be affected by other mechanisms such 
as anabolism, catabolism and protein glutathionylation. Thus, the 
quantities of aminoacid cysteine and the peptide Cys-Gly were 
determined (Fig. 5.4 B-C). In order to assess protein 
glutathionylation, the percentage of the total glutathione that is not 
free intracellularly was calculated (Fig. 5.4D).  
Glutathione anabolism (Fig. 5.4 B) seems to be unchanged by 
CORM-A1 supplementation: intracellular levels of total and free 
cysteine are similar between control cells (only treated with RA) and 
cells treated with CORM-A1 (RA + CORM-A1). On other hand, CORM-
A1 slightly decreases glutathione catabolism (Fig. 5.4 C) because 
cells treated with CORM-A1 presented less extracellular levels of Cys-
Gly peptide. Accordingly, CORM-A1 promotes an accumulation of 
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glutathione intracellularly. Inside the cell, glutathione can exist in the 
reduced form (free) or bound to other proteins (protein 
glutathionylation). In Fig. 5.4 D is possible to observe that the 
quantity of glutathione in the bounded form is significantly higher in 
cells treated with CORM-A1 than in control cells. In conclusion, the 
accumulation of intracellular glutathione is associated with the 























Figure 5.4 – CO modulation of 
glutathione metabolism. (A) 
Scheme of cellular metabolic net 
composed by PPP and glutathione 
metabolism; (B) Intracellular cysteine 
and (C) extracellular peptide 
cysteine-glycine (Cys-Gly) 
quantification 2 hour after CORM-A1 
supplementation; (D) Protein 
glutathionylation level 2h after 
CORM-A1 treatment. All values are 
mean ± SD, n≥3 and p-value is 




CO promotes cytoprotection, limits inflammation, prevents 
cell death and modulates neuronal differentiation [3], [4], [6]–[10], 
through generation of low amounts of ROS, which function as 
signalling molecules, and increase mitochondrial oxidized 
glutathione [6], [12]–[15].  
In this study, human SH-SY5Y neuroblastoma cell line was 
used in order to understand whether the CO’s modulatory effect in 
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neuronal differentiation was related to cell metabolism. Because 
glucose oxidation was not altered by CORM-A1 supplementation, PPP 
flux was targeted as potential involved pathway. Actually, it was 
observed that not only glycolysis was not affected by CORM-A1 
supplementation, but also mitochondrial metabolism is slightly 
diminished. These results are not in accordance with data previously 
published by our group [11], where it was shown that CORM-A1 
promotes neuronal differentiation of NT2 cells by reinforcing 
mitochondrial metabolism. In fact, the discrepancy between results 
can be due to the different cell models used. NT2 are 
teratocarcinoma-derived cells that present a pluripotent phenotype, 
while SH-SY5Y cells present already a neuronal predisposition given 
its morphology and the ability to differentiate along the neuronal 
lineage. Thus, one can speculate that NT2 cell line differentiation 
represents an early stage of neurogenesis process and SH-SY5Y cell 
line differentiation is a better model to characterize end phases of 
the process.  
In addition to the results previously published by our group; 
neurogenic process is widely described to be accompanied to a 
metabolic shift, where cells become more dependent on oxidative 
metabolism than on glycolysis, resulting in neuronal population 
relying mostly on oxidative metabolism. In the present study, upon 
treatment with CORM-A1, we observed that glycolysis seems not to 
be altered, although there was an increase on LDH expression. On 














other hand, mitochondrial metabolism diminished and even PDH 
expression decreased. Thus, one can speculate that CORM-A1 
modulates other pathways of glucose metabolism, such as PPP.  
Although PPP is a minor contributor to total glucose 
oxidation, it is essential for cell due to the importance of their 
products: (i) the electron donor NADPH and (ii) ribose-5-phosphate, 
both essential for biosynthetic processes, as neurogenesis. It is 
known that, in the brain, the flux through PPP is higher in the 
oxidative part than in the non oxidative one, thus the yield of the 
whole pathway is made taking in account the non oxidative part [49].  
In order to understand if PPP was improved by CORM-A1, two key 
enzymes were chosen to assess the pathway: (i) 6-phosphogluconate 
dehydrogenase (PGDH) that catalyses the first step of PPP in the 
oxidative part and (ii) transketolase (TKT), an enzyme from the 
nonoxidative part, responsible for the production of fructose-6-
phosphate and glyceraldeyde-3-phosphate, both intermediates that 
connect PPP to glycolysis. These are key enzymes that catalyse non-
reversible reactions in PPP. Both PGDH and TKT mRNA expression 
increased in cells treated with CORM-A1, leading us to conclude that 
PPP is being reinforced by CO supplementation during neuronal 
differentiation of SH-SY5Y cells. Also, PGDH and TKT are expressed in 
the various cell types in the brain [50]–[52], but PGDH activity 
decreases after birth [53] while  TKT activity increases during 
postnatal development [54], [55]. Taking in account the present data 
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(low mRNA expression of PGDH and higher mRNA expression of TKT) 
we can claim that SH-SY5Y cells mimic adult neurogenesis.  
NADPH synthesis in PPP is extremely important in what 
regards to cell’s antioxidant defences [56]–[61]. Moreover, in 
embryonic stem cells, it was observed that oxidative part of PPP was 
essential to generate NADPH to protect cells against oxidative stress 
but dispensable for the synthesis of ribose-5-phosphate (due to the 
interconnection to glycolysis) [62], [63].  Therefore, cellular ROS and 
glutathione levels were quantified in order to assess the relationship 
between CO supplementation, ROS as signalling molecules and 
glutathione as a measurement of antioxidant defences, which is also 
an indirect way to assess PPP. As expected, CORM-A1 
supplementation increased cellular ROS levels that were not enough 
to cause oxidative stress (data not shown) but acted as signaling 
molecules, slightly increasing GSH/GSSG ratio.  
Neuronal differentiation supplemented with CORM-A1 did not 
altered the intracellular levels of cysteine compared to control cells 
but decreased the extracellular levels of Cys-Gly, what indicates that 
glutathione synthesis does not increase and glutathione catabolism is 
reduced by CO. Concomitantly, CORM-A1 promotes protein 
glutathionylation. Glutathionylation is an oxidative post-translational 
modification that consists in the formation of disulphide bonds 
between protein thiols and glutathione. This process ensures 
protection of protein thiols against irreversible over-oxidation, 














operates as a biological redox switch in both cell survival and cell 
death, acting as signalling regulator at organelle level.   Further 
studies are needed concerning this issue during neuronal 
differentiation; but it is already known that glutathionylation in prone 
to occur in modulation of metabolism, cystoskeletal remodelling, 
apoptosis and DNA modifications [48], [64], [65]. Concerning our 
study, further validation is needed, such as (i) ROS scavenger prior to 
CORM-A1 supplementation in order to verify that CO-induced ROS are 
promoting PPP and (ii) gene expression silencing of glucose-6-
phosphate dehydrogenase, once this enzyme controls PPP flux and 
will allow the confirmation that CO boosts this pathway and the 
concomitant modulation of glutathione metabolism. 
In summary, our results (i) corroborate the importance of 
antioxidant defences during neuronal differentiation, (ii) present PPP 
as one more important pathway for modulation of neurogenesis and 
(iii) validate CO to improve neuronal yield by modulating PPP and 
glutathione metabolism. Altogether, this study helps to elucidate the 
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In Neurosciences, the dogma that no new neurons can be 
born after the end of embryonic and early postnatal development 
was accepted for decades [1], [2]. However, since 1960s, some 
reports started to suggest that adult brain retains the capacity to 
generate new neurons in particular brain zones [3], [4]. In 1970, 
The Boulder Committee claimed the existence of multipotent 
progenitor cells in ventricular zone (VZ) and subventricular zone 
(SVZ) [5], [6]. Despite the existence of several studies about this 
issue [6]–[8], the acceptance of lifelong neurogenesis in 
mammalian brain just became broadly accepted in the beginning 
of the 21st century [9], [10]. 
 The study of adult neurogenesis is extremely important due 
to the fact that brain can potentially restore some functions after 
acute or chronic injuries. Nevertheless, the endogenous 
mechanisms of repair have clear limitations, originating a large 
percentage of patients with brain injuries that have to daily lead 
to permanent functional deficits. Consequently, it is imperative to 
continue searching for strategies to enhance the course of 
degenerative or traumatic brain diseases. The main targets for 
brain injury repair are the modulation of endogenous 
neurogenesis for improving it and/or cell therapy by in vitro 















production of neural cells for transplantation and their integration 
in existing neuronal circuits [11]. 
Carbon monoxide (CO) is an endogenous anti-apoptotic and 
anti-proliferative molecule, which can modulate several cellular 
pathways by ROS signaling (Chapter I). Thus, this thesis has 
explored the potential application of CO to improve neuronal 
differentiation process. Two distinct objectives can be reached by 
CO-induced increase on neuronal production yield: (i) 
improvement of neuronal cell production for potential future 
transplantation and (ii) disclosing the molecular mechanisms 
underlying this process for developing improved in vivo 
modulation of neurogenesis.  
As presented in Figure 1.11 (Chapter I), the general aim of 
this thesis is the evaluation of CO effect in different in vitro 
models of neuronal differentiation, with particular regard to the 
balance between cell proliferation, cell differentiations, cell death 
and metabolic shifts. The main achievements concerning CO 
modulation of specific pathways that lead to an increased 
neuronal yield are summarized in Figure 6.1 and are discussed 
throughout this chapter. The achievements clearly contribute to 
spread knowledge about adult neurogenesis and to open a new 














Figure 6.1 – Main achievements of this PhD thesis. CO does increase final yield of 
neuronal differentiation, through prevention of cell death (Chapter II and III) and 
modulation of cell metabolism: increase of mitochondrial metabolism (Chapter IV), 
increase of PPP flux and stimulation of glutathione recycling and protein 
glutathionylation (Chapter V). 
















1.1. In vitro neuronal production 
In the adult brain, NSCs can be found in stem cell niches. These 
are anatomical compartments that includes cellular and acellular 
components that integrate the signalling network to regulate stem 
cells biology [12]–[14]. The ability to isolate and culture stem cells in 
vitro has greatly contributed for understanding the role, structure 
and regulation of stem cells niches and neuronal differentiation 
process [14], [15]. 
 
1.1.1. Perspective on the different models used in this thesis 
In this thesis four different models were used: two cancer cell 
lines (NT2 and SH-SY5Y), one human neural stem cell line (hVMbcl-XL) 
and organotipic cultures of hippocampal slices. The human origin of 
NT2 and SH-SY5Y cell lines is a clear advantage to study human 
neuronal differentiation processes and cell manipulation for potential 
use in cell therapy. Furthermore, these cell lines have similar 
characteristics of human cells expressing a number of specific 
proteins, contrary to primary cultures of rodent precursor cells. 
Nonetheless, they are tumor cells presenting mutagenic and 
oncogenic potential, being less representative of physiological 
neuronal differentiation [16], [17].  
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In contrast, hVMbcl-XL cells were generated from ventral 
mesencephalic region of a human fetus, presenting genuine 
characteristics of their regional identity, which exempt the need of 
complex patterning procedures. However, in order to be maintained 
in culture, these cells over-express the anti-apoptotic protein BclXL. 
This features should be taken into consideration when evaluating 
proliferation and differentiation, since cell death is extremely related 
with neurogenesis [18], [19]. 
Cell lines are a powerful tools that offer several advantages: 
they are easy to use, provide an unlimited supply of material, provide 
consistent samples and reproducible results and bypass ethical 
concerns associated with the use of animal and human tissues. 
However, cell lines are genetically manipulated which can alter their 
phenotype, native functions and their responsiveness to stimuli. 
Moreover, it is important to consider physiologically relevant models 
that allow the neurogenesis assessment within an intact neuronal 
circuitry [20]–[22]. Thus, organotypic hippocampal slice cultures 
(OHSCs) represent a valuable model of adult neurogenesis, allowing 
the assessment of three key steps: neural stem cell proliferation, 
differentiation and migration [20]–[22]. The use of slice cultures is 
more common in studies of excitotoxicity and ischemia. However 
OHSCs can be used for assessing neurogenesis since the SGZ is a 
neurogenic zone preserving its property in vitro (reviewed in [20], 
[21]). Since 2004, these slice cultures have been used as 















representative models for neurogenesis studies, allowing the follow-





1.2. Cellular mechanisms behind adult neurogenesis 
To improve the outcome in the injured brain, one must acquire 
knowledge about the potential of the endogenous stem cells for 
neural repair. Although all the efforts, the knowledge about 
physiological adult neurogenesis and about their regulatory 
mechanisms are scarce [11].  
Data generated in this thesis demonstrated that CO increases 
neuronal production in different in vitro models of neuronal 
differentiation. Because it is known that in other biological systems 
CO limits cell death and modulates cell metabolism (Chapter I), these 
features were the main targets for studying the mechanisms behind 
the improvement of neuronal yield promoted by CO (Chapters II to 
V). 
 
1.2.1. Programmed cell death  
Cell death during embryonic development of the nervous system 
mainly occurs in order to regulate the size of progenitor populations 
and to remove erroneous or unwanted neural populations [29]. Also, 
adult neurogenesis and integration of young neurons into mature 
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neural circuits are regulated by cell death events [30]. In adult brain, 
survival and integration of young neurons is dependent on the 
competition of these cells with a diversity of neuronal cells in 
different stages of maturation. Thus, cell death role in adult 
neurogenesis may have unique regulatory mechanisms that are not 
properly studied yet [29]. Identification and quantification of cell 
death in adult brain is not easy because the presence of dead cells 
are transient as a result of active clearance by immune cells [31]. 
Because programmed cell death is tightly associated with 
neuronal differentiation in vivo, it can also originate limitations in in 
vitro neuronal production approaches. In Chapter II and III, it was 
demonstrated that CO improves adult neurogenesis yield by 
preventing apoptotic cell death. Thus, CO appears as an agent 
capable of increasing in vitro neuronal production for cell therapy 
strategies. Additionally, the use of genetically modified models that 
limit to execute cell death, such as hMVbxl-XL cell line (Chapter III), is 
essential to assess not only the extent and distribution of cell death 
but also to identify cellular changes responsible for cell death 
modulation. Using this cell line one is able to keep the majority of 
cells alive in order to observe the intracellular changes occurring 
during neuronal differentiation. In the context of this thesis, this 
approach allowed the detection that, besides preventing cell death 
(Chapter II), CO can modulate cytokine expression and glucose 
metabolism (Chapter III). Based on this data, the work on metabolic 















modulation was carried on and is now presented in Chapters IV and 
V. 
Despite the challenges about assessing cell death during neuronal 
differentiation, it was demonstrated that CO is able to reduce 
apoptosis in the different chosen models of adult neurogenesis 
(Chapter II), promoting an increased neuronal population suitable for 
potential cell therapies, such as (i) cell transplantation in the case of 
neuronal production using cell lines and (ii) stimulation of 
endogenous neurogenesis occurring in hippocampus and mimicked 
by HOSCs. However, further studies are needed to establish the 
applicability of CO to stimulate endogenous neurogenesis by cell 
death prevention, once it was observed that knocking out regulatory 
apoptotic genes lead to supernumerary neurons in mouse brains [32]. 
Since this kind of cell death has the final aim of eliminating 
dysfunctional cells, one must consider that probably the modulation 
of neurogenesis by CO could not be applied in vivo, otherwise one 
can obtain brains with abnormal and dysfunctional cell populations 
which can cause more harm than beneficial effects. Nevertheless, CO 
supplementation appears as a promising factor for cell production 







1.2.2. Bioenergetics and metabolism 
Metabolic alterations are essential for stem cell proliferation and 
differentiation. Although existing few information about intermediary 
metabolism of stem cells, it is known that NSCs are more dependent 
on glycolytic metabolism than neurons [33]. Also, recent data showed 
that activation of quiescent NSCs is accompanied by downregulation 
of glycolytic metabolism and upregulation of mitochondrial oxidation 
[34], [35].  
In Chapter IV, NT2 cell line was used to disclose the relationship 
between the improvement of neuronal production by CO and the 
effect of CO in the shift from glycolysis to oxidative metabolism 
during neuronal differentiation process. In fact, it was observed that 
CO stimulated neuronal production by promoting mitochondrial 
metabolism over glycolysis. These data strongly support the currently 
accepted model in which stem cells predominantly utilize glycolytic 
metabolism in order to maintain self-renew and lineage potency; 
while differentiated cells mainly use oxidative metabolism to support 
the high energetic demands of specialized progeny [36], [37].   
Nevertheless, one cannot disregard that during neurogenesis 
there is the need of building blocks such as nucleotides and electron 
donors like NADPH, both acquired in PPP. Also, the known 
improvement of oxidative metabolism during differentiation lead to 
an increase in ROS levels that are controlled by antioxidant defenses, 















such as glutathione recycling coupled with PPP. In Chapter V, it was 
demonstrated that CO improves the yield of SH-SY5Y cell line 
neuronal differentiation by increasing PPP flux that boosts 
glutathione metabolism.  
Despite the important role of PPP by providing building blocks 
and electron donors that support the active cellular proliferation 
during neurogenesis, its role in maintaining the redox status is 
crucial. Signaling ROS mediate the loss of self-renewal capacity 
through control of mitochondrial biogenesis and metabolic shifts 
[38]–[42]. It has been suggested that low levels of ROS mediate cell 
proliferation, while higher levels (but still in signaling, non harmful 
concentrations) promote an activated state of NSCs [43]. This is line 
with the described mechanism behind CO effect: CO uses ROS as 
signaling molecules. Despite the fact that CO increases ROS levels 
(Chapter II), further studies with ROS scavengers would be necessary 
to fully support the hypothesis that CO modulation of neuronal 
differentiation is dependent on ROS signaling. 
 
2. FUTURE PROSPECTS   
In this thesis it was demonstrated that CO has the ability to 
improve neuronal production by modulating cell death and some 
metabolic pathways. Nevertheless, it is imperative to understand the 
potential applicability of CO as modulator of endogenous 
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neurogenesis. Thus, in vivo approaches should be taken in account in 
further studies.  
CORMs are promising molecules that increase the potential 
application of CO in therapeutics, once they can have the ability to 
release CO under appropriate conditions in a controlled-directed 
fashion, which can be tissue specific [44]–[46]. However, their 
capacity to cross the blood-brain barrier can be a drawback. 
Moreover, the hypothesis of increasing endogenous CO by 
modulation of HO-1 activity should be explored in order to avoid the 
presence and subsequent metabolization of foreigner chemical 
structures in the biological system during neuronal differentiation. 
HO-2, the constitutive form of heme oxygenase only present in brain 
and testis, can also be targeted in order to increase CO concentration 
in these areas. 
By assessing the mechanisms underlying CO improvement of 
neuronal differentiation, it was possible to identify key pathways 
involved in neuronal differentiation. However, other pathways from 
the cell integrated metabolism should also be explored. For instance, 
it is important to understand whether the observed increased flux 
through TCA cycle could be related to any CO modulation in the 
contribution of fatty acids and aminoacids oxidation in this pathway. 
Particularly in in vivo approaches, one must consider the β-oxidation 
of fatty acids (i) in acetyl-CoA and further distribution through 
bloodstream to the brain and posterior entrance of this metabolite in 















TCA cycle and (ii) in ketone bodies that can be directly consumed by 
the brain. Also, the NADH and FADH2 produced in the process of β-
oxidation are an added-value for the bioenergetics of the organism. 
Likewise, aminoacid catabolism should be assessed due to the Krebs 
bicycle that links the Urea cycle with TCA cycle. Basically, the carbon 
structure of the aminoacid can be transformed into α-ketoacids and 
feed TCA cycle. On the other hand, the ammonia group will enter 
Urea cycle. Through the Malate-aspartate shuttle and/or the 
Aspartate-arginino-succinate shunt the two cycles can communicate 
and feed themselves.  
Moreover, the crosstalk between programmed cell death and 
autophagy is an essential topic in further studies. Over the last years 
some studies claimed that CO can improve autophagy in lung and 
heart models, through modulation of mitochondrial function [47]–
[49]. Additionally, the association of apoptosis and autophagy in 
quality control of NSCs has been assessed. Autophagy may be critical 
not only for controlling self-renewal and proliferation, but also for 
regulating differentiation and maintenance of pluripotency in stem 
cells [50]. Finally, one cannot disregard that NSCs proliferation and 
differentiation require a dynamic turnover of intracellular 
components and cellular remodeling. This places autophagy in a 
crucial position because it can modulate both cellular metabolic 
directions: (i) catabolic activity through degradation and elimination 
of intracellular components and aggregates and (ii) anabolic activity 
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through supplying the energy recycling intermediates and providing 
the building blocks for the repair of intracellular structures [51], [52]. 
In conclusion, it would be very interesting to study whether CO 
modulation of neuronal differentiation is dependent on autophagy 
regulation.  
 All the experiments done in the scope of this thesis were done 
under ambient air conditions, considered normoxic by conventional 
standards of cell-culture practice. However, it is known that by the 
time inspired air reaches organs and tissues, pO2 levels have 
dropped to 2%-9% [53] and, consequently, oxygen concentration 
between 2%-9% have recently been appreciated by some scientists to 
constitute physiologic normoxia [15], [54]. Moreover, low oxygen 
tension is known to modulate the balance between proliferation and 
differentiation [54]–[56]. One cannot disregard also the fact that, in 
vivo, CO competes with O2 for bounding to hemoglobin, leading to 
less oxygen in the brain. It is known that, in neurogenic zones, pO2 
can be in the range of 0,5%-8% [57], thus it is extremely important to 
mimic this hypoxic or even anoxic conditions when studying adult 
neurogenesis and in particular when using CO as modulator. 
Therefore, CO effect on adult neurogenesis should be assessed in low 
levels of oxygen in order to guarantee the evaluation in a more 
physiological environment. It is important to keep in mind that 
optimal concentrations for CO supplementation and even the 
mechanistic effect of CO can be different under low oxygen levels. 
















This thesis demonstrated that CO has potential as therapeutic 
molecule to improve neuronal production for cell therapy strategies. 
During neuronal differentiation, CO (i) modulates cell death 
promoting NSCs proliferation and differentiation, (ii) boosts the 
natural metabolic shift from glycolytic to oxidative metabolism and 
(iii) improves PPP flux, leading to a modulation of glutathione 
metabolism and promotion of protein glutathionylation. Moreover, 
disclosing molecular mechanisms underlying adult neurogenesis has 
the potential to facilitate novel cell therapies aiming at improving the 





[1] P. Rakic, “Limits of neurogenesis in primates.,” Science, vol. 227, no. 
4690, pp. 1054–1056, Mar. 1985. 
[2] P. Rakic, “Adult neurogenesis in mammals: an identity crisis.,” J. 
Neurosci., vol. 22, no. 3, pp. 614–618, Feb. 2002. 
[3] J. ALTMAN, “Are new neurons formed in the brains of adult 
mammals?,” Science, vol. 135, no. 3509, pp. 1127–1128, Mar. 1962. 
[4] M. S. Kaplan and J. W. Hinds, “Neurogenesis in the adult rat: electron 
microscopic analysis of light radioautographs.,” Science, vol. 197, no. 
4308, pp. 1092–1094, Sep. 1977. 
[5] The Boulder Committee, “Embryonic vertebrate central nervous 
system: revised terminology,” Anat. Rec., vol. 166, no. 2, pp. 257–
261, Feb. 1970. 
[6] S. J. Franco and U. Muller, “Shaping our minds: stem and progenitor 
cell diversity in the mammalian neocortex.,” Neuron, vol. 77, no. 1, 
pp. 19–34, Jan. 2013. 
[7] I. H. Smart, “Proliferative characteristics of the ependymal layer during 
the early development of the mouse neocortex: a pilot study based on 
Chapter VI 
 
recording the number, location and plane of cleavage of mitotic 
figures.,” J. Anat., vol. 116, no. Pt 1, pp. 67–91, Oct. 1973. 
[8] T. Takahashi, R. S. Nowakowski, and V. S. J. Caviness, “Early ontogeny 
of the secondary proliferative population of the embryonic murine  
cerebral wall.,” J. Neurosci., vol. 15, no. 9, pp. 6058–6068, Sep. 1995. 
[9] F. H. Gage, “Mammalian neural stem cells.,” Science, vol. 287, no. 
5457, pp. 1433–1438, Feb. 2000. 
[10] A. Alvarez-Buylla and J. M. Garcia-Verdugo, “Neurogenesis in adult 
subventricular zone.,” J. Neurosci., vol. 22, no. 3, pp. 629–634, Feb. 
2002. 
[11] S. Jessberger, “Neural repair in the adult brain.,” F1000Research, vol. 
5, 2016. 
[12] D. L. Jones and A. J. Wagers, “No place like home: anatomy and 
function of the stem cell niche.,” Nat. Rev. Mol. Cell Biol., vol. 9, no. 1, 
pp. 11–21, Jan. 2008. 
[13] L. Li and T. Xie, “Stem cell niche: structure and function.,” Annu. Rev. 
Cell Dev. Biol., vol. 21, pp. 605–631, 2005. 
[14] D. T. Scadden, “The stem-cell niche as an entity of action.,” Nature, 
vol. 441, no. 7097, pp. 1075–1079, Jun. 2006. 
[15] A. Mohyeldin, T. Garzón-Muvdi, and A. Quiñones-Hinojosa, “Oxygen in 
Stem Cell Biology: A Critical Component of the Stem Cell Niche,” Cell 
Stem Cell, vol. 7, no. 2, pp. 150–161, 2010. 
[16] J. Kovalevich and D. Langford, “Considerations for the Use of SH - 
SY5Y Neuroblastoma Cells in Neurobiology,” in Neuronal Cell Culture: 
Methods and Protocols, vol. 1078, 2013, pp. 9–21. 
[17] Y. Haile, W. Fu, B. Shi, D. Westaway, G. Baker, J. Jhamandas, and F. 
Giuliani, “Characterization of the NT2-derived neuronal and astrocytic 
cell lines as alternative in vitro models for primary human neurons 
and astrocytes,” J. Neurosci. Res., vol. 92, no. 9, pp. 1187–1198, Sep. 
2014. 
[18] A. Villa, I. Liste, E. T. Courtois, E. G. Seiz, M. Ramos, M. Meyer, B. 
Juliusson, P. Kusk, and A. Mart??nez-Serrano, “Generation and 
properties of a new human ventral mesencephalic neural stem cell 
line,” Exp. Cell Res., vol. 315, no. 11, pp. 1860–1874, 2009. 
[19] I. Liste, E. Garcia-Garcia, C. Bueno, and A. Martinez-Serrano, “Bcl-XL 
modulates the differentiation of immortalized human neural stem 
cells,” Cell Death Differ., vol. 14, no. 11, pp. 1880–1892, 2007. 
[20] I. E. Holopainen, “Organotypic hippocampal slice cultures: a model 
system to study basic cellular and molecular mechanisms of neuronal 
cell death, neuroprotection, and synaptic plasticity.,” Neurochem. 
Res., vol. 30, no. 12, pp. 1521–1528, Dec. 2005. 
[21] J. Noraberg, F. R. Poulsen, M. Blaabjerg, B. W. Kristensen, C. Bonde, M. 
Montero, M. Meyer, J. B. Gramsbergen, and J. Zimmer, “Organotypic 
hippocampal slice cultures for studies of brain damage, 
neuroprotection and neurorepair.,” Curr. Drug Targets. CNS Neurol. 
Disord., vol. 4, no. 4, pp. 435–452, Aug. 2005. 
[22] L. Sundstrom, B. M. Iii, M. Bradley, and A. Pringle, “Organotypic 
cultures as tools for functional screening in the CNS to act as an 
important link between high-throughput approaches and animal 
models . REVIEWS,” Drug Discov. Today, vol. 10, no. 14, 2005. 
[23] O. Raineteau, L. Rietschin, G. Gradwohl, F. Guillemot, and B. H. 
Gähwiler, “Neurogenesis in hippocampal slice cultures.,” Mol. Cell. 
Neurosci., vol. 26, no. 2, pp. 241–50, Jun. 2004. 















[24] T. Namba, H. Mochizuki, M. Onodera, H. Namiki, and T. Seki, 
“Postnatal neurogenesis in hippocampal slice cultures: Early in vitro 
labeling of neural precursor cells leads to efficient neuronal 
production,” J. Neurosci. Res., vol. 85, no. 8, pp. 1704–1712, Jun. 
2007. 
[25] M. Kamada, R.-Y. Li, M. Hashimoto, M. Kakuda, H. Okada, Y. Koyanagi, 
T. Ishizuka, and H. Yawo, “Intrinsic and spontaneous neurogenesis in 
the postnatal slice culture of rat hippocampus.,” Eur. J. Neurosci., vol. 
20, no. 10, pp. 2499–2508, Nov. 2004. 
[26] F. R. Poulsen, M. Blaabjerg, M. Montero, and J. Zimmer, “Glutamate 
receptor antagonists and growth factors modulate dentate granule 
cell neurogenesis in organotypic, rat hippocampal slice cultures.,” 
Brain Res., vol. 1051, no. 1–2, pp. 35–49, Jul. 2005. 
[27] M. P. Sadgrove, A. Laskowski, and W. P. Gray, “Examination of granule 
layer cell count, cell density, and single-pulse BrdU incorporation in 
rat organotypic hippocampal slice cultures with respect to culture 
medium, septotemporal position, and time in vitro.,” J. Comp. Neurol., 
vol. 497, no. 3, pp. 397–415, Jul. 2006. 
[28] L. Lossi, S. Alasia, C. Salio, and A. Merighi, “Cell death and 
proliferation in acute slices and organotypic cultures of mammalian 
CNS.,” Prog. Neurobiol., vol. 88, no. 4, pp. 221–245, Aug. 2009. 
[29] J. R. Ryu, C. J. Hong, J. Y. Kim, E.-K. Kim, W. Sun, and S.-W. Yu, 
“Control of adult neurogenesis by programmed cell death in the 
mammalian brain.,” Mol. Brain, vol. 9, p. 43, 2016. 
[30] P. Perez-Domper, S. Gradari, and J. L. Trejo, “The growth factors 
cascade and the dendrito-/synapto-genesis versus cell survival in 
adult hippocampal neurogenesis: the chicken or the egg.,” Ageing 
Res. Rev., vol. 12, no. 3, pp. 777–785, Jun. 2013. 
[31] A. Sierra, J. M. Encinas, J. J. P. Deudero, J. H. Chancey, G. Enikolopov, 
L. S. Overstreet-Wadiche, S. E. Tsirka, and M. Maletic-Savatic, 
“Microglia shape adult hippocampal neurogenesis through apoptosis-
coupled phagocytosis.,” Cell Stem Cell, vol. 7, no. 4, pp. 483–495, 
Oct. 2010. 
[32] P. Boya and E. J. De La Rosa, “Cell death in early neural life,” Birth 
Defects Res. Part C - Embryo Today Rev., vol. 75, no. 4, pp. 281–293, 
Dec. 2005. 
[33] K. M. Candelario, C. W. Shuttleworth, and L. A. Cunningham, “Neural 
stem/progenitor cells display a low requirement for oxidative 
metabolism independent of hypoxia inducible factor-1alpha 
expression.,” J. Neurochem., vol. 125, no. 3, pp. 420–429, May 2013. 
[34] E. Llorens-Bobadilla, S. Zhao, A. Baser, G. Saiz-Castro, K. Zwadlo, and 
A. Martin-Villalba, “Single-Cell Transcriptomics Reveals a Population of 
Dormant Neural Stem Cells that Become Activated upon Brain Injury.,” 
Cell Stem Cell, vol. 17, no. 3, pp. 329–340, Sep. 2015. 
[35] J. Shin, D. A. Berg, Y. Zhu, J. Y. Shin, J. Song, M. A. Bonaguidi, G. 
Enikolopov, D. W. Nauen, K. M. Christian, G. Ming, and H. Song, 
“Single-Cell RNA-Seq with Waterfall Reveals Molecular Cascades 
underlying Adult Neurogenesis.,” Cell Stem Cell, vol. 17, no. 3, pp. 
360–372, Sep. 2015. 
[36] A. M. Bond, G.-L. Ming, and H. Song, “Adult Mammalian Neural Stem 
Cells and Neurogenesis: Five Decades Later.,” Cell Stem Cell, vol. 17, 
no. 4, pp. 385–395, Oct. 2015. 
[37] C. C. F. Homem, V. Steinmann, T. R. Burkard, A. Jais, H. Esterbauer, 
Chapter VI 
 
and J. A. Knoblich, “Ecdysone and mediator change energy 
metabolism to terminate proliferation in Drosophila neural stem 
cells.,” Cell, vol. 158, no. 4, pp. 874–888, Aug. 2014. 
[38] C. Chen, Y. Liu, R. Liu, T. Ikenoue, K.-L. Guan, Y. Liu, and P. Zheng, 
“TSC-mTOR maintains quiescence and function of hematopoietic stem 
cells by repressing mitochondrial biogenesis and reactive oxygen 
species.,” J. Exp. Med., vol. 205, no. 10, pp. 2397–2408, Sep. 2008. 
[39] K. V Tormos, E. Anso, R. B. Hamanaka, J. Eisenbart, J. Joseph, B. 
Kalyanaraman, and N. S. Chandel, “Mitochondrial complex III ROS 
regulate adipocyte differentiation.,” Cell Metab., vol. 14, no. 4, pp. 
537–544, Oct. 2011. 
[40] M. Maryanovich, Y. Zaltsman, A. Ruggiero, A. Goldman, L. Shachnai, S. 
L. Zaidman, Z. Porat, K. Golan, T. Lapidot, and A. Gross, “An MTCH2 
pathway repressing mitochondria metabolism regulates 
haematopoietic stem cell fate.,” Nat. Commun., vol. 6, p. 7901, 2015. 
[41] C. Perez Estrada, R. Covacu, S. R. Sankavaram, M. Svensson, and L. 
Brundin, “Oxidative stress increases neurogenesis and 
oligodendrogenesis in adult neural progenitor cells.,” Stem Cells Dev., 
vol. 23, no. 19, pp. 2311–2327, Oct. 2014. 
[42] D. H. Margineantu and D. M. Hockenbery, “Mitochondrial functions in 
stem cells.,” Curr. Opin. Genet. Dev., vol. 38, pp. 110–117, Jun. 2016. 
[43] J. E. Le Belle, N. M. Orozco, A. A. Paucar, J. P. Saxe, J. Mottahedeh, A. 
D. Pyle, H. Wu, and H. I. Kornblum, “Proliferative neural stem cells 
have high endogenous ROS levels that regulate self-renewal and 
neurogenesis in a PI3K/Akt-dependant manner,” Cell Stem Cell, vol. 8, 
no. 1, pp. 59–71, 2011. 
[44] A. R. Marques, L. Kromer, D. J. Gallo, N. Penacho, S. S. Rodrigues, J. D. 
Seixas, G. J. L. Bernardes, P. M. Reis, S. L. Otterbein, R. a. Ruggieri, A. 
S. G. Gonçalves, A. M. L. Gonçalves, M. N. De Matos, I. Bento, L. E. 
Otterbein, W. a. Blättler, and C. C. Romão, “Generation of carbon 
monoxide releasing molecules (CO-RMs) as drug candidates for the 
treatment of acute liver injury: Targeting of CO-RMs to the liver,” 
Organometallics, vol. 31, no. 16, pp. 5810–5822, 2012. 
[45] R. Motterlini, J. E. Clark, R. Foresti, P. Sarathchandra, B. E. Mann, and 
C. J. Green, “Carbon monoxide-releasing molecules: characterization 
of biochemical and vascular activities.,” Circ. Res., vol. 90, no. 2, pp. 
E17–24, Feb. 2002. 
[46] R. Motterlini, P. Sawle, J. Hammad, S. Bains, R. Alberto, R. Foresti, and 
C. J. Green, “CORM-A1: a new pharmacologically active carbon 
monoxide-releasing molecule.,” FASEB J., vol. 19, no. 2, pp. 284–6, 
Feb. 2005. 
[47] S.-J. Lee, S. W. Ryter, J.-F. Xu, K. Nakahira, H. P. Kim, A. M. K. Choi, and 
Y. S. Kim, “Carbon monoxide activates autophagy via mitochondrial 
reactive oxygen species formation.,” Am. J. Respir. Cell Mol. Biol., vol. 
45, no. 4, pp. 867–873, Oct. 2011. 
[48] S. Lee, S.-J. Lee, A. A. Coronata, L. E. Fredenburgh, S. W. Chung, M. A. 
Perrella, K. Nakahira, S. W. Ryter, and A. M. K. Choi, “Carbon 
monoxide confers protection in sepsis by enhancing beclin 1-
dependent autophagy and phagocytosis.,” Antioxid. Redox Signal., vol. 
20, no. 3, pp. 432–442, Jan. 2014. 
[49] S. Lancel, D. Montaigne, X. Marechal, C. Marciniak, S. M. Hassoun, B. 
Decoster, C. Ballot, C. Blazejewski, D. Corseaux, B. Lescure, R. 
Motterlini, and R. Neviere, “Carbon monoxide improves cardiac 















function and mitochondrial population quality in a mouse model of 
metabolic syndrome,” PLoS One, vol. 7, no. 8, 2012. 
[50] H. Pan, N. Cai, M. Li, G.-H. Liu, and J. C. Izpisua Belmonte, 
“Autophagic control of cell ‘stemness’.,” EMBO Mol. Med., vol. 5, no. 3, 
pp. 327–331, Mar. 2013. 
[51] C. J. Hong, H. Park, and S.-W. Yu, “Autophagy for the quality control of 
adult hippocampal neural stem cells.,” Brain Res., pp. 1–8, 2016. 
[52] K. M. Chung and S. W. Yu, “Interplay between autophagy and 
programmed cell death in mammalian neural stem cells,” BMB Rep., 
vol. 46, no. 8, pp. 383–390, 2013. 
[53] M. C. Brahimi-Horn and J. Pouyssegur, “Oxygen, a source of life and 
stress.,” FEBS Lett., vol. 581, no. 19, pp. 3582–3591, Jul. 2007. 
[54] M. C. Simon and B. Keith, “The role of oxygen availability in embryonic 
development and stem cell function.,” Nat. Rev. Mol. Cell Biol., vol. 9, 
no. 4, pp. 285–96, 2008. 
[55] R. Lin and L. Iacovitti, “Classic and novel stem cell niches in brain 
homeostasis and repair,” Brain Res., vol. 1628, pp. 327–342, 2015. 
[56] D. M. Panchision, “The role of oxygen in regulating neural stem cells 
in development and disease.,” J. Cell. Physiol., vol. 220, no. 3, pp. 
562–8, Sep. 2009. 
[57] M. Erecińska and I. A. Silver, “Tissue oxygen tension and brain 
sensitivity to hypoxia,” Respir. Physiol., vol. 128, no. 3, pp. 263–276, 
2001. 
 

